,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,9,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
3,15,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
4,19,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
5,21,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
6,23,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
7,25,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
8,29,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
9,31,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
10,33,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
11,35,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
12,37,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
13,39,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
14,41,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
15,43,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
16,45,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
17,47,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
18,49,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
19,53,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
20,55,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
21,59,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
22,65,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
23,67,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
24,71,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
25,73,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
26,77,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
27,79,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
28,81,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
29,83,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
30,85,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
31,87,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
32,89,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
33,91,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
34,93,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
35,97,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
36,99,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
37,103,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
38,105,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
39,107,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
40,109,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
41,113,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
42,115,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
43,119,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
44,121,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
45,123,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
46,125,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
47,131,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
48,133,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
49,137,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
50,139,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
51,141,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
52,143,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
53,145,1,1,,138460,3672,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
54,155,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
55,157,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
56,161,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
57,165,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
58,167,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
59,175,1,1,,138460,3672,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
60,179,1,1,,138460,3672,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
61,248,1,1,,138460,3672,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
62,357,2,1,,855602,3672,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
63,361,1,2,,855602,3672,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
64,364,1,3,,855602,3672,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
65,368,2,3,,855602,3672,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
66,371,1,1,,855602,3672,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
67,372,1,3,,8062120,3672,Inactive,28949057.0,,,,HIV-1 RNase H Inhibition,Screening,,
68,373,1,4,,855602,3672,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
69,374,2,3,,855602,3672,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
70,375,2,3,,855602,3672,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
71,411,2,1,,855602,3672,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
72,422,1,5,,855602,3672,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
73,422,1,5,,17405252,3672,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
74,425,3,2,,855602,3672,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
75,429,1,5,,855602,3672,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
76,429,1,5,,855602,3672,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
77,429,1,5,,17405252,3672,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
78,429,1,5,,17405252,3672,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
79,430,2,4,,855602,3672,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
80,431,2,4,,855602,3672,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
81,432,2,4,,855602,3672,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
82,436,2,1,,855602,3672,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
83,436,2,1,,17405252,3672,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
84,438,1,4,,855602,3672,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
85,440,3,3,,855602,3672,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
86,441,3,3,,855602,3672,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
87,444,1,1,,855602,3672,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
88,446,1,1,,855602,3672,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
89,449,1,5,,855602,3672,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
90,450,1,2,,855602,3672,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
91,453,2,2,,855602,3672,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
92,454,1,7,,855602,3672,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
93,455,1,7,,855602,3672,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
94,456,1,7,,855602,3672,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
95,457,1,7,,855602,3672,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
96,460,2,2,,855602,3672,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
97,483,1,6,,855602,3672,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
98,485,1,8,,855602,3672,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
99,487,1,2,,855602,3672,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
100,488,2,1,,855602,3672,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
101,501,2,2,,855602,3672,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
102,518,2,6,,855602,3672,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
103,521,2,5,,855602,3672,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
104,522,1,2,,855602,3672,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
105,524,1,3,,855602,3672,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
106,525,1,3,,855602,3672,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
107,527,3,1,,855602,3672,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
108,528,1,4,,855602,3672,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
109,529,1,4,,855602,3672,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
110,538,2,2,,855602,3672,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
111,539,1,2,,855602,3672,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
112,547,1,4,,17405252,3672,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
113,552,1,3,,855602,3672,Inactive,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
114,555,1,2,,855602,3672,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
115,556,1,3,,855602,3672,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
116,559,2,2,,855602,3672,Inactive,147728.0,,,,RNA polymerase,Screening,,
117,560,1,2,,855602,3672,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
118,561,1,3,,855602,3672,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
119,565,1,4,,855602,3672,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
120,567,1,4,,855602,3672,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
121,568,1,7,,855602,3672,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
122,568,1,7,,855602,3672,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
123,570,1,4,,855602,3672,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
124,571,1,4,,855602,3672,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
125,572,1,5,,855602,3672,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
126,573,1,4,,855602,3672,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
127,574,1,3,,855602,3672,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
128,575,1,4,,855602,3672,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
129,576,1,2,,855602,3672,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
130,577,1,1,,855602,3672,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
131,580,1,5,,855602,3672,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
132,581,2,2,,855602,3672,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
133,583,2,6,,855602,3672,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
134,587,1,5,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
135,588,1,4,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
136,589,1,3,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
137,590,1,3,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
138,591,1,4,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
139,592,1,6,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
140,593,1,4,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
141,594,1,4,,855602,3672,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
142,597,1,3,,855602,3672,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
143,598,1,4,,855602,3672,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
144,601,1,4,,855602,3672,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
145,602,1,4,,855602,3672,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
146,604,1,3,,855602,3672,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
147,606,1,3,,855602,3672,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
148,606,1,3,,855602,3672,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
149,609,1,2,,855602,3672,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
150,614,1,6,,855602,3672,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
151,615,1,6,,855602,3672,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
152,618,2,6,,855602,3672,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
153,620,2,5,,855602,3672,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
154,622,1,2,,855602,3672,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
155,623,1,3,,855602,3672,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
156,624,1,2,,855602,3672,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
157,625,1,2,,855602,3672,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
158,626,1,3,,855602,3672,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
159,628,2,4,,855602,3672,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
160,629,1,3,,855602,3672,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
161,630,1,1,,855602,3672,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
162,631,1,4,,855602,3672,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
163,631,1,4,,855602,3672,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
164,633,1,3,,855602,3672,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
165,636,1,4,,855602,3672,Inactive,,,,,Modulators of Post-Golgi Transport - 384-well pilot screen,Screening,,
166,637,1,4,,855602,3672,Inactive,,,,,Modulators of Post-Golgi Transport - 1536-well pilot screen,Screening,,
167,639,1,2,,855602,3672,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
168,641,1,4,,855602,3672,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
169,645,1,4,,855602,3672,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
170,648,1,3,,855602,3672,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
171,680,1,10,,855602,3672,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
172,684,1,12,,855602,3672,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
173,686,1,1,,855602,3672,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
174,687,1,17,,855602,3672,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
175,694,1,1,,17405252,3672,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
176,701,1,17,,855602,3672,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
177,708,1,4,,855602,3672,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
178,709,1,2,,855602,3672,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
179,719,1,3,,855602,3672,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
180,731,1,5,,855602,3672,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
181,731,1,5,,855602,3672,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
182,732,1,2,,17405252,3672,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
183,741,1,4,,855602,3672,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance - Dose Response,Confirmatory,,
184,746,1,1,,855602,3672,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
185,750,1,3,,855602,3672,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
186,751,1,3,,855602,3672,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
187,757,1,4,,855602,3672,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
188,758,1,4,,855602,3672,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
189,759,1,4,,855602,3672,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
190,760,1,4,,855602,3672,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
191,761,1,4,,855602,3672,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
192,764,1,4,,855602,3672,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
193,770,1,1,,855602,3672,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
194,771,1,2,,855602,3672,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
195,772,1,2,,855602,3672,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
196,774,1,2,,855602,3672,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
197,775,1,3,,855602,3672,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
198,781,1,1,,855602,3672,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
199,782,1,2,,855602,3672,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
200,782,1,2,,855602,3672,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
201,793,1,2,,855602,3672,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
202,795,1,1,,855602,3672,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
203,797,1,1,,855602,3672,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
204,798,2,12,,855602,3672,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
205,799,1,5,,855602,3672,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
206,800,2,11,,855602,3672,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
207,803,1,4,,855602,3672,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
208,804,1,3,,855602,3672,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
209,813,1,4,,855602,3672,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
210,817,1,1,,855602,3672,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
211,818,1,2,,855602,3672,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
212,827,1,2,,855602,3672,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
213,828,1,5,,855602,3672,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
214,834,1,3,,855602,3672,Inactive,,,,,C. albicans biofilm killing,Screening,,
215,841,1,1,,855602,3672,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
216,847,1,2,,855602,3672,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
217,861,1,1,,855602,3672,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
218,862,1,2,,855602,3672,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
219,868,1,3,,855602,3672,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
220,871,1,2,,855602,3672,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
221,873,1,13,,855602,3672,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
222,875,1,2,,855602,3672,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
223,878,1,2,,855602,3672,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
224,879,1,2,,855602,3672,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
225,879,1,2,,855602,3672,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
226,880,2,1,,855602,3672,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
227,880,2,1,,855602,3672,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
228,880,2,1,,26747223,3672,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
229,880,2,1,,26747223,3672,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
230,880,2,1,,50105276,3672,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
231,880,2,1,,50105276,3672,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
232,881,2,2,,855602,3672,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
233,884,1,2,,855602,3672,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
234,885,1,2,,855602,3672,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
235,886,1,2,,855602,3672,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
236,886,1,2,,855602,3672,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
237,887,1,2,,855602,3672,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
238,889,1,3,,855602,3672,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
239,892,1,2,,855602,3672,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
240,893,1,2,,855602,3672,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
241,893,1,2,,855602,3672,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
242,894,2,1,,855602,3672,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
243,894,2,1,,26747223,3672,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
244,894,2,1,,50105276,3672,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
245,895,1,2,,855602,3672,Inconclusive,21620132.0,4790.0,0.2239,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
246,898,1,1,,855602,3672,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
247,900,1,3,,855602,3672,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
248,901,1,2,,855602,3672,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
249,902,1,2,,855602,3672,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
250,910,1,2,,855602,3672,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
251,914,1,3,,855602,3672,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
252,915,1,3,,855602,3672,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
253,917,1,3,,855602,3672,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
254,918,1,3,,855602,3672,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
255,920,1,2,,855602,3672,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
256,923,1,2,,855602,3672,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
257,924,1,2,,855602,3672,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
258,927,1,3,,855602,3672,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
259,928,1,2,,855602,3672,Inconclusive,21620132.0,4790.0,0.2239,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
260,930,1,2,,855602,3672,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
261,932,1,4,,855602,3672,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
262,940,1,2,,855602,3672,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
263,940,1,2,,17405252,3672,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
264,940,1,2,,26611780,3672,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
265,943,1,2,,855602,3672,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
266,944,1,2,,855602,3672,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
267,945,1,4,,855602,3672,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
268,950,1,1,,855602,3672,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
269,951,1,1,,855602,3672,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
270,952,1,1,,855602,3672,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
271,954,1,2,,855602,3672,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
272,957,1,2,,855602,3672,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
273,958,1,2,,855602,3672,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
274,959,1,4,,855602,3672,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
275,992,1,3,,855602,3672,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
276,995,1,2,,855602,3672,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
277,997,1,2,,855602,3672,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
278,998,1,2,,855602,3672,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
279,1001,2,2,,855602,3672,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
280,1006,1,6,,855602,3672,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
281,1007,1,1,,855602,3672,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
282,1008,1,2,,855602,3672,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
283,1009,1,2,,855602,3672,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
284,1012,1,4,,855602,3672,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
285,1016,1,4,,855602,3672,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
286,1018,2,5,,855602,3672,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
287,1019,1,4,,855602,3672,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
288,1020,1,5,,855602,3672,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
289,1021,1,1,,855602,3672,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
290,1022,1,1,,855602,3672,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
291,1027,1,3,,855602,3672,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
292,1030,2,1,,855602,3672,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
293,1030,2,1,,26747223,3672,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
294,1030,2,1,,50105276,3672,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
295,1032,1,2,,855602,3672,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
296,1032,1,2,,855602,3672,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
297,1040,1,2,,855602,3672,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
298,1046,1,6,,855602,3672,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
299,1048,1,1,,855602,3672,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
300,1048,1,1,,855602,3672,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
301,1049,1,1,,855602,3672,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
302,1049,1,1,,855602,3672,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
303,1051,1,1,,855602,3672,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
304,1051,1,1,,855602,3672,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
305,1063,1,1,,855602,3672,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
306,1066,1,2,,855602,3672,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
307,1085,1,1,,855602,3672,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
308,1135,1,3,,855602,3672,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
309,1136,1,3,,855602,3672,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
310,1189,1,5,,48413891,3672,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
311,1195,1,2,,48416098,3672,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
312,1203,1,3,,855602,3672,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
313,1208,1,3,,48413891,3672,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
314,1209,2,2,,855602,3672,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
315,1214,1,4,,855602,3672,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
316,1216,1,5,,855602,3672,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
317,1217,1,4,,855602,3672,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
318,1220,2,2,,855602,3672,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
319,1222,1,6,,855602,3672,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
320,1229,1,3,,855602,3672,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
321,1235,1,2,,855602,3672,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
322,1236,1,1,,855602,3672,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
323,1239,1,3,,855602,3672,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
324,1239,1,3,,855602,3672,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
325,1242,1,1,,855602,3672,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
326,1251,1,1,,855602,3672,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
327,1273,1,1,,855602,3672,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
328,1274,1,2,,855602,3672,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
329,1276,1,1,,855602,3672,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
330,1285,1,1,,855602,3672,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
331,1296,1,1,,855602,3672,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
332,1304,1,2,,855602,3672,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
333,1321,1,2,,855602,3672,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
334,1325,1,2,,855602,3672,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
335,1326,1,4,,855602,3672,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
336,1359,1,4,,855602,3672,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
337,1362,1,2,,855602,3672,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
338,1376,1,2,,855602,3672,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
339,1377,1,1,,855602,3672,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
340,1379,1,2,,855602,3672,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
341,1379,1,2,,26747223,3672,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
342,1379,1,2,,50105276,3672,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
343,1381,1,1,,855602,3672,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
344,1385,2,2,,855602,3672,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
345,1415,1,2,,855602,3672,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
346,1415,1,2,,855602,3672,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
347,1416,1,2,,855602,3672,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
348,1422,1,1,,855602,3672,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
349,1422,1,1,,17405252,3672,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
350,1422,1,1,,26611780,3672,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
351,1423,1,2,,855602,3672,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
352,1423,1,2,,855602,3672,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
353,1424,1,1,,855602,3672,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
354,1430,1,1,,855602,3672,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
355,1434,2,3,,855602,3672,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
356,1434,2,3,,855602,3672,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
357,1439,1,1,,855602,3672,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
358,1439,1,1,,855602,3672,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
359,1440,1,1,,855602,3672,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
360,1440,1,1,,855602,3672,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
361,1441,1,1,,855602,3672,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
362,1441,1,1,,855602,3672,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
363,1443,1,3,,855602,3672,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
364,1445,1,1,,855602,3672,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
365,1446,1,3,,855602,3672,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
366,1448,1,3,,855602,3672,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
367,1452,1,1,,855602,3672,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
368,1454,1,1,,26747223,3672,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
369,1454,1,1,,50105276,3672,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
370,1456,1,1,,855602,3672,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
371,1457,1,1,,855602,3672,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
372,1457,1,1,,26747223,3672,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
373,1457,1,1,,50105276,3672,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
374,1458,1,1,,855602,3672,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
375,1458,1,1,,26747223,3672,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
376,1458,1,1,,50105276,3672,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
377,1459,1,1,,50105276,3672,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
378,1460,1,3,,855602,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
379,1460,1,3,,26747223,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
380,1460,1,3,,50105276,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
381,1461,1,2,,855602,3672,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
382,1461,1,2,,50105276,3672,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
383,1463,1,1,,855602,3672,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
384,1463,1,1,,26747223,3672,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
385,1463,1,1,,50105276,3672,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
386,1465,1,1,,855602,3672,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
387,1466,1,2,,855602,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
388,1467,1,3,,855602,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
389,1467,1,3,,26747223,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
390,1467,1,3,,50105276,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
391,1468,1,1,,855602,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
392,1468,1,1,,26747223,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
393,1468,1,1,,50105276,3672,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
394,1469,1,1,,855602,3672,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
395,1469,1,1,,26747223,3672,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
396,1469,1,1,,26752326,3672,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
397,1469,1,1,,50105276,3672,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
398,1469,1,1,,50105278,3672,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
399,1471,2,1,,26747223,3672,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
400,1471,2,1,,26752326,3672,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
401,1476,2,1,,855602,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
402,1476,2,1,,26747223,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
403,1476,2,1,,50105276,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
404,1477,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
405,1477,1,1,,26747223,3672,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
406,1477,1,1,,50105276,3672,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
407,1477,1,1,,50105278,3672,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
408,1478,2,1,,855602,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
409,1478,2,1,,26747223,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
410,1478,2,1,,50105276,3672,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
411,1479,1,2,,855602,3672,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
412,1479,1,2,,26747223,3672,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
413,1479,1,2,,26752326,3672,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
414,1479,1,2,,50105276,3672,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
415,1479,1,2,,50105278,3672,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
416,1481,1,2,,855602,3672,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
417,1486,1,3,,855602,3672,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
418,1487,1,1,,855602,3672,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
419,1487,1,1,,50105276,3672,Inconclusive,27436948.0,4000.0,0.0056,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
420,1490,2,1,,855602,3672,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
421,1490,2,1,,26747223,3672,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
422,1490,2,1,,26752326,3672,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
423,1490,2,1,,50105278,3672,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
424,1496,1,4,,855602,3672,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
425,1496,1,4,,855602,3672,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
426,1509,1,2,,855602,3672,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
427,1510,1,3,,855602,3672,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
428,1511,1,3,,855602,3672,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
429,1515,1,2,,855602,3672,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
430,1519,1,3,,26747223,3672,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
431,1519,1,3,,50105276,3672,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
432,1527,1,3,,855602,3672,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
433,1529,1,1,,855602,3672,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
434,1530,1,1,,855602,3672,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
435,1531,1,1,,855602,3672,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
436,1532,1,1,,855602,3672,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
437,1554,1,1,,855602,3672,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
438,1556,1,4,,855602,3672,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
439,1565,2,2,,855602,3672,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
440,1566,2,3,,855602,3672,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
441,1578,3,2,,855602,3672,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
442,1580,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
443,1581,1,1,,8149384,3672,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
444,1582,1,1,,8149384,3672,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
445,1583,1,1,,8149384,3672,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
446,1584,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
447,1585,1,1,,8149384,3672,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
448,1586,1,1,,8149384,3672,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
449,1587,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
450,1588,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
451,1589,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
452,1590,1,1,,8149384,3672,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
453,1593,1,1,,8149384,3672,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
454,1594,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
455,1595,1,1,,8149384,3672,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
456,1596,1,1,,8149384,3672,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
457,1597,1,1,,8149384,3672,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
458,1598,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
459,1599,1,1,,8149384,3672,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
460,1600,1,1,,8149384,3672,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
461,1601,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
462,1602,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
463,1603,1,1,,8149384,3672,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
464,1604,1,1,,8149384,3672,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
465,1605,1,1,,8149384,3672,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
466,1606,1,1,,8149384,3672,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
467,1607,1,1,,8149384,3672,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
468,1608,1,1,,8149384,3672,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
469,1609,1,1,,8149384,3672,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
470,1610,1,1,,8149384,3672,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
471,1612,1,1,,8149384,3672,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
472,1613,1,1,,8149384,3672,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
473,1614,1,1,,8149384,3672,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
474,1616,1,1,,8149384,3672,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
475,1619,1,2,,855602,3672,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
476,1621,1,2,,855602,3672,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
477,1626,1,2,,855602,3672,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
478,1631,3,1,,855602,3672,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
479,1634,3,1,,855602,3672,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
480,1654,2,2,,855602,3672,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
481,1656,2,2,,855602,3672,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
482,1662,1,2,,855602,3672,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
483,1663,1,2,,855602,3672,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
484,1665,2,2,,855602,3672,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
485,1672,1,3,,855602,3672,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
486,1688,1,1,,855602,3672,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
487,1688,1,1,,26752326,3672,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
488,1700,1,2,,855602,3672,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
489,1705,1,2,,50105276,3672,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
490,1706,1,2,,855602,3672,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
491,1707,1,3,,50105276,3672,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
492,1708,1,3,,50105276,3672,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
493,1721,1,2,,855602,3672,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
494,1722,1,2,,855602,3672,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
495,1766,1,1,,855602,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
496,1766,1,1,,855602,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
497,1766,1,1,,26747223,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
498,1766,1,1,,26747223,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
499,1766,1,1,,26752326,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
500,1766,1,1,,26752326,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
501,1766,1,1,,50105276,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
502,1766,1,1,,50105276,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
503,1766,1,1,,50105278,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
504,1766,1,1,,50105278,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
505,1768,1,1,,855602,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
506,1768,1,1,,855602,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
507,1768,1,1,,26747223,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
508,1768,1,1,,26747223,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
509,1768,1,1,,26752326,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
510,1768,1,1,,26752326,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
511,1768,1,1,,50105276,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
512,1768,1,1,,50105276,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
513,1768,1,1,,50105278,3672,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
514,1768,1,1,,50105278,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
515,1775,1,2,,855602,3672,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
516,1776,1,2,,855602,3672,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
517,1777,3,2,,855602,3672,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
518,1778,3,3,,855602,3672,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
519,1779,2,2,,855602,3672,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
520,1789,1,2,,855602,3672,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
521,1800,1,2,,855602,3672,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
522,1813,1,2,,855602,3672,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
523,1814,1,2,,855602,3672,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
524,1815,1,1,,50105276,3672,Inconclusive,,,17.7828,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
525,1816,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
526,1817,2,2,,855602,3672,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
527,1822,1,3,,855602,3672,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
528,1825,1,1,,855602,3672,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
529,1828,2,1,,50105276,3672,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
530,1832,2,1,,855602,3672,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
531,1845,1,2,,855602,3672,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
532,1850,2,1,,855602,3672,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
533,1850,2,1,,56422436,3672,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
534,1861,2,1,,855602,3672,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
535,1862,1,4,,855602,3672,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
536,1863,2,1,,855602,3672,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
537,1863,2,1,,56422436,3672,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
538,1865,1,1,,855602,3672,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
539,1865,1,1,,26747223,3672,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
540,1865,1,1,,50105276,3672,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
541,1867,1,4,,855602,3672,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
542,1868,1,4,,855602,3672,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
543,1870,1,4,,855602,3672,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
544,1873,1,4,,855602,3672,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
545,1875,2,1,,855602,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
546,1876,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
547,1877,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
548,1882,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
549,1883,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
550,1885,2,1,,855602,3672,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
551,1886,1,1,,50105276,3672,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
552,1887,1,4,,855602,3672,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
553,1899,1,3,,56422436,3672,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
554,1903,2,3,,855602,3672,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
555,1903,2,3,,56422436,3672,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
556,1906,1,3,,56422436,3672,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
557,1910,1,2,,855602,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
558,1947,1,2,,56422436,3672,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
559,1948,1,1,,26747223,3672,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
560,1948,1,1,,50105276,3672,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
561,1949,1,3,,49761821,3672,Inactive,,,,,"High Throughput Screen of 100,000 compound library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv",Confirmatory,,
562,1950,1,3,,56422436,3672,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
563,1956,1,1,,855602,3672,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
564,1961,2,2,,855602,3672,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
565,1962,1,2,,56422436,3672,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
566,1967,1,1,,85231082,3672,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
567,1974,1,2,,56422436,3672,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
568,1984,1,3,,855602,3672,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
569,1986,1,2,,855602,3672,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
570,1987,1,2,,56422436,3672,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
571,2006,3,2,,855602,3672,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
572,2006,3,2,,855602,3672,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
573,2006,3,2,,855602,3672,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
574,2012,3,2,,855602,3672,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
575,2013,2,2,,855602,3672,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
576,2014,3,2,,855602,3672,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
577,2016,1,3,,56422436,3672,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
578,2023,1,3,,56422436,3672,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
579,2025,1,3,,56422436,3672,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
580,2029,1,3,,56422436,3672,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
581,2052,2,1,,56422436,3672,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
582,2057,1,2,,56422436,3672,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
583,2058,3,2,,855602,3672,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
584,2066,1,4,,56422436,3672,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
585,2071,2,2,,855602,3672,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
586,2073,2,3,,855602,3672,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
587,2073,2,3,,855602,3672,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
588,2094,1,2,,855602,3672,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
589,2094,1,2,,855602,3672,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
590,2094,1,2,,855602,3672,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
591,2097,1,2,,855602,3672,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
592,2098,1,1,,855602,3672,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
593,2099,1,1,,855602,3672,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
594,2100,1,1,,855602,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
595,2101,1,1,,855602,3672,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
596,2101,1,1,,26747223,3672,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
597,2101,1,1,,50105276,3672,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
598,2101,1,1,,50105278,3672,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
599,2107,1,1,,855602,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
600,2107,1,1,,26747223,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
601,2107,1,1,,50105276,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
602,2107,1,1,,50105278,3672,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
603,2112,1,1,,855602,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
604,2112,1,1,,26747223,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
605,2112,1,1,,50105276,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
606,2112,1,1,,50105278,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
607,2129,1,2,,56422436,3672,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
608,2130,1,3,,56422436,3672,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
609,2147,1,1,,855602,3672,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
610,2147,1,1,,26747223,3672,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
611,2147,1,1,,50105276,3672,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
612,2156,2,2,,855602,3672,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
613,2174,1,3,,56422436,3672,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
614,2177,1,3,,56422436,3672,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
615,2205,1,1,,855602,3672,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
616,2216,1,3,,855602,3672,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
617,2221,1,2,,855602,3672,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
618,2227,1,2,,855602,3672,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
619,2234,1,2,,56422436,3672,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
620,2235,1,2,,56422436,3672,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
621,2237,1,2,,855602,3672,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
622,2239,1,2,,855602,3672,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
623,2240,1,1,,85789193,3672,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
624,2241,1,1,,85789193,3672,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
625,2242,1,1,,855602,3672,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
626,2247,1,2,,855602,3672,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
627,2275,1,1,,85789193,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
628,2280,2,3,,56422436,3672,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
629,2288,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
630,2289,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
631,2300,1,3,,56422436,3672,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
632,2313,1,1,,85789193,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
633,2314,1,2,,855602,3672,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
634,2314,1,2,,855602,3672,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
635,2315,1,2,,855602,3672,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
636,2315,1,2,,855602,3672,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
637,2322,1,1,,85789193,3672,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
638,2323,1,1,,50105276,3672,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
639,2326,1,1,,855602,3672,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
640,2326,1,1,,50105276,3672,Inactive,194352380.0,,14.1254,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
641,2330,1,1,,85789193,3672,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
642,2353,1,3,,50105276,3672,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
643,2364,1,2,,50105276,3672,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
644,2380,1,2,,855602,3672,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
645,2391,1,1,,56422436,3672,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
646,2417,1,1,,855602,3672,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
647,2435,1,2,,56422436,3672,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
648,2445,1,2,,56422436,3672,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
649,2451,1,2,,855602,3672,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
650,2451,1,2,,26747223,3672,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
651,2451,1,2,,50105276,3672,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
652,2451,1,2,,50105278,3672,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
653,2462,1,1,,56422436,3672,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
654,2462,1,1,,56422436,3672,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
655,2472,1,2,,855602,3672,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
656,2472,1,2,,26747223,3672,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
657,2472,1,2,,50105278,3672,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
658,2517,2,1,,855602,3672,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
659,2517,2,1,,26747223,3672,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
660,2517,2,1,,50105276,3672,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
661,2517,2,1,,50105278,3672,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
662,2520,1,4,,855602,3672,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
663,2521,1,3,,855602,3672,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
664,2523,1,1,,855602,3672,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
665,2524,1,2,,855602,3672,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
666,2528,1,2,,855602,3672,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
667,2528,1,2,,26747223,3672,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
668,2528,1,2,,26752326,3672,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
669,2528,1,2,,50105276,3672,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
670,2528,1,2,,50105278,3672,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
671,2540,1,2,,855602,3672,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
672,2544,1,2,,855602,3672,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
673,2546,1,1,,855602,3672,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
674,2546,1,1,,26747223,3672,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
675,2546,1,1,,26752326,3672,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
676,2546,1,1,,50105278,3672,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
677,2549,1,1,,855602,3672,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
678,2549,1,1,,26747223,3672,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
679,2549,1,1,,50105276,3672,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
680,2549,1,1,,50105278,3672,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
681,2550,1,3,,855602,3672,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
682,2551,1,1,,855602,3672,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
683,2551,1,1,,26747223,3672,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
684,2551,1,1,,26752326,3672,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
685,2551,1,1,,50105278,3672,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
686,2553,1,2,,855602,3672,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
687,2557,1,3,,56422436,3672,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
688,2563,1,1,,855602,3672,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
689,2599,1,2,,855602,3672,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
690,2606,1,2,,56422436,3672,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
691,2629,1,1,,56422436,3672,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
692,2642,1,2,,855602,3672,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
693,2648,1,2,,855602,3672,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
694,2650,2,1,,56422436,3672,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
695,2660,1,1,,90341584,3672,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
696,2661,1,1,,56422436,3672,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
697,2662,2,1,,855602,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
698,2662,2,1,,85231082,3672,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
699,2666,1,1,,90341584,3672,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
700,2667,1,1,,90341584,3672,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
701,2668,1,1,,90341584,3672,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
702,2674,1,1,,855602,3672,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
703,2675,1,1,,855602,3672,Inactive,41281591.0,4154.0,0.1,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
704,2675,1,1,,50105276,3672,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
705,2676,1,2,,855602,3672,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
706,2685,1,1,,855602,3672,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
707,2690,1,2,,56422436,3672,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
708,2706,1,1,,855602,3672,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
709,2716,1,1,,56422436,3672,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
710,2717,1,2,,56422436,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
711,2718,1,1,,56422436,3672,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
712,2732,1,1,,855602,3672,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
713,2732,1,1,,17405252,3672,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
714,2751,2,2,,56422436,3672,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
715,2774,1,3,,92304084,3672,Inactive,,,,,LOPAC Circadian Assay,Screening,,
716,2796,1,4,,56422436,3672,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
717,2797,1,2,,56422436,3672,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
718,2805,2,2,,855602,3672,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
719,2806,2,2,,855602,3672,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
720,2825,1,2,,855602,3672,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
721,6710,6,7,,103174500,3672,Active,126407.0,240.0,17.0,IC50,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Confirmatory,9057869.0,
722,6771,7,1,,103174500,3672,Unspecified,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Other,7739006.0,
723,6773,7,1,,103174500,3672,Unspecified,,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Other,7739006.0,
724,6860,9,1,,103174500,3672,Unspecified,,,,IC50,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Confirmatory,2115586.0,
725,6861,6,7,,103174500,3672,Active,729945.0,25290.0,14.0,IC50,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Confirmatory,9057869.0,
726,19006,4,3,,103174500,3672,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
727,19262,5,1,,103174500,3672,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
728,27167,3,4,,103174500,3672,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
729,28681,3,4,,103174500,3672,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
730,28921,3,3,,103174500,3672,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
731,28923,3,4,,103174500,3672,Unspecified,,,,,Effective permeability measured with Caco-2 cells,Other,11300874.0,
732,28926,3,3,,103174500,3672,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
733,28927,3,3,,103174500,3672,Unspecified,,,,,Effective permeability measured with HDM assay,Other,11300874.0,
734,28928,3,3,,103174500,3672,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
735,28929,3,3,,103174500,3672,Unspecified,,,,,Intrinsic permeability measured with HDM assay,Other,11300874.0,
736,29359,3,3,,103174500,3672,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
737,29811,4,3,,103174500,3672,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
738,54405,6,5,,103174500,3672,Unspecified,,,50.0,Ki,Binding affinity measured on human cytochrome P450 2C9 (CYP2C9) enzyme,Confirmatory,10956186.0,
739,80721,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory effect was studied in a rat carrageenan paw edema (CE) assay at 50 mg/kg,Other,2104935.0,
740,112288,6,2,,103174500,3672,Unspecified,,,,,Compound was tested for antianalgesic activity by phenylquinone writhing method in mice.,Other,6708056.0,
741,112417,3,3,,103174500,3672,Unspecified,,,,,Tested for antiinflammatory activity in the mouse active Arthus (MAA) test by peroral administration,Other,6461764.0,
742,112577,6,2,,103174500,3672,Unspecified,,,,,Tested for antiinflammatory activity in the mouse active Arthus (MAA) test by intraperitoneal administration,Other,6461764.0,
743,112578,6,2,,103174500,3672,Unspecified,,,,,Tested for antiinflammatory activity in the mouse active Arthus (MAA) test by peroral administration,Other,6461764.0,
744,112732,5,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model",Other,15203134.0,
745,113334,6,2,,103174500,3672,Unspecified,,,,,ED50 value was evaluated for analgesic activity by phenylquinone -induced writhing test in ddN strain mice on peroral administration; value ranges from 32.7-76.20,Other,6827540.0,
746,116723,6,2,,103174500,3672,Unspecified,,,,,Acute toxicity as LD50 value was determined in mice administered orally,Other,6218302.0,
747,118143,5,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity, administered ip at 150 uM/kg dose was determined against carrageenan-induced mice paw edema model",Other,15203134.0,
748,128888,3,3,,103174500,3672,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 10 mg/kg,Other,6972450.0,
749,128890,3,3,,103174500,3672,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 3 mg/kg,Other,6972450.0,
750,129025,3,3,,103174500,3672,Unspecified,,,,,Percent analgesia in phenylquinone writhing assay at 30 mg/kg,Other,6972450.0,
751,129306,7,2,,103174500,3672,Unspecified,,,,,"Antinociceptive activity in mice, determined using abdominal constriction test.",Other,1495016.0,
752,129311,5,2,,103174500,3672,Inactive,,,,,Antinociceptive activity using mouse tail flick test; Inactive,Other,1495016.0,
753,131339,6,2,,103174500,3672,Unspecified,,,,,Dose giving one-half of average maximal [40%] response in carrageenan assay,Other,6972450.0,
754,131340,6,2,,103174500,3672,Unspecified,,,,,Dose giving one-half of average maximal [40%] response in phenylquinone writhing assay,Other,6972450.0,
755,132231,6,2,,103174500,3672,Unspecified,,,,,Effective dose required for writhing response in mouse after 20 minutes on ig administration,Other,7901416.0,
756,132251,5,2,,103174500,3672,Unspecified,,,,,Inhibition of arachidonic acid oedema in mouse ear.,Other,8568814.0,
757,134578,6,2,,103174500,3672,Unspecified,,,,,Lethal dose evaluated in NPP assay,Other,6972450.0,
758,135276,3,3,,103174500,3672,Unspecified,,,,,Neurotoxic dose that causes minimal recognizable neurotoxicity in 50% of animals tested,Other,6972450.0,
759,157039,5,2,,103174500,3672,Unspecified,,,87096400000.0,IC50,Antiaggregatory effect against arachidonic acid induced platelet aggregation in the human platelet rich plasma(PRP),Confirmatory,11585451.0,
760,160237,9,5,,103174500,3672,Active,3915797.0,5743.0,30.0,IC50,Inhibition of Prostaglandin G/H synthase 2 (COX-2).,Confirmatory,9544212.0,
761,160863,7,3,,103174500,3672,Active,,,0.22,IC50,Inhibition of PGE-2 production in 3T3 (murine fibroblast) cell culture.,Confirmatory,8568814.0,
762,160868,9,1,,103174500,3672,Active,,,,,Inhibition of prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of TXB2 at 10 uM.,Other,7739006.0,
763,160899,9,2,,103174500,3672,Active,,,13.0,IC50,Concentration required to inhibit 50% activity of prostaglandin synthetase was determined in vitro in mouse brain microsomes,Confirmatory,1900533.0,
764,161005,9,1,,103174500,3672,Active,,,2.0,IC50,Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line,Confirmatory,2115586.0,
765,161496,9,2,,103174500,3672,Active,,,11.1,IC50,Inhibition activity against recombinant human Prostaglandin G/H synthase 1,Confirmatory,9057869.0,
766,161655,9,2,,103174500,3672,Active,,,3.0,IC50,Inhibitory activity against prostaglandin G/H synthase 1 (COX-1),Confirmatory,9719605.0,
767,161679,9,1,,103174500,3672,Active,,,3.0,IC50,Concentration (in uM) to inhibit 50% of Prostaglandin G/H synthase 1 (COX-1) and is expressed in IC50.,Confirmatory,9544211.0,
768,161680,9,5,,103174500,3672,Active,317373262.0,5742.0,3.0,IC50,Inhibition of Prostaglandin G/H synthase 1 (COX-1).,Confirmatory,9544212.0,
769,162150,10,5,,103174500,3672,Active,754286265.0,443551.0,1.06,IC50,Reversible competitive inhibition of prostaglandin G/H synthase 1,Confirmatory,14741265.0,
770,162151,10,1,,103174500,3672,Active,754286265.0,443551.0,9.0,IC50,Tested for inhibitory activity against Prostaglandin G/H synthase 1 from ovine,Confirmatory,7562922.0,
771,162309,9,3,,103174500,3672,Active,,,6.3,IC50,Compound was evaluated for inhibition of Prostaglandin G/H synthase 1,Confirmatory,,
772,162632,9,2,,103174500,3672,Active,,,0.1,IC50,Inhibition activity against recombinant human Prostaglandin G/H synthase 2,Confirmatory,9057869.0,
773,162645,9,2,,103174500,3672,Active,,,30.0,IC50,Inhibitory activity against prostaglandin G/H synthase 2 (COX-2),Confirmatory,9719605.0,
774,162666,9,2,,103174500,3672,Active,,,8.0,IC50,Tested for inhibitory activity against Prostaglandin G/H synthase 2 from human,Confirmatory,7562922.0,
775,162671,9,1,,103174500,3672,Active,,,30.0,IC50,Concentration (in uM) to inhibit 50% of Prostaglandin G/H synthase 2 (COX-2) and is expressed in IC50.,Confirmatory,9544211.0,
776,169240,4,2,,103174500,3672,Unspecified,,,,,Incidence of melena defecation was recorded 24 hrs of last treatment given once daily for 4 days; Positive,Other,15203134.0,
777,171174,3,3,,103174500,3672,Unspecified,,,,,Body weight change after once daily administration at 1600 uM/kg for 4 days in rats was determined,Other,15203134.0,
778,171858,3,3,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity by rat acute gast irritation assay, activity is expressed as Ulcerogenic dose (UD50).",Other,7739006.0,
779,171859,3,3,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity by rat adjuvant Arthritis assay. (3h edema).,Other,7739006.0,
780,171863,5,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity by rat Carrageenan edema assay at 50 mg/kg peroral administration (3h edema).,Other,7739006.0,
781,173208,3,3,,103174500,3672,Unspecified,,,,,Gastrointestinal tolerability was evaluated in rats and amount blood loss was reported,Other,6608000.0,
782,173356,3,3,,103174500,3672,Unspecified,,,,,Hypolipidemic action at 300 uM/kg was determined as reduction in low density lipoprotein in rat plasma,Other,15203134.0,
783,173357,3,3,,103174500,3672,Unspecified,,,,,Hypolipidemic action at 300 uM/kg was determined as reduction in total cholesterol in rat plasma,Other,15203134.0,
784,173358,3,4,,103174500,3672,Unspecified,,,,,Hypolipidemic action at 300 uM/kg was determined as reduction in triglycerides in rat plasma,Other,15203134.0,
785,176728,6,2,,103174500,3672,Unspecified,,,,,Dose causing 50% inhibition of edema by carrageenan paw edema assay.,Other,3373493.0,
786,176730,7,2,,103174500,3672,Unspecified,,,,,Dose causing an analgesic effect in 50% of rats (Randall-Selitto assay),Other,3373493.0,
787,177075,6,2,,103174500,3672,Unspecified,,,,,Compound was evaluated for highest non-ulcerogenic dose (less than 50% ulcer incidence),Other,6502598.0,
788,177114,6,2,,103174500,3672,Unspecified,,,,,ED50 value was evaluated for antiinflammatory activity by carrageenan-induced rat paw edema method (CPE) on peroral administration; value may range from 10.6 to 39.2,Other,6827540.0,
789,177164,8,1,,103174500,3672,Unspecified,,,484.8,ED50,In vivo effective dose required for antiinflammatory activity in rat adjuvant arthritis model,Confirmatory,7562922.0,
790,177359,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory activity was evaluated in an adjuvant arthritis (subchronic inflammation) test after administering compound orally in rats,Other,6608000.0,
791,178383,7,2,,103174500,3672,Unspecified,,,,,Effective dose for Anti-inflammatory activity was determined by carrageenan induced rat hind paw edema model,Other,15013005.0,
792,178492,4,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in the rat foot edema at the dose of 3.2-100 mg/kg po,Other,2113951.0,
793,178493,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against adjuvant induced arthritis in male charles river rats,Other,8151626.0,
794,178649,6,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity was evaluated in an carrageenan edema (acute inflammation) test, after administering compound orally in rats; 50-100",Other,6608000.0,
795,179451,7,2,,103174500,3672,Unspecified,,,,,Analgesic activity on peroral administration against Scald induced pain in rat paw,Other,6607354.0,
796,181535,6,2,,103174500,3672,Unspecified,,,100.0,IC50,Inhibition of neutrophil release in rat adjuvant arthritis model as measure of antiinflammatory activity,Confirmatory,3104589.0,
797,182196,3,5,,103174500,3672,Unspecified,,,,,Compound was tested for antiinflammatory activity and the % inhibition was reported 3 hr after carrageenan injection in the hind paw edema test in rats: dose=80 mg/kg,Other,6708056.0,
798,182609,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity on peroral administration against carrageenan paw edema,Other,6607354.0,
799,182616,6,2,,103174500,3672,Unspecified,,,,,Biological activity against carrageenan-induced edema,Other,6461764.0,
800,182619,6,2,,103174500,3672,Unspecified,,,,,Carrageenan-induced edema was determined value for oral administration,Other,6218302.0,
801,183305,3,3,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity at 3h post drug administration using the carrageenan-induced rat paw edema assay,Other,11520200.0,
802,183306,3,3,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity at 5 hr post drug administration using the carrageenan-induced rat paw edema assay,Other,11520200.0,
803,183666,3,3,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity (% inhibition of paw swelling)in rat adjuvant arthritis model at 25 mg/kg oral dose,Other,3104589.0,
804,183818,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.278 mM/kg (57.2 mg),Other,6502598.0,
805,183819,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.55 mM/kg (113 mg),Other,6502598.0,
806,183820,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test; 0.139-40,Other,6502598.0,
807,184177,3,4,,103174500,3672,Unspecified,,,,,In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 3 hr following a 1 mg/kg oral dose,Other,14584938.0,
808,184179,3,4,,103174500,3672,Unspecified,,,,,In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 5 hr following a 1 mg/kg oral dose,Other,14584938.0,
809,184533,3,3,,103174500,3672,Unspecified,,,,,Mortality caused by the compound in rats after administration at 1600 uM/kg for 4 days,Other,15203134.0,
810,185300,3,4,,103174500,3672,Unspecified,,,,,The mean increase in paw volume was compared between drug treated groups and placebo to calculate the percent inhibition in rats at 0.08 mmol/kg by carrageenan Edema Assay; 30-39,Other,6502598.0,
811,185332,3,3,,103174500,3672,Unspecified,,,,,Ulcerogenic property after intragastric administration to conscious rats for 6 hrs,Other,11585451.0,
812,185439,3,3,,103174500,3672,Unspecified,,,,,The percent inhibition was calculated from the average differences in hind paw volume between the adjuvant injected controls and the adjuvant-injected medicated rats at 0.08 mmol/kg; 40-49,Other,6502598.0,
813,186302,3,4,,103174500,3672,Unspecified,,,,,Tested for % inhibition in carrageenan-induced rat paw adema after intraperitoneal administration of 100 mg/kg dose at 2 hours,Other,,
814,186303,3,4,,103174500,3672,Unspecified,,,,,Tested for % inhibition in carrageenan-induced rat paw adema after intraperitoneal administration of 100 mg/kg dose at 3.5 hours,Other,,
815,186304,3,4,,103174500,3672,Unspecified,,,,,Tested for % inhibition in carrageenan-induced rat paw adema after peroral administration of 100 mg/kg dose at 2 hours,Other,,
816,186427,3,4,,103174500,3672,Unspecified,,,,,Tested for % inhibition in carrageenan-induced rat paw adema after peroral administration of 100 mg/kg dose at 3.5 hours,Other,,
817,187310,3,3,,103174500,3672,Unspecified,,,,,Potency relative to phenylbutazone at 0.278 mM/kg,Other,6502598.0,
818,189984,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal tolerability was evaluated under acute conditions, in rats. The ulcerogenic dose was reported",Other,6608000.0,
819,189989,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal tolerability was evaluated under chronic conditions, in rats. The ulcerogenic dose was reported; 30-100",Other,6608000.0,
820,189996,3,3,,103174500,3672,Unspecified,,,,,Dose at which 50% of the rats had a positive gastrointestinal irritation / ulceration on a quantal all-or-none basis.,Other,3373493.0,
821,190001,3,3,,103174500,3672,Unspecified,,,,,Evaluated for the UD50 value by gastric ulcer assay in rats on peroral administration of dose; value ranges from 82.3-182,Other,6827540.0,
822,190165,3,3,,103174500,3672,Unspecified,,,,,"Ulcerogenic dose that produced gastric lesions, ulcers and/or hemorrhage in 50% of the animals tested",Other,6972450.0,
823,190505,3,3,,103174500,3672,Unspecified,,,,,Ulcerogenic activity administered once daily at 1600 uM/kg for 4 days was determined as no of animals showing perforating ulcers,Other,15203134.0,
824,190514,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 3 animals tested at 0.97 mM/kg (200 mg) was reported",Other,6502598.0,
825,190521,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 4 animals tested at 0.278 mM/kg (57.2 mg) was reported",Other,6502598.0,
826,190522,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 4 animals tested at 0.97 mM/kg (200 mg) was reported",Other,6502598.0,
827,190533,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in intestine during the 3 week adjuvant arthritis test, no of animals with ulcers out of 8 animals tested at 0.55 mM/kg (113 mg) was reported",Other,6502598.0,
828,190682,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test, no of animals with ulcers out of 4 animals tested at 0.278 mM/kg (57.2 mg) was reported",Other,6502598.0,
829,190694,3,4,,103174500,3672,Unspecified,,,,,"Ulcerogenicity was measured in stomach during the 3 week adjuvant arthritis test, no of animals with ulcers out of 8 animals tested at 0.55 mM/kg (113 mg) was reported",Other,6502598.0,
830,192196,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.278 mM/kg (57.2 mg),Other,6502598.0,
831,192199,3,3,,103174500,3672,Unspecified,,,,,Antiinflammatory efficacy is measured by the weight gain in rats during the 3 week adjuvant arthritis test at 0.55 mM/kg (113 mg),Other,6502598.0,
832,192529,3,3,,103174500,3672,Unspecified,,,,,Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 120 mg/kg was administered and observed after 4 hours of incubation,Other,11585451.0,
833,192530,3,3,,103174500,3672,Unspecified,,,,,Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 120 mg/kg was administered and observed after 6 hours of incubation,Other,11585451.0,
834,192531,3,3,,103174500,3672,Unspecified,,,,,Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 40 mg/kg was administered and observed after 4 hours of incubation,Other,11585451.0,
835,192532,3,3,,103174500,3672,Unspecified,,,,,Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 40 mg/kg was administered and observed after 6 hours of incubation,Other,11585451.0,
836,193991,3,3,,103174500,3672,Unspecified,,,,,Gastrointestinal tolerability was evaluated in rats and compound dose that causes lethality was reported,Other,6608000.0,
837,194121,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 120 mg/kg (p.o.),Other,6461764.0,
838,194122,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 120 mg/kg (p.o.); 65/57,Other,6461764.0,
839,194125,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 30 mg/kg (p.o.),Other,6461764.0,
840,194126,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 30 mg/kg (p.o.); 30/30,Other,6461764.0,
841,194257,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 60 mg/kg (p.o.),Other,6461764.0,
842,194258,3,3,,103174500,3672,Unspecified,,,,,Biological activity against adjuvant-induced arthritis at the dose of 60 mg/kg (p.o.); 56/61,Other,6461764.0,
843,194266,3,4,,103174500,3672,Unspecified,,,,,Compound administered intraperitoneally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 2 hours,Other,,
844,194268,3,4,,103174500,3672,Unspecified,,,,,Compound administered intraperitoneally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 3.5 hours,Other,,
845,194270,3,4,,103174500,3672,Unspecified,,,,,Compound administered orally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 2 hours,Other,,
846,194271,4,4,,103174500,3672,Unspecified,,,,,Compound administered orally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 3.5 hours,Other,,
847,195758,6,2,,103174500,3672,Unspecified,,,,,Inhibitory activity against carrageenan induced rat paw edema after peroral administration,Other,11520200.0,
848,210601,3,3,,103174500,3672,Unspecified,,,,,"Therapeutic index (LD50/ID50, MAA) value of the compound",Other,6461764.0,
849,212894,6,2,,103174500,3672,Unspecified,,,,,Evaluated for the acute lethal toxicity in Std:ddY mice on peroral administration of dose; value ranges from 1082-1672,Other,6827540.0,
850,213227,6,2,,103174500,3672,Unspecified,,,,,Lethal dose required to produce acute toxicity in mice(ip),Other,6461764.0,
851,213228,6,2,,103174500,3672,Unspecified,,,,,Lethal dose required to produce acute toxicity in mice(po),Other,6461764.0,
852,225117,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against 3h carrageenan pleurisy (cells) in rat at 20 mg/kg peroral administration,Other,12540240.0,
853,225119,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against 3h carrageenan pleurisy (edma) in rat at 20 mg/kg peroral administration,Other,12540240.0,
854,225122,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against 3h carrageenan pleurisy in rat at 20 mg/kg peroral administration,Other,12540240.0,
855,225499,7,2,,103174500,3672,Unspecified,,,,,Dose causing 50% inhibition of writhing in mouse (PBQ writhing test),Other,3373493.0,
856,225621,3,3,,103174500,3672,Unspecified,,,,,Mild analgesia activity in the THA assay po,Other,12540240.0,
857,227084,3,5,,103174500,3672,Unspecified,,,,,Relative binding affinity to 5-lipoxygenase and cyclooxygenase,Other,2115586.0,
858,227718,7,1,,103174500,3672,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
859,229957,3,7,,103174500,3672,Unspecified,,,,,IC50 ratio measured as the IC50 values of COX-1 to that of COX-2.,Other,7562922.0,
860,231697,3,4,,103174500,3672,Unspecified,,,,,Ratio between UD50 and ED50 in carrageenan paw edema was determined,Other,6827540.0,
861,231760,3,3,,103174500,3672,Unspecified,,,,,Ratio of carrageenan paw edema ED50/Randall-Sellitto ED50,Other,3373493.0,
862,234481,3,7,,103174500,3672,Unspecified,,,,,Ratio IC50 for binding to COX-1 and COX-2,Other,9544212.0,
863,235405,3,3,,103174500,3672,Unspecified,,,,,Therapeutic ratio was determined for peroral administration,Other,6218302.0,
864,235527,3,6,,103174500,3672,Unspecified,,,,,Tested for selectivity for inhibition of human platelet derived COX-1 and recombinant human COX-2 (),Other,9544211.0,
865,235829,3,3,,103174500,3672,Unspecified,,,,,Ratio of acute ulcerogenesis UD50/Randall-Selitto ED50,Other,3373493.0,
866,237685,4,3,,103174500,3672,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
867,239787,3,10,,103174500,3672,Unspecified,3914304.0,443460.0,,,Ratio of IC50 against COX-1 to that of COX-2,Other,15943479.0,
868,239787,3,10,,103174500,3672,Unspecified,754286265.0,443551.0,,,Ratio of IC50 against COX-1 to that of COX-2,Other,15943479.0,
869,240795,9,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,In vitro inhibitory concentration against COX-1 enzyme,Confirmatory,15943479.0,
870,240796,9,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,In vitro inhibitory concentration against COX-2 enzyme,Confirmatory,15943479.0,
871,242201,9,5,,103174500,3672,Active,754286265.0,443551.0,14.4,IC50,Inhibitory concentration against Prostaglandin G/H synthase 1 of ram seminal vesicles at 100 uM,Confirmatory,15780608.0,
872,242224,9,5,,103174500,3672,Unspecified,3914304.0,443460.0,265.5,IC50,Inhibitory concentration against Prostaglandin G/H synthase 2 from sheep placenta at 100 uM,Confirmatory,15780608.0,
873,243230,4,1,,103174500,3672,Unspecified,113576.0,213.0,165959000000.0,Ki,Binding affinity towards human serum albumin,Confirmatory,15801837.0,
874,243603,3,10,,103174500,3672,Unspecified,548484.0,29527.0,,,Anti-inflammatory activity in rat paw edema assay at 75 mg/kg,Other,15780608.0,
875,243647,3,8,,103174500,3672,Unspecified,,,,,In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive,Other,15369391.0,
876,249064,6,7,,103174500,3672,Unspecified,548484.0,29527.0,,,Inhibitory dose against carrageenan induced rat paw edema assay at 50 mg/kg oral dose,Other,15267236.0,
877,249066,6,2,,103174500,3672,Unspecified,,,,,In vivo antiinflammatory activity after 3 hr of oral administration was determined using rat carrageenan induced paw edema model,Other,15943479.0,
878,251749,3,3,,103174500,3672,Unspecified,,,,,inhibition of acute TPA-induced ear swelling in mice on oral administration of 0.1 nmol/kg,Other,15454241.0,
879,251803,3,3,,103174500,3672,Unspecified,,,,,Percent inhibition of acute TPA-induced ear swelling in mice upon topical application at 2x 100 ug,Other,15454241.0,
880,252988,3,3,,103174500,3672,Unspecified,,,,,Acute ulcerogenic activity is measured as gastric ulcer index upon administration at dose equivalent to 250 mg of aspirin/kg,Other,15943479.0,
881,257049,9,5,,103174500,3672,Active,308153646.0,8644.0,33.0,IC50,Inhibition of recombinant human AKR1C3,Confirmatory,16183274.0,
882,263718,3,12,,103174500,3672,Unspecified,1709856.0,5663.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
883,263718,3,12,,103174500,3672,Unspecified,1709858.0,5664.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
884,263718,3,12,,103174500,3672,Unspecified,12231037.0,23385.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
885,263718,3,12,,103174500,3672,Unspecified,37077707.0,51107.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
886,263718,3,12,,103174500,3672,Unspecified,37081820.0,55851.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
887,263718,3,12,,103174500,3672,Unspecified,61252592.0,83464.0,,,Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM,Other,16455248.0,
888,263722,3,6,,103174500,3672,Unspecified,,,,,Inhibition of beta amyloid protein 42 in HEK cell lines overexpressing APP695 at 100 uM,Other,16455248.0,
889,263725,3,3,,103174500,3672,Unspecified,,,,,Decrease in beta amyloid protein 42 level in Tg2576 transgenic mouse at 21 mg/kg relative to control,Other,16455248.0,
890,263726,3,3,,103174500,3672,Unspecified,,,,,Decrease in beta amyloid protein 40 level in Tg2576 transgenic mouse at 21 mg/kg relative to control,Other,16455248.0,
891,263727,7,1,,103174500,3672,Active,,,,,"Drug level in mouse brain at 50 mg/kg, po",Other,16455248.0,
892,263728,7,1,,103174500,3672,Unspecified,,,,,"Drug level in mouse plasma at 50 mg/kg, po",Other,16455248.0,
893,263729,3,3,,103174500,3672,Unspecified,,,,,"Ratio of drug level in brain against plasma in mice at 50 mg/kg, po",Other,16455248.0,
894,263731,3,3,,103174500,3672,Active,,,,,GI permeability in Sprague-Dawley rat at 30 mg/kg by 51Cr-EDTA excretion assay,Other,16455248.0,
895,266338,5,6,,103174500,3672,Unspecified,,,,,Inhibition of COX2 at 30 uM,Other,16513348.0,
896,266339,3,4,,103174500,3672,Unspecified,,,,,Antiangiogenic activity against HUVEC cells by tube formation assay at 100 uM,Other,16513348.0,
897,279778,3,3,,103174500,3672,Unspecified,,,,,"Effect on viability of Mycobacterium tuberculosis H37Rv bacilli in BALB/c mouse lung at 20 mg/kg, po five times/week after 1 month relative to contro",Other,17145791.0,
898,279784,3,3,,103174500,3672,Inactive,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse lung at 20 mg/kg, po five times/week after 1 month relative to control",Other,17145791.0,
899,279785,3,4,,103174500,3672,Inactive,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse spleen at 20 mg/kg, po five times/week after 1 month relative to control",Other,17145791.0,
900,279786,4,3,,103174500,3672,Active,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse lung at 20 mg/kg, po in presence of 25 mg/kg isoniazid five times/week after 1 month relative to control",Other,17145791.0,
901,279787,3,4,,103174500,3672,Active,,,,,"Clearance of Mycobacterium tuberculosis H37Rv in BALB/c mouse spleen at 20 mg/kg, po in presence of 25 mg/kg isoniazid five times/week after 1 month relative to control",Other,17145791.0,
902,284851,3,3,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity against of FCA-induced odema in BALB/c mouse assessed as oedema inhibition at 0.30 mmol/kg, ip",Other,17126019.0,
903,284852,3,3,,103174500,3672,Unspecified,,,,,"Increase of oedema in BALB/c mouse with FCA-induced inflammation at 0.30 mmol/kg, ip",Other,17126019.0,
904,284865,9,1,,103174500,3672,Unspecified,,,,,"Total cholesterol level in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs",Other,17126019.0,
905,284866,9,1,,103174500,3672,Unspecified,,,,,"LDL level in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs",Other,17126019.0,
906,284867,9,1,,103174500,3672,Unspecified,,,,,"Triglyceride level in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs",Other,17126019.0,
907,284868,3,3,,103174500,3672,Unspecified,,,,,"Mortality rate in Fischer 344 rat at 1.6 mmol/kg, sc after 4 days",Other,17126019.0,
908,284869,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Fischer 344 rat assessed as gastrointestinal ulceration at 1.6 mmol/kg, sc after 4 days",Other,17126019.0,
909,284870,3,3,,103174500,3672,Unspecified,,,,,"Body weight change per 100g in Fischer 344 rat at 1.6 mmol/kg, sc after 4 days",Other,17126019.0,
910,284871,3,9,,103174500,3672,Unspecified,584716.0,83817.0,,,Inhibition of Fischer 344 rat brain acetylcholine esterase at 0.6 mM,Other,17126019.0,
911,284873,3,3,,103174500,3672,Unspecified,,,,,"Decrease in total cholesterol in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs relative to control",Other,17126019.0,
912,284874,3,3,,103174500,3672,Unspecified,,,,,"Decrease in LDL level in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs relative to control",Other,17126019.0,
913,284875,3,3,,103174500,3672,Unspecified,,,,,"Decrease in triglyceride level in Fischer 344 rat plasma at 0.3 mmol/kg, ip after 24 hrs relative to control",Other,17126019.0,
914,287140,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Albino rat at 30 mg/kg body weight, sc",Other,17052805.0,
915,288184,9,1,,103174500,3672,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
916,288185,7,1,,103174500,3672,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
917,288192,3,4,,103174500,3672,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
918,288193,3,4,,103174500,3672,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
919,288194,3,5,,103174500,3672,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
920,288821,9,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,17509888.0,
921,288822,9,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,17509888.0,
922,288823,3,3,,103174500,3672,Unspecified,,,,,Selectivity index COX1 over COX2,Other,17509888.0,
923,288824,7,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced rat paw edema in orally dosed rat after 3 hrs,Other,17509888.0,
924,288828,3,3,,103174500,3672,Unspecified,,,,,"Gastric damage production in rat assessed as gastric ulcer index at 1.21 mmol/kg, po after 6 hrs",Other,17509888.0,
925,289114,6,2,,103174500,3672,Active,,,27.5,IC50,Inhibition of fMLP-induced superoxide production in human neutrophils,Confirmatory,17559265.0,
926,294902,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Albino rat assessed as protection against carrageenan-induced hind paw oedema at 20 mg/kg, po after 3 hrs",Other,17336429.0,
927,294904,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Albino mouse assessed as protection against acetic acid-induced writhing at 10 mg/kg, ip within 30 mins",Other,17336429.0,
928,295373,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Albino rat at 100 mg/kg, po after 3 hrs",Other,17383186.0,
929,295374,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity against phenylquinone-induced in Swiss mouse assessed as effect on writhings at 50 mg/kg, po after 20 mins",Other,17383186.0,
930,295377,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity against phenylquinone-induced in Swiss mouse assessed as effect on writhings at 100 mg/kg, po after 20 mins",Other,17383186.0,
931,299899,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Sprague-Dawley rat assessed as swelling thickness at 70 mg/kg, po after 2 hrs",Other,17517512.0,
932,299900,4,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Sprague-Dawley rat assessed as swelling thickness at 70 mg/kg, po after 3 hrs",Other,17517512.0,
933,299901,4,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Sprague-Dawley rat assessed as swelling thickness at 70 mg/kg, po after 4 hrs",Other,17517512.0,
934,299902,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 2 hrs relative to control",Other,17517512.0,
935,299903,5,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 3 hrs relative to control",Other,17517512.0,
936,299904,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 4 hrs relative to control",Other,17517512.0,
937,299905,3,9,,103174500,3672,Unspecified,78099241.0,170635.0,,,Inhibition of rat liver 3alphaHSD assessed as 5-beta-dihydrocortisone reduction at 1 mM,Other,17517512.0,
938,299906,9,5,,103174500,3672,Unspecified,78099241.0,170635.0,100.0,IC50,Inhibition of rat liver 3-alpha-HSD assessed as 5-beta-dihydrocortisone reduction,Confirmatory,17517512.0,
939,299909,9,5,,103174500,3672,Active,317373262.0,5742.0,6.9,IC50,Inhibition of COX1 in human whole blood after 15 mins,Confirmatory,17517512.0,
940,299910,9,5,,103174500,3672,Active,3915797.0,5743.0,6.2,IC50,Inhibition of COX2 in human whole blood after 15 mins,Confirmatory,17517512.0,
941,299911,3,3,,103174500,3672,Unspecified,,,,,Selectivity for human COX2 over human COX1,Other,17517512.0,
942,308403,4,9,,103174500,3672,Unspecified,113576.0,213.0,,,Displacement of fluorescent 5-Cyano-2-[(E)-2-(1-methyl-1H-indol-2-yl)-vinyl]-benzoic acid from human serum albumin,Other,17560104.0,
943,311335,6,2,,103174500,3672,Active,,,32.55,IC50,Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry,Confirmatory,17822293.0,
944,311367,3,6,,103174500,3672,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
945,323982,9,5,,103174500,3672,Active,1351907.0,280717.0,3.0,IC50,Binding affinity to bovine serum albumin,Confirmatory,18024138.0,
946,339052,3,4,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po after 3.5 hrs",Other,1624939.0,
947,339218,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat after 3 hrs,Other,18541424.0,
948,344873,9,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,18930406.0,
949,344874,9,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,18930406.0,
950,344875,7,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against po dosed carrageenan-induced rat foot paw edema after 3 hrs,Other,18930406.0,
951,351040,5,9,,103174500,3672,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 10 uM,Other,18835505.0,
952,351041,5,9,,103174500,3672,Unspecified,3914304.0,443460.0,,,Inhibition of ovine COX2 at 1 uM,Other,18835505.0,
953,351042,5,9,,103174500,3672,Unspecified,754286265.0,443551.0,,,Inhibition of ovine COX1 at 10 uM,Other,18835505.0,
954,352495,9,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,19419861.0,
955,352496,9,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immunoassay,Confirmatory,19419861.0,
956,352499,3,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for ovine COX2,Other,19419861.0,
957,352503,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced rat inflammation model assessed as inhibition of paw edema at 327 umol/kg, po after 3 hrs",Other,19419861.0,
958,352592,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Charles Foster albino rat at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 to 3 hrs",Other,18701196.0,
959,352593,4,3,,103174500,3672,Unspecified,,,,,"Analgesic activity against acetic acid-induced writhes in mouse at 50 mg/kg, po administered 30 mins before acetic acid challenge measured for 60 mins",Other,18701196.0,
960,360149,11,2,,103174500,3672,Active,56404586.0,381203.0,1.12202,Ki,Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
961,360150,11,2,,103174500,3672,Active,81901833.0,18399.0,4.67735,Ki,Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
962,360151,3,4,,103174500,3672,Unspecified,,,,,Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes,Other,17553798.0,
963,360152,8,1,,103174500,3672,Unspecified,56404586.0,381203.0,,,Activity of mouse Oat6 expressed in Xenopus oocytes assessed as drug uptake,Other,17553798.0,
964,360153,7,1,,103174500,3672,Unspecified,81901833.0,18399.0,,,Activity of mouse Oat1 expressed in Xenopus oocytes assessed as drug uptake,Other,17553798.0,
965,362014,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po after 4 hrs relative to control",Other,18667305.0,
966,362015,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing responses at 70 mg/kg, po after 4 hrs relative to control",Other,18667305.0,
967,364307,3,10,,103174500,3672,Unspecified,13432234.0,5468.0,,,Activity at PPARgamma in human Caco-2 cells assessed as luciferase activity at 1000 uM relative to control,Other,18222570.0,
968,368225,9,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,19136259.0,
969,368228,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in orally dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,19136259.0,
970,368229,9,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,19136259.0,
971,373867,6,3,,103174500,3672,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
972,376410,3,9,,103174500,3672,Unspecified,754286265.0,443551.0,,,Inhibition of sheep COX1 at 2.06 ug/mL,Other,10579873.0,
973,378690,11,1,,103174500,3672,Active,,,25.0,IC50,Inhibition of PGHS1 assessed as conversion of arachidonic acid to prostaglandin,Confirmatory,10075763.0,
974,382410,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced acute paw edema Sprague-Dawley rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 3 hrs relative to control",Other,17467123.0,
975,382411,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 1 day relative to control",Other,17467123.0,
976,382412,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 2 days relative to control",Other,17467123.0,
977,382413,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 3 days relative to control",Other,17467123.0,
978,382415,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 5 days relative to control",Other,17467123.0,
979,382420,3,3,,103174500,3672,Unspecified,,,,,"Toxic gastric-ulcerogenic effect in Sprague-Dawley rat assessed as lesion score at 100 mg/kg, po after 7 days",Other,17467123.0,
980,382655,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 100 mg/kg, po after 4 days relative to control",Other,17467123.0,
981,385232,3,3,,103174500,3672,Unspecified,,,,,Inhibition of COX2 synthesis in pig skin,Other,18412394.0,
982,385235,3,3,,103174500,3672,Active,,,,,Suppression of COX2 expression in pig skin by immunostaining after 6 hrs,Other,18412394.0,
983,386623,4,8,,103174500,3672,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
984,386883,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po measured 4 hrs after carrageenan challenge",Other,18023930.0,
985,386885,7,2,,103174500,3672,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus ATCC 19433 by cup plate method,Other,18023930.0,
986,386886,7,2,,103174500,3672,Inconclusive,,,,,Antibacterial activity against sEscherichia coli ATCC 25922 by cup plate method,Other,18023930.0,
987,386887,7,2,,103174500,3672,Inconclusive,,,,,Antimicrobial activity against Candida albicans ATCC 2091 by cup plate method,Other,18023930.0,
988,386890,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as effect on reaction time for tail withdrawal administered at 70 mg/kg, po after 4 hrs by tail immersion method",Other,18023930.0,
989,386894,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in rat assessed as gastric mucosal damage severity index at 210 mg/kg, po",Other,18023930.0,
990,386898,4,3,,103174500,3672,Unspecified,,,,,"Inhibition of lipid peroxidation in rat assessed as malondialdehyde level per 100 mg of tissue at 210 mg/kg, po",Other,18023930.0,
991,391917,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 0.5 hrs after carrageenan challenge",Other,17845827.0,
992,391918,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 1 hr after carrageenan challenge",Other,17845827.0,
993,391919,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 2 hrs after carrageenan challenge",Other,17845827.0,
994,391920,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 3 hrs after carrageenan challenge",Other,17845827.0,
995,391921,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 4 hrs after carrageenan challenge",Other,17845827.0,
996,391922,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 5 hrs after carrageenan challenge",Other,17845827.0,
997,393818,9,5,,103174500,3672,Active,166897622.0,282022.0,2.9,IC50,Inhibition of bovine COX1 by enzyme immunoassay,Confirmatory,19296694.0,
998,393820,9,5,,103174500,3672,Active,3914301.0,282023.0,1.1,IC50,Inhibition of bovine COX2 by enzyme immunoassay,Confirmatory,19296694.0,
999,393822,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced foot paw edema in po dosed rat after 3 hrs,Other,19296694.0,
1000,396567,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured 3 hrs after post drug dose",Other,18068271.0,
1001,396570,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured 24 hrs after post drug dose",Other,18068271.0,
1002,396573,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as protection against acetic acid-induced writhing at 20 mg/kg, po administered 3 hrs mins before acetic acid challenge relative to control",Other,18068271.0,
1003,396576,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed ulcer index at 100 mg/kg, po after 17 hrs",Other,18068271.0,
1004,397202,4,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as protection against carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,19064304.0,
1005,399401,9,5,,103174500,3672,Active,166897622.0,282022.0,13.0,IC50,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production,Confirmatory,9461646.0,
1006,399402,7,6,,103174500,3672,Unspecified,3914304.0,443460.0,370.0,IC50,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production,Confirmatory,9461646.0,
1007,399403,3,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1,Other,9461646.0,
1008,399404,9,5,,103174500,3672,Unspecified,166897622.0,282022.0,,IC50,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production preincubated for 10 mins,Confirmatory,9461646.0,
1009,399405,10,5,,103174500,3672,Unspecified,3914304.0,443460.0,,IC50,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production preincubated for 10 mins,Confirmatory,9461646.0,
1010,399406,3,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1 preincubated for 10 mins,Other,9461646.0,
1011,402402,9,2,,103174500,3672,Unspecified,,,1030.0,IC50,Inhibition of COX2-catalyzed prostaglandin biosynthesis after 10 mins of preincubation,Confirmatory,9784154.0,
1012,402403,9,2,,103174500,3672,Active,,,18.0,IC50,Inhibition of COX1-catalyzed prostaglandin biosynthesis 10 mins of preincubation,Confirmatory,9784154.0,
1013,402404,3,3,,103174500,3672,Unspecified,,,,,Ratio of IC50 for COX2 to IC50 for COX1,Other,9784154.0,
1014,403349,3,7,,103174500,3672,Unspecified,,,,,Inhibition of COX1 at 10 uM,Other,16038536.0,
1015,403350,3,7,,103174500,3672,Unspecified,,,,,Inhibition of COX2 at 10 uM,Other,16038536.0,
1016,404304,3,10,,103174500,3672,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1017,407366,9,5,,103174500,3672,Active,119810.0,24360.0,47.6,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
1018,407369,9,5,,103174500,3672,Unspecified,119810.0,24360.0,448.0,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
1019,408486,6,2,,103174500,3672,Inactive,,,,IC50,Inhibition of recombinant Curvularia lunata trihydroxynaphthalene reductase,Confirmatory,18482840.0,
1020,409942,11,2,,103174500,3672,Inactive,113978.0,4128.0,,IC50,Inhibition of human recombinant MAOA by fluorimetric method,Confirmatory,18834112.0,
1021,409943,11,2,,103174500,3672,Inactive,113980.0,4129.0,,IC50,Inhibition of human recombinant MAOB by fluorimetric method,Confirmatory,18834112.0,
1022,409958,3,9,,103174500,3672,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
1023,409960,3,9,,103174500,3672,Inactive,124028638.0,338445.0,,,Inhibition of bovine brain MAOB,Other,18834112.0,
1024,419806,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 2 hrs",Other,18977556.0,
1025,419808,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 3 hrs",Other,18977556.0,
1026,419810,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 4 hrs",Other,18977556.0,
1027,419812,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 8 hrs",Other,18977556.0,
1028,419814,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 12 hrs",Other,18977556.0,
1029,419816,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing response at 20 mg/kg, po pretreated 3 hrs before acetic acid challenge",Other,18977556.0,
1030,419818,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed ulcer index at 60 mg/kg, po after 17 hrs",Other,18977556.0,
1031,419820,5,4,,103174500,3672,Unspecified,,,,,"Inhibition of lipid peroxidation assessed as malondialdehyde level per 100 mg of gastric mucosa isolated from Wistar rat treated 60 mg/kg, po by UV spectrophotometry",Other,18977556.0,
1032,420430,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 2 hrs relative to control",Other,19059680.0,
1033,420431,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 3 hrs relative to control",Other,19059680.0,
1034,420432,3,4,,103174500,3672,Unspecified,,,,,"Central analgesic activity in Swiss albino mouse assessed as reaction time required to elicit thermal stimulus-induced hind paw licking at 20 mg/kg, po after 60 mins by Turner hotplate method",Other,19059680.0,
1035,420433,3,3,,103174500,3672,Unspecified,,,,,"Peripheral analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing response at 20 mg/kg, po pretreated 1 hr before acetic acid challenge",Other,19059680.0,
1036,420434,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed ulcer index at 60 mg/kg, po after 17 hrs",Other,19059680.0,
1037,420435,5,4,,103174500,3672,Unspecified,,,,,"Inhibition of lipid peroxidation assessed as malondialdehyde level per mg of protein in gastric mucosa isolated from albino rat treated 60 mg/kg, po by UV spectrophotometry",Other,19059680.0,
1038,421491,7,1,,103174500,3672,Unspecified,,,,,"Drug level in C57BL/6 mouse blood at 260.935 mg/kg, ip measured after 1 hr by LC-MS/MS analysis",Other,19233517.0,
1039,421492,7,1,,103174500,3672,Unspecified,,,,,"Drug level in C57BL/6 mouse brain at 260.935 mg/kg, ip measured after 1 hr by LC-MS/MS analysis",Other,19233517.0,
1040,421493,3,5,,103174500,3672,Unspecified,,,,,"Ratio of drug level in brain to blood in C57BL/6 mouse at 260.935 mg/kg, ip measured after 1 hr by LC-MS/MS analysis",Other,19233517.0,
1041,421503,3,4,,103174500,3672,Active,,,,,Antioxidant activity in Sprague-Dawley rat brain homogenate assessed as attenuation of toxin-induced lipid peroxidation at 1 mM by modified TBA assay,Other,19233517.0,
1042,425652,7,2,,103174500,3672,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1043,425653,7,2,,103174500,3672,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1044,429532,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 0.5 hrs",Other,19398345.0,
1045,429533,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr",Other,19398345.0,
1046,429534,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs",Other,19398345.0,
1047,429535,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs",Other,19398345.0,
1048,429536,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs",Other,19398345.0,
1049,429537,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs",Other,19398345.0,
1050,429661,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as complete damage of mucosal layer and ulceration of submucosal cells at 150 mg/kg, po after 24 hrs by electron microscopy",Other,19398345.0,
1051,434304,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity against acetic acid-induced writhing in Swiss albino mouse assessed as protection at 20 mg/kg, po",Other,19321237.0,
1052,434305,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in albino rat assessed as ulcerogenic index at 50 mg/kg, po",Other,19321237.0,
1053,434955,1,2,,56422436,3672,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1054,434959,1,1,,85789193,3672,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1055,434962,1,2,,56422436,3672,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1056,434973,1,3,,855602,3672,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1057,434989,1,1,,56422436,3672,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1058,435003,1,3,,855602,3672,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1059,435005,1,1,,56422436,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1060,435022,2,2,,855602,3672,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1061,435030,1,2,,56422436,3672,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1062,435030,1,2,,56422436,3672,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1063,436152,5,3,,103174500,3672,Unspecified,,,54.3,IC50,Immunomodulatory activity in whole blood assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay,Confirmatory,18950230.0,
1064,436153,5,2,,103174500,3672,Active,,,12.1,IC50,Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay,Confirmatory,18950230.0,
1065,436370,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenen challenge measured after 3 hrs relative to control",Other,19423197.0,
1066,436848,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 70 mg/kg, po pretreated 1 hr before carrageenan challenge measured after 4 hrs by plethysmometer",Other,19541393.0,
1067,436849,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing response at 70 mg/kg, po pretreated 1 hr before acetic acid challenge",Other,19541393.0,
1068,436850,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Wistar rat assessed as ulcerogenic induces at 200 mg/kg, po after 17 hrs",Other,19541393.0,
1069,441338,3,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino mouse assessed as protection against acetic acid-induced writhing at 20 mg/kg, po administered 1 hr before acetic acid challenge measured for 5 to 15 mins",Other,19713009.0,
1070,441344,3,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Albino rat assessed as severity index at 60 mg/kg, po after 17 hrs relative to control",Other,19713009.0,
1071,442339,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in albino Charles-Foster rat assessed as inhibition of carrageenan-induced paw oedema at 50 mg/kg, po administered 30 mins before carrageenan challenge measured at 10 uM after 1-3 hrs relative to control",Other,19926172.0,
1072,443725,8,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX-2 by enzyme immuno assay,Confirmatory,19884005.0,
1073,443726,8,5,,103174500,3672,Active,166897622.0,282022.0,2.9,IC50,Inhibition of bovine COX-1 by enzyme immuno assay,Confirmatory,19884005.0,
1074,443727,3,3,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for bovine COX-1 to IC50 for human recombinant COX-2",Other,19884005.0,
1075,443729,8,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against assessed as inhibition of carrageenan-induced foot paw edema in po dosed rat after 3 hrs,Other,19884005.0,
1076,444050,7,1,,103174500,3672,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1077,444051,6,2,,103174500,3672,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1078,444052,6,2,,103174500,3672,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1079,444053,6,2,,103174500,3672,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1080,444054,6,1,,103174500,3672,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1081,444055,3,3,,103174500,3672,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1082,444056,3,3,,103174500,3672,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1083,444057,3,3,,103174500,3672,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1084,444058,6,2,,103174500,3672,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1085,447528,8,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,19500994.0,
1086,447529,8,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,19500994.0,
1087,447532,3,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for human COX2,Other,19500994.0,
1088,447533,8,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,19500994.0,
1089,449728,1,2,,56422436,3672,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1090,449762,1,2,,56422436,3672,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1091,449763,1,3,,855602,3672,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1092,449768,1,1,,855602,3672,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1093,455986,3,5,,103174500,3672,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
1094,457928,8,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immunoassay,Confirmatory,20097072.0,
1095,457929,8,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2 by enzyme immunoassay,Confirmatory,20097072.0,
1096,457930,3,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2,Other,20097072.0,
1097,457933,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema,Other,20097072.0,
1098,461111,8,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,20045320.0,
1099,461113,8,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,20045320.0,
1100,461116,6,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat,Other,20045320.0,
1101,461303,10,2,,103174500,3672,Unspecified,6225312.0,29347.0,263.027,IC50,Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate by liquid scintillation spectroscopy,Confirmatory,20143779.0,
1102,461304,3,9,,103174500,3672,Unspecified,6225312.0,29347.0,,,Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate by liquid scintillation spectroscopy relative to control,Other,20143779.0,
1103,461306,5,7,,103174500,3672,Unspecified,6225312.0,29347.0,500.0,IC50,Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate at pH 9.0 by liquid scintillation spectroscopy,Confirmatory,20143779.0,
1104,461307,3,9,,103174500,3672,Unspecified,6225312.0,29347.0,,,Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate at 100 uM in pH 6.0 by liquid scintillation spectroscopy,Other,20143779.0,
1105,461308,6,6,,103174500,3672,Unspecified,6225312.0,29347.0,240.0,IC50,Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate at pH 7.4 by liquid scintillation spectroscopy,Confirmatory,20143779.0,
1106,461316,4,8,,103174500,3672,Inactive,47117287.0,11343.0,,,Inhibition of human recombinant MGL at 100 uM,Other,20143779.0,
1107,463073,1,2,,855602,3672,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1108,463075,1,1,,855602,3672,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1109,463079,1,2,,56422436,3672,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1110,463082,1,1,,56422436,3672,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1111,463096,1,1,,50105276,3672,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1112,463097,1,1,,50105276,3672,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1113,463104,1,2,,855602,3672,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1114,463106,1,2,,90341584,3672,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1115,463111,1,1,,855602,3672,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1116,463115,1,1,,855602,3672,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1117,463141,1,2,,56422436,3672,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1118,463165,1,1,,855602,3672,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1119,463187,1,1,,855602,3672,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1120,463189,1,1,,855602,3672,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1121,463189,1,1,,53777797,3672,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1122,463190,1,2,,855602,3672,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1123,463193,1,1,,855602,3672,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1124,463195,1,2,,855602,3672,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1125,463210,1,2,,56422436,3672,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1126,463212,1,1,,855602,3672,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1127,463254,1,1,,855602,3672,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1128,467611,3,6,,103174500,3672,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
1129,467612,3,6,,103174500,3672,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1130,467613,5,3,,103174500,3672,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1131,468463,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw oedema in Charles Foster albino rat at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 to 3 hrs by water plethysmometer",Other,19959259.0,
1132,468464,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human HCT15 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1133,468465,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human HepG32 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1134,468466,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human A549 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1135,468467,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human HOP62 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1136,468468,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human IMR32 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1137,468469,3,4,,103174500,3672,Inactive,,,,,Anticancer activity against human DU145 cells at 10 uM after 48 hrs by sulforhodamine B assay,Other,19959259.0,
1138,471921,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 0.5 hrs",Other,19427713.0,
1139,471922,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hrs",Other,19427713.0,
1140,471923,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1.5 hrs",Other,19427713.0,
1141,471924,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs",Other,19427713.0,
1142,471925,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2.5 hrs",Other,19427713.0,
1143,471926,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs",Other,19427713.0,
1144,473256,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat assessed as paw volume at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 to 3 hrs by water plethysmometer relative to control",Other,20188544.0,
1145,474247,8,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,20202839.0,
1146,474248,8,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2 by enzyme immuno assay,Confirmatory,20202839.0,
1147,474382,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat assessed as reduction in paw volume at 50 mg/kg, po dosed 1 hr before carrageenan challenge measured after 3 hrs by plethysmometry",Other,20335039.0,
1148,478959,5,2,,103174500,3672,Unspecified,,,552.0,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,20171760.0,
1149,478960,5,2,,103174500,3672,Unspecified,,,448.0,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,20171760.0,
1150,478961,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as listlessness up to 5 days",Other,20171760.0,
1151,478962,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as diarrhea up to 5 days",Other,20171760.0,
1152,478963,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as breathing problem up to 5 days",Other,20171760.0,
1153,478964,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as fur ruffling up to 5 days",Other,20171760.0,
1154,478965,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as weight loss up to 5 days",Other,20171760.0,
1155,478966,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as mortality up to 5 days",Other,20171760.0,
1156,478967,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as reduction of body weight gain after 14 days",Other,20171760.0,
1157,478968,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 500 mg/kg, po assessed as reduction of body weight gain after 14 days",Other,20171760.0,
1158,478969,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 500 mg/kg, po assessed as mortality after 14 days",Other,20171760.0,
1159,478970,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as mortality after 14 days",Other,20171760.0,
1160,478971,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 2000 mg/kg, po assessed as pathological changes after 14 days",Other,20171760.0,
1161,478972,3,3,,103174500,3672,Unspecified,,,,,"Acute toxicity in WIST rat at 500 mg/kg, po assessed as pathological changes after 14 days",Other,20171760.0,
1162,481439,3,4,,103174500,3672,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
1163,481442,3,6,,103174500,3672,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
1164,485270,1,1,,56422436,3672,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1165,485272,1,1,,56422436,3672,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1166,485273,2,1,,855602,3672,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1167,485275,1,3,,56422436,3672,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1168,485281,1,1,,855602,3672,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1169,485290,1,1,,855602,3672,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1170,485290,1,1,,26747223,3672,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1171,485290,1,1,,26752326,3672,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1172,485290,1,1,,50105276,3672,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1173,485290,1,1,,50105278,3672,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1174,485294,1,1,,855602,3672,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1175,485295,1,2,,90341584,3672,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1176,485297,1,1,,855602,3672,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1177,485297,1,1,,90341584,3672,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1178,485298,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1179,485298,1,1,,90341584,3672,Inconclusive,,,11.5821,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1180,485313,1,2,,855602,3672,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1181,485313,1,2,,90341584,3672,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1182,485314,1,1,,855602,3672,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1183,485314,1,1,,50105276,3672,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1184,485317,1,2,,56422436,3672,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1185,485341,1,1,,855602,3672,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1186,485342,1,2,,90341584,3672,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1187,485344,1,1,,855602,3672,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1188,485345,1,2,,90341584,3672,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1189,485346,1,1,,855602,3672,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1190,485346,1,1,,855602,3672,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1191,485347,1,2,,855602,3672,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1192,485349,1,1,,855602,3672,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1193,485350,1,2,,92124039,3672,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1194,485353,2,1,,855602,3672,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1195,485358,1,1,,855602,3672,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1196,485360,1,1,,855602,3672,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1197,485364,1,1,,855602,3672,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1198,485366,1,2,,90341584,3672,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1199,485367,1,2,,855602,3672,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1200,485368,1,2,,90341584,3672,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1201,488745,1,4,,85231082,3672,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1202,488752,1,4,,85231082,3672,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1203,488772,1,1,,90341584,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1204,488773,1,2,,90341584,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1205,488806,1,2,,855602,3672,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1206,488816,1,1,,90341584,3672,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1207,488837,1,1,,855602,3672,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1208,488837,1,1,,90341584,3672,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1209,488839,1,1,,56422436,3672,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1210,488839,1,1,,56422436,3672,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1211,488847,1,3,,56422436,3672,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1212,488862,1,1,,56422436,3672,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1213,488890,1,2,,56422436,3672,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1214,488895,1,2,,56422436,3672,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1215,488896,1,1,,56422436,3672,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1216,488899,1,1,,56422436,3672,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1217,488922,1,2,,855602,3672,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1218,488949,1,2,,85231082,3672,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1219,488949,1,2,,90341584,3672,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1220,488953,1,1,,90341584,3672,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1221,488965,1,2,,56422436,3672,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1222,488966,1,1,,56422436,3672,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1223,488975,1,2,,56422436,3672,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1224,488977,1,2,,56422436,3672,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1225,488978,1,1,,90341584,3672,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1226,488979,1,1,,50105276,3672,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1227,488980,1,1,,85231082,3672,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1228,488981,1,1,,90341584,3672,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1229,488982,1,1,,90341584,3672,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1230,488983,1,1,,90341584,3672,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1231,489030,2,1,,855602,3672,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1232,489031,2,1,,855602,3672,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1233,490307,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 1 hr before carrageenan challenge measured after 1 hr relative to control",Other,20399543.0,
1234,490308,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 2 hrs before carrageenan challenge measured after 1 hr relative to control",Other,20399543.0,
1235,490309,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 3 hrs before carrageenan challenge measured after 1 hr relative to control",Other,20399543.0,
1236,490310,3,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 4 hrs before carrageenan challenge measured after 1 hr relative to control",Other,20399543.0,
1237,492858,8,5,,103174500,3672,Unspecified,3915797.0,5743.0,80.0,IC50,Inhibition of human recombinant COX2 after 5 mins,Confirmatory,20503989.0,
1238,492859,8,5,,103174500,3672,Active,754286265.0,443551.0,12.0,IC50,Inhibition of ovine COX1 after 5 mins,Confirmatory,20503989.0,
1239,492867,5,2,,103174500,3672,Unspecified,,,200.0,IC50,Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA,Confirmatory,20503989.0,
1240,492947,1,1,,855602,3672,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1241,492953,1,1,,56422436,3672,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1242,492956,1,1,,56422436,3672,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1243,492967,1,2,,99301975,3672,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1244,492972,1,1,,56422436,3672,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1245,493005,1,1,,56422436,3672,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1246,493008,1,1,,56422436,3672,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1247,493008,1,1,,56422436,3672,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1248,493008,1,1,,56422436,3672,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1249,493008,1,1,,56422436,3672,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1250,493011,1,1,,855602,3672,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1251,493012,1,1,,855602,3672,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1252,493014,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1253,493027,1,2,,56422436,3672,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1254,493027,1,2,,56422436,3672,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1255,493033,1,2,,92124039,3672,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1256,493035,1,2,,56422436,3672,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1257,493035,1,2,,56422436,3672,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1258,493036,1,2,,855602,3672,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1259,493056,1,1,,855602,3672,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1260,493084,1,1,,855602,3672,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1261,493087,1,1,,56422436,3672,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1262,493091,1,1,,56422436,3672,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1263,493098,1,1,,56422436,3672,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1264,493106,1,1,,90341584,3672,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1265,493107,1,1,,90341584,3672,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1266,493127,1,1,,50105276,3672,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1267,493131,1,1,,56422436,3672,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1268,493153,1,1,,90341584,3672,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1269,493153,1,1,,90341584,3672,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1270,493160,1,1,,56422436,3672,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1271,493162,1,2,,99301975,3672,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1272,493164,1,2,,90341584,3672,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1273,493164,1,2,,90341584,3672,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1274,493164,1,2,,90341584,3672,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1275,493187,1,2,,56422436,3672,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1276,493189,1,1,,50105276,3672,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1277,493244,1,1,,56422436,3672,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1278,493244,1,1,,56422436,3672,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1279,493244,1,1,,56422436,3672,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1280,493244,1,1,,56422436,3672,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1281,494634,7,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of sheep COX1 by enzyme immunoassay,Confirmatory,20576432.0,
1282,494635,7,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human COX2 by enzyme immunoassay,Confirmatory,20576432.0,
1283,494636,2,3,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for sheep COX1 to IC50 for human COX2",Other,20576432.0,
1284,494637,5,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,20576432.0,
1285,494989,2,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po after 4 hrs",Other,20643545.0,
1286,494990,2,3,,103174500,3672,Unspecified,,,,,Analgesic activity in po dosed mouse assessed as decrease in tail flick tendency after 4 hrs by tail flick test,Other,20643545.0,
1287,494992,2,3,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in rat assessed as ulcerogenic index at 210 mg/kg, po",Other,20643545.0,
1288,494994,2,4,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in rat liver assessed as ulcerogenic activity-related malonaldehyde level per 100 mg of tissue at 210 mg/kg, po (RVb = 3.26 nmol)",Other,20643545.0,
1289,494995,4,1,,103174500,3672,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum SGOT level (Rvb = 143.71 +/- 1.1 U/mL),Other,20643545.0,
1290,494996,4,1,,103174500,3672,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum SGPT level (Rvb = 32.46 +/- 0.76 U/mL),Other,20643545.0,
1291,494997,4,1,,103174500,3672,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on serum alkaline phosphatase level (Rvb = 12.17 +/- 0.16 U/mL),Other,20643545.0,
1292,494998,6,1,,103174500,3672,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on total serum protein level (Rvb = 1.72+/- 0.02 g/dl),Other,20643545.0,
1293,494999,6,1,,103174500,3672,Unspecified,,,,,Hepatotoxicity in po dosed rat assessed as effect on total albumin level (Rvb = 1.63 +/- 0.02 g/dl),Other,20643545.0,
1294,496817,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
1295,496818,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
1296,496819,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
1297,496820,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
1298,496821,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
1299,496823,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
1300,496824,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1301,496825,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
1302,496826,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
1303,496827,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
1304,496828,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
1305,496829,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
1306,496830,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
1307,496831,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1308,496832,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
1309,497005,4,2,,103174500,3672,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1310,504326,1,2,,56422436,3672,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1311,504326,1,2,,56422436,3672,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1312,504327,1,1,,855602,3672,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1313,504327,1,1,,90341584,3672,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1314,504329,1,1,,56422436,3672,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1315,504332,1,1,,855602,3672,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1316,504332,1,1,,50105276,3672,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1317,504332,1,1,,90341584,3672,Inactive,168985070.0,,1.3371,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1318,504333,1,1,,855602,3672,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1319,504339,1,1,,56422436,3672,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1320,504357,1,1,,56422436,3672,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1321,504357,1,1,,56422436,3672,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1322,504364,1,1,,85231082,3672,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1323,504406,1,1,,56422436,3672,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1324,504408,2,1,,855602,3672,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1325,504411,1,1,,56422436,3672,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1326,504414,1,1,,56422436,3672,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1327,504414,1,1,,56422436,3672,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1328,504423,1,1,,56422436,3672,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1329,504441,1,1,,56422436,3672,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1330,504444,1,1,,56422436,3672,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1331,504454,1,3,,56422436,3672,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1332,504459,1,3,,855602,3672,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1333,504462,1,1,,56422436,3672,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1334,504466,1,1,,855602,3672,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1335,504467,1,1,,855602,3672,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1336,504490,1,2,,56422436,3672,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1337,504523,1,1,,56422436,3672,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1338,504523,1,1,,56422436,3672,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1339,504536,1,1,,90341584,3672,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1340,504541,1,1,,855602,3672,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1341,504547,1,1,,90341584,3672,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1342,504548,1,2,,90341584,3672,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1343,504558,1,1,,56422436,3672,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1344,504577,2,2,,56422436,3672,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1345,504582,2,1,,56422436,3672,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1346,504594,1,1,,56422436,3672,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1347,504600,1,2,,855602,3672,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1348,504621,1,1,,56422436,3672,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1349,504634,1,1,,56422436,3672,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1350,504648,1,1,,56422436,3672,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1351,504651,1,1,,855602,3672,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1352,504652,1,1,,855602,3672,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1353,504660,1,1,,855602,3672,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1354,504690,1,3,,56422436,3672,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1355,504692,2,2,,56422436,3672,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1356,504700,1,1,,56422436,3672,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1357,504700,1,1,,56422436,3672,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1358,504706,1,1,,855602,3672,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1359,504707,1,1,,56422436,3672,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1360,504707,1,1,,56422436,3672,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1361,504720,1,1,,56422436,3672,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1362,504734,1,1,,56422436,3672,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1363,504749,1,3,,26752326,3672,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1364,504749,1,3,,104171175,3672,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1365,504749,1,3,1.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1366,504749,1,3,2.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1367,504749,1,3,3.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1368,504749,1,3,4.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1369,504749,1,3,5.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1370,504749,1,3,6.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1371,504749,1,3,7.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1372,504749,1,3,8.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1373,504749,1,3,9.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1374,504749,1,3,10.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1375,504749,1,3,11.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1376,504749,1,3,12.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1377,504749,1,3,13.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1378,504749,1,3,14.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1379,504749,1,3,15.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1380,504749,1,3,16.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1381,504749,1,3,17.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1382,504749,1,3,18.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1383,504749,1,3,19.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1384,504749,1,3,20.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1385,504749,1,3,21.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1386,504749,1,3,22.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1387,504749,1,3,23.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1388,504749,1,3,24.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1389,504749,1,3,25.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1390,504749,1,3,26.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1391,504749,1,3,27.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1392,504749,1,3,28.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1393,504749,1,3,29.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1394,504749,1,3,30.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1395,504749,1,3,31.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1396,504749,1,3,32.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1397,504749,1,3,33.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1398,504749,1,3,34.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1399,504749,1,3,35.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1400,504749,1,3,36.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1401,504749,1,3,37.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1402,504749,1,3,38.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1403,504749,1,3,39.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1404,504749,1,3,40.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1405,504749,1,3,41.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1406,504749,1,3,42.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1407,504749,1,3,43.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1408,504749,1,3,44.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1409,504749,1,3,45.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1410,504749,1,3,46.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1411,504749,1,3,47.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1412,504749,1,3,48.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1413,504749,1,3,49.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1414,504749,1,3,50.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1415,504749,1,3,51.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1416,504749,1,3,52.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1417,504749,1,3,53.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1418,504749,1,3,54.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1419,504749,1,3,55.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1420,504749,1,3,56.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1421,504749,1,3,57.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1422,504749,1,3,58.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1423,504749,1,3,59.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1424,504749,1,3,60.0,104171175,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1425,504749,1,3,61.0,26752326,3672,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1426,504766,2,1,,56422436,3672,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1427,504770,1,2,,92124039,3672,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1428,504775,1,1,,56422436,3672,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1429,504803,1,1,,56422436,3672,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1430,504810,1,2,,855602,3672,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1431,504810,1,2,,90341584,3672,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1432,504812,1,2,,855602,3672,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1433,504812,1,2,,90341584,3672,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1434,504821,1,1,,85231082,3672,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1435,504832,1,1,,855602,3672,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1436,504832,1,1,,104171175,3672,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1437,504834,1,1,,855602,3672,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1438,504834,1,1,,104171175,3672,Inactive,,,21.3313,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1439,504836,1,2,,90341584,3672,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1440,504842,1,1,,855602,3672,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1441,504845,1,1,,56422436,3672,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1442,504845,1,1,,90341584,3672,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1443,504847,1,1,,56422436,3672,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1444,504847,1,1,,90341584,3672,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1445,504847,1,1,,104171175,3672,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1446,504865,1,1,,90341584,3672,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1447,504865,1,1,,104171175,3672,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1448,504884,1,2,,56422436,3672,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1449,504891,1,1,,56422436,3672,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1450,504894,1,1,,56422436,3672,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1451,504937,1,2,,56422436,3672,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1452,521220,3,3,,103174500,3672,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1453,527147,4,2,,103174500,3672,Active,,,27.53,IC50,Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins,Confirmatory,20839880.0,
1454,536420,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 5 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1455,536421,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 24 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1456,536422,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 4 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1457,536423,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 2 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1458,536424,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, ip after 0.5 hrs relative to control",Other,20813431.0,
1459,536425,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 1 hr before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1460,536427,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 3 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1461,536428,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, po administered 3 hrs before xylene challenge measured after 3 hrs post dose",Other,20813431.0,
1462,539464,4,2,,103174500,3672,Unspecified,,,,,Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis,Other,21055935.0,
1463,539469,6,1,,103174500,3672,Unspecified,,,,,Solubility of the compound in PBS at pH 7.4,Other,21055935.0,
1464,540209,4,3,,103174500,3672,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1465,540210,4,3,,103174500,3672,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1466,540211,2,5,,103174500,3672,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1467,540212,4,3,,103174500,3672,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1468,540213,4,3,,103174500,3672,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1469,540253,1,1,,56422436,3672,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1470,540253,1,1,,56422436,3672,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1471,540253,1,1,,56422436,3672,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1472,540256,1,2,,855602,3672,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1473,540256,1,2,,50105276,3672,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1474,540256,1,2,,90341584,3672,Inconclusive,,,20.5878,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1475,540263,1,1,,56422436,3672,Inconclusive,5031833.0,10073.0,125.89299999999999,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1476,540263,1,1,,56422436,3672,Inconclusive,19923142.0,3837.0,125.89299999999999,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1477,540267,1,1,,56422436,3672,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1478,540275,1,1,,855602,3672,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1479,540276,1,2,,855602,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1480,540276,1,2,,26747223,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1481,540276,1,2,,26747224,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1482,540276,1,2,,26752326,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1483,540276,1,2,,50105276,3672,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1484,540276,1,2,,50105277,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1485,540276,1,2,,50105278,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1486,540276,1,2,,56422436,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1487,540276,1,2,,85231082,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1488,540276,1,2,,90341584,3672,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1489,540276,1,2,,104171175,3672,Inconclusive,420597.0,,3.6626,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1490,540277,1,1,,855602,3672,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1491,540295,1,1,,56422436,3672,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1492,540299,1,2,,92124039,3672,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1493,540303,1,1,,56422436,3672,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1494,540303,1,1,,56422436,3672,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1495,540303,1,1,,56422436,3672,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1496,540308,1,1,,56422436,3672,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1497,540317,1,1,,56422436,3672,Inactive,187960037.0,10951.0,100.0,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1498,540336,1,1,,56422436,3672,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1499,540336,1,1,,56422436,3672,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1500,540364,1,2,,56422436,3672,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1501,567091,2,6,,103174500,3672,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
1502,587448,7,5,,103174500,3672,Active,754286265.0,443551.0,4.0,IC50,Inhibition of ovine COX-1,Confirmatory,21280601.0,
1503,587449,7,5,,103174500,3672,Active,3915797.0,5743.0,1.4,IC50,Inhibition of human recombinant COX-2,Confirmatory,21280601.0,
1504,587450,1,5,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,21280601.0,
1505,587451,5,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed Sprague-Dawley rat assessed as inhibition of carrageenam-induced paw edema administered 1 hr before carrageenan challenge measured after 3 hrs by Plethysmometer,Other,21280601.0,
1506,587694,2,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling weight at 100 mg, ip administered 2 hrs post challenge measured after 30 mins",Other,21295381.0,
1507,587695,2,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling thickness at 100 mg, ip administered 2 hrs post challenge measured after 30 mins",Other,21295381.0,
1508,588209,2,3,,103174500,3672,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1509,588210,2,4,,103174500,3672,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1510,588211,2,3,,103174500,3672,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1511,588212,2,3,,103174500,3672,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1512,588213,2,3,,103174500,3672,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1513,588214,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1514,588215,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1515,588216,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1516,588217,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1517,588218,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1518,588219,2,3,,103174500,3672,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1519,588334,1,1,,56422436,3672,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1520,588335,1,1,,56422436,3672,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1521,588342,1,1,,855602,3672,Inconclusive,160794.0,,21.3313,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1522,588349,1,1,,90341584,3672,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1523,588352,1,2,,56422436,3672,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1524,588354,1,1,,56422436,3672,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1525,588358,1,2,,56422436,3672,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1526,588368,1,2,,855602,3672,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
1527,588378,1,1,,90341584,3672,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1528,588391,1,1,,56422436,3672,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1529,588405,1,1,,56422436,3672,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1530,588413,1,2,,56422436,3672,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1531,588436,1,1,,56422436,3672,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1532,588453,1,1,,56422436,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1533,588453,1,1,,85231082,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1534,588453,1,1,,90341584,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1535,588456,1,1,,56422436,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1536,588456,1,1,,90341584,3672,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1537,588458,1,1,,56422436,3672,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1538,588459,1,2,,855602,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
1539,588459,1,2,,855602,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
1540,588459,1,2,,855602,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
1541,588460,1,2,,855602,3672,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
1542,588460,1,2,,855602,3672,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
1543,588460,1,2,,855602,3672,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
1544,588461,1,2,,855602,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
1545,588461,1,2,,855602,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
1546,588461,1,2,,855602,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
1547,588473,1,1,,56422436,3672,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1548,588473,1,1,,56422436,3672,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1549,588475,1,2,,56422436,3672,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1550,588475,1,2,,56422436,3672,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1551,588478,1,2,,124799572,3672,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1552,588489,1,1,,56422436,3672,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1553,588492,1,1,,56422436,3672,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1554,588493,1,2,,56422436,3672,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1555,588497,1,2,,56422436,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1556,588497,1,2,,56422436,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1557,588497,1,2,,56422436,3672,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1558,588499,1,3,,56422436,3672,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1559,588499,1,3,,56422436,3672,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1560,588499,1,3,,56422436,3672,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1561,588501,1,2,,56422436,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1562,588501,1,2,,56422436,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1563,588501,1,2,,56422436,3672,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1564,588506,1,2,,855602,3672,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
1565,588511,1,2,,56422436,3672,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1566,588513,1,1,,26752326,3672,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1567,588514,1,1,,26752326,3672,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1568,588515,1,1,,26752326,3672,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1569,588516,1,1,,26752326,3672,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1570,588519,1,2,,92124039,3672,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1571,588526,1,1,,26752326,3672,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1572,588527,1,1,,26752326,3672,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1573,588532,1,1,,26752326,3672,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1574,588533,1,1,,26752326,3672,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1575,588534,1,1,,26752326,3672,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1576,588535,1,1,,26752326,3672,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1577,588536,1,1,,26752326,3672,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1578,588537,1,1,,26752326,3672,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1579,588541,1,1,,26752326,3672,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1580,588543,1,1,,26752326,3672,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1581,588544,1,1,,26752326,3672,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1582,588545,1,1,,26752326,3672,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1583,588546,1,1,,26752326,3672,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1584,588547,1,1,,26752326,3672,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1585,588549,1,1,,56422436,3672,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1586,588550,1,1,,855602,3672,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
1587,588579,1,1,,56422436,3672,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1588,588579,1,1,,90341584,3672,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1589,588579,1,1,,104171175,3672,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1590,588579,1,1,,124880372,3672,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1591,588579,1,1,,124880375,3672,Inactive,7705344.0,51426.0,15.003,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1592,588590,1,1,,50105276,3672,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1593,588590,1,1,,56422436,3672,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1594,588591,1,1,,50105276,3672,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1595,588591,1,1,,56422436,3672,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1596,588621,1,1,,56422436,3672,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1597,588627,1,1,,56422436,3672,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1598,588664,1,2,,56422436,3672,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1599,588664,1,2,,56422436,3672,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1600,588674,1,2,,56422436,3672,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1601,588675,1,1,,56422436,3672,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1602,588676,1,1,,56422436,3672,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1603,588685,1,1,,855602,3672,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
1604,588689,1,1,,56422436,3672,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1605,588692,2,1,,56422436,3672,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1606,588726,1,2,,56422436,3672,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1607,588727,1,1,,56422436,3672,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1608,588795,1,1,,56422436,3672,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1609,588795,1,1,,90341584,3672,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1610,588814,1,3,,56422436,3672,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1611,588819,1,4,,56422436,3672,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1612,588834,2,1,,26752326,3672,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1613,588834,2,1,,50105276,3672,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1614,588850,1,1,,56422436,3672,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1615,588852,1,3,,56422436,3672,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1616,588855,1,1,,56422436,3672,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1617,588856,1,1,,56422436,3672,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1618,589069,1,10,,103174500,3672,Unspecified,549152.0,54659.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A3,Other,,
1619,589071,1,10,,103174500,3672,Unspecified,29840832.0,54578.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A6,Other,,
1620,589074,1,10,,103174500,3672,Unspecified,29839451.0,54600.0,,,Substrate of human UDP-glucuronosyltransferase UGT1A9,Other,,
1621,589076,1,10,,103174500,3672,Unspecified,296452854.0,10941.0,,,Substrate of human UDP-glucuronosyltransferase UGT2A1,Other,,
1622,589078,1,10,,103174500,3672,Unspecified,136727.0,7364.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B7,Other,,
1623,589081,1,10,,103174500,3672,Unspecified,6136104.0,7367.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B17,Other,,
1624,592681,1,4,,103174500,3672,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
1625,602123,1,1,,56422436,3672,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1626,602141,1,1,,56422436,3672,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1627,602162,1,1,,56422436,3672,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1628,602163,1,1,,56422436,3672,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1629,602179,1,2,,56422436,3672,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1630,602229,1,1,,56422436,3672,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1631,602233,1,1,,56422436,3672,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1632,602244,1,2,,56422436,3672,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1633,602247,1,2,,56422436,3672,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1634,602248,1,2,,56422436,3672,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1635,602250,1,2,,56422436,3672,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1636,602252,1,1,,56422436,3672,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1637,602252,1,1,,56422436,3672,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1638,602261,1,1,,56422436,3672,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1639,602274,1,2,,56422436,3672,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1640,602276,1,1,,855602,3672,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
1641,602277,1,1,,855602,3672,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
1642,602281,1,1,,56422436,3672,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1643,602281,1,1,,56422436,3672,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1644,602310,1,2,,56422436,3672,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1645,602313,1,1,,56422436,3672,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1646,602314,1,2,,92124039,3672,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1647,602329,1,1,,56422436,3672,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1648,602332,1,1,,56422436,3672,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1649,602332,1,1,,90341584,3672,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1650,602332,1,1,,104171175,3672,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1651,602332,1,1,,124880372,3672,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1652,602332,1,1,,124880375,3672,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1653,602340,1,2,,56422436,3672,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1654,602342,2,1,,56422436,3672,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1655,602346,1,1,,56422436,3672,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1656,602363,1,1,,56422436,3672,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1657,602393,1,1,,56422436,3672,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1658,602396,1,2,,56422436,3672,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1659,602399,1,2,,56422436,3672,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1660,602405,1,1,,56422436,3672,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1661,602410,1,1,,56422436,3672,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1662,602429,1,1,,56422436,3672,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1663,602438,1,1,,56422436,3672,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1664,602440,1,1,,56422436,3672,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1665,602449,1,2,,56422436,3672,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1666,602481,1,1,,56422436,3672,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1667,603428,6,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,21641217.0,
1668,603429,6,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2 by enzyme immuno assay,Confirmatory,21641217.0,
1669,603504,4,2,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced foot paw edema after 3 hrs,Other,21641217.0,
1670,604300,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr relative to control",Other,21689936.0,
1671,604301,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs relative to control",Other,21689936.0,
1672,604302,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,21689936.0,
1673,604303,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced paw edema in rat at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs relative to control",Other,21689936.0,
1674,604741,1,9,,103174500,3672,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1675,604742,1,9,,103174500,3672,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1676,604743,1,9,,103174500,3672,Unspecified,113576.0,213.0,,,Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1677,604744,1,9,,103174500,3672,Unspecified,113576.0,213.0,,,Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy,Other,20869876.0,
1678,608534,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in male Sprague-Dawley rat assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 1 hr post carrageenan challenge relative to control",Other,21549457.0,
1679,608535,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 2 hrs post carrageenan challenge relative to control",Other,21549457.0,
1680,608536,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 3 hrs post carrageenan challenge relative to control",Other,21549457.0,
1681,608537,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 4 hrs post carrageenan challenge relative to control",Other,21549457.0,
1682,609263,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in albino rat assessed as inhibition of carrageenin-induced paw oedema at 100 mg/kg, po after 3 hrs by plethysmographic analysis relative to control",Other,21723119.0,
1683,614597,3,2,,103174500,3672,Unspecified,,,200.0,IC50,Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA,Confirmatory,21873070.0,
1684,614601,6,5,,103174500,3672,Active,754286265.0,443551.0,12.0,IC50,Inhibition of ovine COX-1 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis,Confirmatory,21873070.0,
1685,614602,6,5,,103174500,3672,Unspecified,3915797.0,5743.0,80.0,IC50,Inhibition of human recombinant COX-2 assessed as residual activity by measuring formation of 12-HHT from arachidonic acid by HPLC analysis,Confirmatory,21873070.0,
1686,622470,4,3,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced hind paw edema measured after 3 hrs post dose,Other,21890358.0,
1687,622472,1,5,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for ovine COX2",Other,21890358.0,
1688,622474,6,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1 by enzyme immuno assay,Confirmatory,21890358.0,
1689,622556,6,5,,103174500,3672,Active,3914304.0,443460.0,1.1,IC50,Inhibition of ovine COX2 by enzyme immuno assay,Confirmatory,21890358.0,
1690,623870,1,1,,56422436,3672,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1691,623870,1,1,,56422436,3672,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1692,623877,1,1,,56422436,3672,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1693,623901,1,1,,56422436,3672,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1694,624030,1,2,,104171175,3672,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1695,624031,1,2,,104171175,3672,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1696,624032,1,2,,104171175,3672,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1697,624037,1,3,,56422436,3672,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1698,624038,1,3,,56422436,3672,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1699,624040,1,3,,56422436,3672,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1700,624044,1,2,,104171175,3672,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1701,624101,1,2,,85789193,3672,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1702,624125,1,4,,56422436,3672,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1703,624126,1,3,,56422436,3672,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1704,624127,1,2,,56422436,3672,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1705,624137,1,1,,85789193,3672,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1706,624146,1,1,,90341584,3672,Inactive,71051501.0,2744.0,35.4813,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1707,624147,1,1,,90341584,3672,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1708,624148,1,2,,90341584,3672,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1709,624149,1,1,,90341584,3672,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1710,624156,1,1,,85789193,3672,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1711,624168,1,1,,56422436,3672,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1712,624169,1,1,,56422436,3672,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1713,624170,1,1,,56422436,3672,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1714,624170,1,1,,104171175,3672,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1715,624171,1,1,,56422436,3672,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1716,624172,1,1,,56422436,3672,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1717,624172,1,1,,104171175,3672,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1718,624173,1,3,,56422436,3672,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1719,624173,1,3,,104171175,3672,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1720,624178,1,1,,56422436,3672,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1721,624202,1,1,,56422436,3672,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1722,624204,1,2,,56422436,3672,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1723,624246,1,1,,56422436,3672,Inconclusive,343478176.0,2078.0,11.2202,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1724,624256,1,2,,56422436,3672,Active,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1725,624260,1,1,,85789193,3672,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1726,624263,1,1,,56422436,3672,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1727,624263,1,1,,56422436,3672,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1728,624267,1,2,,56422436,3672,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1729,624267,1,2,,56422436,3672,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1730,624268,1,3,,56422436,3672,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1731,624288,1,1,,56422436,3672,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1732,624296,1,1,,855602,3672,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1733,624296,1,1,,56422436,3672,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1734,624296,1,1,,104171175,3672,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1735,624297,1,1,,855602,3672,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1736,624297,1,1,,56422436,3672,Inactive,7705682.0,51053.0,1.2589,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1737,624297,1,1,,104171175,3672,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1738,624304,1,2,,56422436,3672,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1739,624330,1,2,,56422436,3672,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1740,624349,1,2,,92124039,3672,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1741,624349,1,2,,92307453,3672,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1742,624349,1,2,,92308981,3672,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1743,624349,1,2,,121362465,3672,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1744,624352,1,1,,56422436,3672,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1745,624354,1,1,,56422436,3672,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1746,624377,1,1,,855602,3672,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1747,624414,1,1,,56422436,3672,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1748,624415,1,2,,56422436,3672,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1749,624416,1,1,,855602,3672,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1750,624417,1,1,,56422436,3672,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1751,624418,1,1,,56422436,3672,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1752,624455,1,1,,90341584,3672,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1753,624463,1,1,,56422436,3672,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1754,624464,1,1,,56422436,3672,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1755,624465,1,1,,56422436,3672,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1756,624466,1,3,,855602,3672,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1757,624467,1,1,,855602,3672,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1758,624483,1,1,,56422436,3672,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1759,624606,1,9,,103174500,3672,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
1760,624608,3,2,,103174500,3672,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
1761,624610,1,9,,103174500,3672,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
1762,624611,1,9,,103174500,3672,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
1763,624612,1,9,,103174500,3672,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
1764,624613,1,9,,103174500,3672,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
1765,624614,1,8,,103174500,3672,Unspecified,296452854.0,10941.0,,,Specific activity of expressed human recombinant UGT2A1,Other,10836148.0,
1766,624615,1,8,,103174500,3672,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
1767,624618,3,2,,103174500,3672,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
1768,624619,3,2,,103174500,3672,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
1769,624632,3,7,,103174500,3672,Unspecified,549152.0,54659.0,230.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT1A3,Confirmatory,15781124.0,
1770,624640,3,7,,103174500,3672,Unspecified,136727.0,7364.0,55.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT2B7,Confirmatory,15781124.0,
1771,625144,5,5,,103174500,3672,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1772,625145,4,7,,103174500,3672,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1773,625146,5,5,,103174500,3672,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1774,625147,4,7,,103174500,3672,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1775,625148,4,7,,103174500,3672,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1776,625149,4,7,,103174500,3672,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1777,625150,5,5,,103174500,3672,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1778,625151,4,7,,103174500,3672,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1779,625152,4,7,,103174500,3672,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1780,625153,4,7,,103174500,3672,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1781,625154,4,7,,103174500,3672,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1782,625155,4,7,,103174500,3672,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1783,625156,1,9,,103174500,3672,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1784,625157,6,2,,103174500,3672,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1785,625158,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1786,625159,5,5,,103174500,3672,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1787,625160,1,9,,103174500,3672,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1788,625161,4,7,,103174500,3672,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1789,625162,4,7,,103174500,3672,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1790,625163,4,7,,103174500,3672,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1791,625164,1,6,,103174500,3672,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1792,625165,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1793,625166,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1794,625167,5,5,,103174500,3672,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1795,625168,4,7,,103174500,3672,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1796,625169,1,6,,103174500,3672,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1797,625170,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1798,625171,4,7,,103174500,3672,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1799,625172,4,7,,103174500,3672,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1800,625173,5,5,,103174500,3672,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1801,625174,5,5,,103174500,3672,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1802,625175,5,5,,103174500,3672,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1803,625176,1,9,,103174500,3672,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1804,625177,5,5,,103174500,3672,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1805,625178,5,5,,103174500,3672,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1806,625179,1,9,,103174500,3672,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1807,625180,5,5,,103174500,3672,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1808,625181,5,5,,103174500,3672,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1809,625182,5,5,,103174500,3672,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1810,625183,5,5,,103174500,3672,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1811,625184,5,5,,103174500,3672,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1812,625185,5,5,,103174500,3672,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1813,625186,5,5,,103174500,3672,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1814,625187,5,5,,103174500,3672,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1815,625188,1,9,,103174500,3672,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1816,625189,1,7,,103174500,3672,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1817,625190,4,5,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1818,625191,4,7,,103174500,3672,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1819,625192,4,7,,103174500,3672,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1820,625193,5,5,,103174500,3672,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1821,625194,4,7,,103174500,3672,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1822,625195,4,7,,103174500,3672,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1823,625196,5,6,,103174500,3672,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1824,625197,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1825,625198,4,7,,103174500,3672,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1826,625199,4,7,,103174500,3672,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1827,625200,4,7,,103174500,3672,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1828,625201,4,7,,103174500,3672,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1829,625202,4,7,,103174500,3672,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1830,625203,4,7,,103174500,3672,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1831,625204,4,7,,103174500,3672,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1832,625205,4,7,,103174500,3672,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1833,625206,4,7,,103174500,3672,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1834,625207,4,7,,103174500,3672,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1835,625208,5,5,,103174500,3672,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1836,625209,4,7,,103174500,3672,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1837,625210,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1838,625211,1,6,,103174500,3672,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1839,625212,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1840,625213,4,7,,103174500,3672,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1841,625214,1,9,,103174500,3672,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1842,625215,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1843,625216,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1844,625217,4,7,,103174500,3672,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1845,625218,4,7,,103174500,3672,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1846,625219,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1847,625220,4,7,,103174500,3672,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1848,625221,4,7,,103174500,3672,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1849,625222,4,7,,103174500,3672,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1850,625223,4,7,,103174500,3672,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1851,625224,3,4,,103174500,3672,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1852,625225,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1853,625226,4,7,,103174500,3672,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1854,625227,4,7,,103174500,3672,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1855,625228,4,7,,103174500,3672,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1856,625229,5,5,,103174500,3672,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1857,625230,1,6,,103174500,3672,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1858,625231,4,7,,103174500,3672,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1859,625232,1,9,,103174500,3672,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1860,625233,4,7,,103174500,3672,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1861,625234,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1862,625235,4,7,,103174500,3672,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1863,625236,5,5,,103174500,3672,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1864,625237,4,7,,103174500,3672,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1865,625238,4,7,,103174500,3672,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1866,625239,4,7,,103174500,3672,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1867,625240,1,9,,103174500,3672,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1868,625241,4,7,,103174500,3672,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1869,625242,4,7,,103174500,3672,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1870,625243,5,5,,103174500,3672,Active,317373262.0,5742.0,0.212,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1871,625244,5,5,,103174500,3672,Active,3915797.0,5743.0,25.53,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1872,625245,5,5,,103174500,3672,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1873,625246,1,9,,103174500,3672,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1874,625247,5,5,,103174500,3672,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1875,625248,5,5,,103174500,3672,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1876,625249,5,5,,103174500,3672,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1877,625250,5,5,,103174500,3672,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1878,625251,5,5,,103174500,3672,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1879,625252,4,7,,103174500,3672,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1880,625253,4,7,,103174500,3672,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1881,625254,4,7,,103174500,3672,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1882,625255,4,7,,103174500,3672,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1883,625256,4,7,,103174500,3672,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1884,625257,4,7,,103174500,3672,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1885,625258,4,7,,103174500,3672,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1886,625259,4,7,,103174500,3672,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1887,625260,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1888,625261,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1889,625262,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1890,625263,4,7,,103174500,3672,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1891,625264,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1892,625265,1,6,,103174500,3672,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1893,625266,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1894,625267,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1895,625268,4,2,,103174500,3672,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1896,625268,4,2,,103174500,3672,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1897,625268,4,2,,103174500,3672,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1898,625268,4,2,,103174500,3672,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1899,625269,4,7,,103174500,3672,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1900,625270,4,7,,103174500,3672,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1901,625271,5,5,,103174500,3672,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1902,625272,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1903,625273,4,6,,103174500,3672,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1904,625274,1,6,,103174500,3672,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1905,625275,3,4,,103174500,3672,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1906,625277,1,3,,103174500,3672,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1907,625279,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1908,625280,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1909,625281,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1910,625282,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1911,625283,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1912,625284,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1913,625285,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1914,625286,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1915,625287,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1916,625288,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1917,625289,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1918,625290,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1919,625291,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1920,625292,1,3,,103174500,3672,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1921,630888,1,3,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in Wister albino mouse assessed as inhibition of carrageenan-induced edema after 3 hrs relative to control,Other,21937153.0,
1922,630889,1,3,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in Wister albino mouse assessed as inhibition of carrageenan-induced edema after 2 hrs relative to control,Other,21937153.0,
1923,640200,1,3,,103174500,3672,Active,,,,,"Antinociceptive activity in po dosed mouse assessed as time of latency at 100 mg/kg, po administered 1 hr before hot plate test",Other,22177784.0,
1924,640447,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 4 hrs (Rvb = 78.14 +/- 7.1 %)",Other,22225915.0,
1925,640448,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of jumping as nociceptive response at 250 mg/kg, po after 0.5 hrs by hot plate test (Rvb = 11.16 +/- 1.66 sec)",Other,22225915.0,
1926,640449,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of jumping as nociceptive response at 250 mg/kg, po after 1 hr by hot plate test (Rvb = 14.3 +/- 0.99 sec)",Other,22225915.0,
1927,640450,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of jumping as nociceptive response at 250 mg/kg, po after 1.5 hrs by hot plate test (Rvb = 16.8 +/- 2.12 sec)",Other,22225915.0,
1928,640451,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenic activity in fasted Wistar albino rat assessed as ulcer index at 100 mg/kg, po after 5 hrs",Other,22225915.0,
1929,640452,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenic activity in fasted Wistar albino rat assessed as severity of ulcer at 100 mg/kg, po after 5 hrs",Other,22225915.0,
1930,640453,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of paw licking as nociceptive response at 250 mg/kg, po after 0.5 hrs by hot plate test (Rvb = 11.16 +/- 1.66 sec)",Other,22225915.0,
1931,640454,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of paw licking as nociceptive response at 250 mg/kg, po after 1 hr by hot plate test (Rvb = 14.3 +/- 0.99 sec)",Other,22225915.0,
1932,640455,1,3,,103174500,3672,Unspecified,,,,,"Analgesic activity in mouse assessed as latency time of paw licking as nociceptive response at 250 mg/kg, po after 1.5 hrs by hot plate test (Rvb = 16.8 +/- 2.12 sec)",Other,22225915.0,
1933,641266,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 1 hr (Rvb = 55.7 +/- 67.84 %)",Other,22225915.0,
1934,641267,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 2 hrs (Rvb = 68.6 +/- 7.14 %)",Other,22225915.0,
1935,641268,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 3 hrs (Rvb = 74.63 +/- 7.13 %)",Other,22225915.0,
1936,644728,1,3,,103174500,3672,Active,,,,,"Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 30 mins before to acetic acid challenge measured for 20 mins relative to control",Other,22305614.0,
1937,644729,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs by plethysmometer",Other,22305614.0,
1938,644730,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs by plethysmometer",Other,22305614.0,
1939,644731,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenicity in Albino Wistar rat assessed as gastric ulceration at 30 mg/kg, po relative to untreated control",Other,22305614.0,
1940,644732,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenicity in mouse assessed as gastric ulceration at 30 mg/kg, po relative to untreated control",Other,22305614.0,
1941,648861,5,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1,Confirmatory,22148253.0,
1942,648862,5,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2,Confirmatory,22148253.0,
1943,648866,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 0.32 mmol/kg, po after 3 hrs relative to control",Other,22148253.0,
1944,648867,4,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema after 3 hrs,Other,22148253.0,
1945,648869,1,3,,103174500,3672,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,22148253.0,
1946,648871,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenic effect in rat assessed as gastric ulcer overall length at 1.4 mmol/kg, po administered for 6 hrs",Other,22148253.0,
1947,648873,1,3,,103174500,3672,Unspecified,,,,,Selectivity ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2,Other,22148253.0,
1948,651550,1,1,,56422436,3672,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1949,651560,1,1,,56422436,3672,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1950,651572,1,2,,855602,3672,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1951,651582,1,1,,56422436,3672,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1952,651602,1,1,,855602,3672,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1953,651602,1,1,,855602,3672,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1954,651602,1,1,,855602,3672,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1955,651610,2,1,,855602,3672,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1956,651631,4,1,,144203721,3672,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1957,651631,4,1,,144208582,3672,Inconclusive,269849759.0,7157.0,78.1343,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1958,651631,4,1,,144213146,3672,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1959,651632,4,1,,144203721,3672,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1960,651632,4,1,,144208582,3672,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1961,651632,4,1,,144213146,3672,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1962,651633,4,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1963,651633,4,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1964,651633,4,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1965,651634,4,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1966,651634,4,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1967,651634,4,1,,144213146,3672,Inactive,,,17.2289,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1968,651635,1,3,,56422436,3672,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1969,651635,1,3,,90341584,3672,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1970,651636,1,1,,56422436,3672,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1971,651640,1,1,,855602,3672,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1972,651644,1,1,,56422436,3672,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1973,651647,1,1,,56422436,3672,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1974,651654,1,1,,56422436,3672,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1975,651658,1,1,,855602,3672,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1976,651660,1,1,,855602,3672,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1977,651661,2,1,,855602,3672,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1978,651699,1,1,,56422436,3672,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1979,651699,1,1,,56422436,3672,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1980,651702,1,2,,56422436,3672,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1981,651704,2,1,,855602,3672,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1982,651710,1,1,,855602,3672,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1983,651711,2,1,,855602,3672,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1984,651718,1,2,,855602,3672,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1985,651724,1,1,,56422436,3672,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1986,651725,1,1,,56422436,3672,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1987,651741,1,1,,144203721,3672,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1988,651743,1,1,,26752326,3672,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1989,651749,1,1,,26752326,3672,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1990,651751,1,1,,26752326,3672,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1991,651768,1,2,,56422436,3672,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1992,651777,1,1,,26752326,3672,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1993,651778,1,1,,26752326,3672,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1994,651800,1,1,,855602,3672,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1995,651803,1,1,,56422436,3672,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: TR assay against cherry picks,Confirmatory,,
1996,651804,1,1,,56422436,3672,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: HTRF assay against cherry picks,Confirmatory,,
1997,651819,1,1,,56422436,3672,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1998,651820,1,1,,855602,3672,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1999,651820,1,1,,56422436,3672,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2000,651821,2,4,,855602,3672,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2001,651828,1,2,,92308981,3672,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2002,651828,1,2,,121361647,3672,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2003,651828,1,2,,121362465,3672,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2004,651838,1,1,,26752326,3672,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2005,651838,1,1,1.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2006,651838,1,1,2.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2007,651838,1,1,3.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2008,651838,1,1,4.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2009,651838,1,1,5.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2010,651838,1,1,6.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2011,651838,1,1,7.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2012,651838,1,1,8.0,26752326,3672,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2013,651957,1,1,,855602,3672,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2014,651958,1,1,,855602,3672,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2015,651965,1,1,,56422436,3672,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2016,651999,1,1,,56422436,3672,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2017,652010,1,1,,855602,3672,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2018,652017,1,1,,855602,3672,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2019,652025,1,1,,56422436,3672,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2020,652039,1,1,,855602,3672,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2021,652048,1,2,,56422436,3672,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2022,652048,1,2,,144203721,3672,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2023,652051,1,1,,56422436,3672,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2024,652051,1,1,,144203721,3672,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2025,652054,1,1,,56422436,3672,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2026,652067,1,4,,855602,3672,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2027,652104,1,1,,56422436,3672,Active,20140568.0,23435.0,11.2202,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2028,652105,1,1,,56422436,3672,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2029,652106,1,1,,56422436,3672,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2030,652106,1,1,,90341584,3672,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2031,652115,1,1,,855602,3672,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2032,652126,1,3,,855602,3672,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2033,652154,1,1,,855602,3672,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2034,652162,2,1,,855602,3672,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2035,652163,1,1,,855602,3672,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2036,652163,1,1,,56422436,3672,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2037,652197,1,1,,855602,3672,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2038,652257,1,1,,855602,3672,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2039,654431,1,3,,103174500,3672,Active,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced hind paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured up to 5 hrs by plethysmometer",Other,22349257.0,
2040,654435,1,3,,103174500,3672,Active,,,,,"Antiarthritic activity in Freund's complete adjuvant-induced Sprague-Dawley rat arthritis model at 50 mg/kg, po administered daily on day 9 to day 19 post challenge",Other,22349257.0,
2041,657248,1,3,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced rat paw oedema at 30 mg/kg, po after 3 hrs",Other,22475926.0,
2042,657249,1,3,,103174500,3672,Unspecified,,,,,"Ulcerogenic activity in rat assessed as ulcer index at 30 mg/kg, po after 6 hrs",Other,22475926.0,
2043,658411,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in overnight fasted Kunming mouse assessed as inhibition of xylene-induced ear swelling at 4 mg/kg, ip administered before challenge for 5 days measured 1 hr post xylene challenge",Other,22450132.0,
2044,658412,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in overnight fasted Kunming mouse assessed as inhibition of xylene-induced ear swelling at 30 mg/kg, ip administered before challenge for 5 days measured 1 hr post xylene challenge",Other,22450132.0,
2045,664053,5,5,,103174500,3672,Active,754286265.0,443551.0,9.0,Ki,Inhibition of sheep placental cotyledons COX1,Confirmatory,22091869.0,
2046,664054,1,7,,103174500,3672,Active,3914304.0,443460.0,,,Reversible binding to sheep placenta COX2 at 300 uM at 600 MHz and 37 degC by saturation transfer difference 1[H]NMR spectroscopy,Other,22091869.0,
2047,664055,1,7,,103174500,3672,Active,754286265.0,443551.0,,,Reversible binding to ram seminal vesicle COX1 at 300 uM at 600 MHz and 37 degC by saturation transfer difference 1[H]NMR spectroscopy,Other,22091869.0,
2048,664056,5,5,,103174500,3672,Active,3914304.0,443460.0,,IC50,Inhibition of sheep placental cotyledons COX2,Confirmatory,22091869.0,
2049,664057,5,5,,103174500,3672,Active,3915797.0,5743.0,1.35,IC50,Inhibition of human COX2 expressed in baculovirus system,Confirmatory,22091869.0,
2050,664060,1,7,,103174500,3672,Inactive,3914304.0,443460.0,,,Inhibition of ibuprofen binding to sheep placenta COX2 at compound/protein ratio of 100:1 where in ibuprofen added previously followed by addition of compound by saturation transfer difference 1[H]NMR spectroscopy,Other,22091869.0,
2051,664061,1,7,,103174500,3672,Inactive,3914304.0,443460.0,,,Inhibition of ibuprofen binding to sheep placenta COX2 at compound/protein ratio of 100:1 where in compound added previously followed by addition of ibuprofen by saturation transfer difference 1[H]NMR spectroscopy,Other,22091869.0,
2052,674769,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 30 mins",Other,22818081.0,
2053,674770,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr",Other,22818081.0,
2054,674771,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs",Other,22818081.0,
2055,674772,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs",Other,22818081.0,
2056,674773,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as protection against carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs",Other,22818081.0,
2057,675627,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced auricle tumefaction at 0.2 mmol/kg, po qd administered prior to challenge for 5 days measured 30 mins post challenge",Other,22901311.0,
2058,675628,1,2,,103174500,3672,Unspecified,,,,,"Ulcerogenic activity in Kunming mouse assessed as ulcer index at 1 mmol/kg, po measured after 4 hrs",Other,22901311.0,
2059,675645,1,2,,103174500,3672,Active,,,,,Prodrug conversion at pH 7.4 assessed as hydrolysis up to 24 hrs by HPLC analysis,Other,22901311.0,
2060,675647,1,2,,103174500,3672,Inactive,,,,,Binding affinity to bone mineral hydroxyapatite after 30 mins by RP-HPLC analysis,Other,22901311.0,
2061,677462,1,2,,103174500,3672,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,22521372.0,
2062,678712,1,8,,103174500,3672,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2063,678713,1,8,,103174500,3672,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2064,678714,1,8,,103174500,3672,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2065,678715,1,8,,103174500,3672,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2066,678716,1,8,,103174500,3672,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2067,678717,1,8,,103174500,3672,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2068,678721,1,5,,103174500,3672,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2069,678722,1,5,,103174500,3672,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2070,678787,3,6,,103174500,3672,Unspecified,81886651.0,29509.0,,IC50,TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes,Confirmatory,11099697.0,
2071,678841,1,8,,103174500,3672,Unspecified,124015184.0,19879.0,,,TP_TRANSPORTER: inhibition of PHA uptake (PHA: 1000uM) in mOat3-expressing oocytes,Other,15100168.0,
2072,679414,1,8,,103174500,3672,Unspecified,313104012.0,11309.0,,,TP_TRANSPORTER: uptake of Ibuprofen at a concentration of 11.3uM in OATP2B1-expressing HEK293 cells,Other,15640378.0,
2073,679493,2,7,,103174500,3672,Unspecified,3914190.0,170698.0,2430.0,Ki,TP_TRANSPORTER: inhibition of Digoxin uptake in Oatp2-expressing LLC-PK1 cells,Confirmatory,11883641.0,
2074,679546,1,8,,103174500,3672,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Ibuprofen: 1000 uM) in OAT1-expressing S2 cells",Other,12130730.0,
2075,679704,1,8,,103174500,3672,Unspecified,27735248.0,80899.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 0.1 uM, Ibuprofen: 1000 uM) in OAT-K1-expressing LLC-PK1 cells",Other,9399974.0,
2076,679830,1,8,,103174500,3672,Unspecified,74762955.0,9356.0,,,TP_TRANSPORTER: uptake in OAT1-expressing CHO cells,Other,10991954.0,
2077,680177,1,7,,103174500,3672,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Ibuprofen: 1000 uM) in OAT4-expressing S2 cells",Other,12130730.0,
2078,680191,1,7,,103174500,3672,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Ibuprofen: 500 uM) in Xenopus laevis oocytes",Other,10660625.0,
2079,681109,1,8,,103174500,3672,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: inhibition of E217betaG in the presence of Ibuprofen at a concentration of 200uM in membrane vesicles from MRP1-expressing Sf9 cells,Other,12835412.0,
2080,681118,1,8,,103174500,3672,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
2081,681141,2,7,,103174500,3672,Unspecified,74730587.0,9376.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11306713.0,
2082,681160,3,6,,103174500,3672,Unspecified,74762955.0,9356.0,8.0,IC50,TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells,Confirmatory,10991954.0,
2083,681340,3,6,,103174500,3672,Unspecified,81886651.0,29509.0,3.5,Ki,TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes,Confirmatory,10220563.0,
2084,681372,3,6,,103174500,3672,Unspecified,74730587.0,9376.0,1170.0,Ki,TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells,Confirmatory,12130730.0,
2085,681929,1,7,,103174500,3672,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of E217betaG in the presence of Ibuprofen at a concentration of 200uM in membrane vesicles from MRP4-expressing Sf9 cells,Other,12835412.0,
2086,682052,2,7,,103174500,3672,Unspecified,1171883.0,50572.0,126.0,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing LLC-PK1 cells,Confirmatory,11883641.0,
2087,682131,1,7,,103174500,3672,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Ibuprofen: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
2088,682446,1,2,,103174500,3672,Unspecified,,,,,"Gastrotoxicity in 24 hrs fasted Wistar rat assessed as ulcer index at 150 mg/kg, po after 6 hrs",Other,22982120.0,
2089,682447,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 5 hrs",Other,22982120.0,
2090,682448,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs",Other,22982120.0,
2091,682449,1,2,,103174500,3672,Unspecified,,,,,"Octanol-buffer partition coefficient, log P of the compound by HPLC analysis",Other,22982120.0,
2092,682454,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr",Other,22982120.0,
2093,682455,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs",Other,22982120.0,
2094,682456,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs",Other,22982120.0,
2095,682457,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 6 hrs",Other,22982120.0,
2096,684463,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 4 mg/kg, ip for 5 days relative to control",Other,22959205.0,
2097,684464,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 30 mg/kg, ip for 5 days relative to control",Other,22959205.0,
2098,686940,1,1,,855602,3672,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2099,686964,1,1,,855602,3672,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2100,686970,1,2,,56422436,3672,Inconclusive,49168486.0,3417.0,29.0929,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2101,686971,1,2,,56422436,3672,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2102,686978,1,1,,56422436,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2103,686978,1,1,,124880372,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2104,686978,1,1,,144203721,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2105,686979,1,1,,56422436,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2106,686979,1,1,,124880372,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2107,686979,1,1,,144203721,3672,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2108,686992,2,1,,855602,3672,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2109,686996,1,1,,855602,3672,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2110,687014,1,1,,855602,3672,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2111,687016,1,1,,855602,3672,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2112,687035,1,1,,163564645,3672,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2113,687037,1,3,,163564645,3672,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2114,699539,1,7,,103174500,3672,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2115,699540,1,7,,103174500,3672,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2116,699541,1,7,,103174500,3672,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2117,701504,4,5,,103174500,3672,Active,754286265.0,443551.0,5.0,IC50,Inhibition of ovine COX1 pre-incubated for 10 mins before arachidonic acid substrate addition by enzyme immunoassay,Confirmatory,23043222.0,
2118,701505,4,5,,103174500,3672,Active,3915797.0,5743.0,36.0,IC50,Inhibition of human COX2 pre-incubated for 10 mins before substrate addition by enzyme immunoassay,Confirmatory,23043222.0,
2119,701506,4,5,,103174500,3672,Inactive,6225312.0,29347.0,,IC50,Inhibition of FAAH in rat brain homogenates pre-incubated for 10 mins before addition of [3H]anandamide and [3H]AEA substrates for 30 mins by liquid scintillation counting,Confirmatory,23043222.0,
2120,703844,3,5,,103174500,3672,Inactive,126407.0,240.0,,IC50,Inhibition of 5-lipoxygenase in A23187-stimulated human neutrophils assessed as inhibition of enzyme product formation by RP-HPLC analysis,Confirmatory,22992107.0,
2121,703845,1,7,,103174500,3672,Unspecified,7387730.0,9536.0,,,Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as remaining activity measuring PGE2 formation from PGH2 at 10 uM after 15 mins by RP-HPLC analysis,Other,22992107.0,
2122,720504,1,1,,56422436,3672,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2123,720508,1,1,,855602,3672,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2124,720509,1,1,,855602,3672,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2125,720511,1,1,,855602,3672,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2126,720516,2,1,,144203721,3672,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2127,720516,2,1,,144208582,3672,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2128,720516,2,1,,144213146,3672,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2129,720532,1,1,,124880372,3672,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2130,720532,1,1,,124880375,3672,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2131,720532,1,1,,144203721,3672,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2132,720533,1,1,,124880372,3672,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2133,720533,1,1,,124880375,3672,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2134,720533,1,1,,144203721,3672,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2135,720538,1,2,,90341584,3672,Inactive,220983390.0,410.0,8.4921,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2136,720542,1,2,,56422436,3672,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2137,720543,1,1,,855602,3672,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2138,720551,1,2,,56422436,3672,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2139,720552,2,1,,144203721,3672,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2140,720552,2,1,,144208582,3672,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2141,720552,2,1,,144213146,3672,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2142,720553,1,2,,56422436,3672,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2143,720554,1,3,,121362465,3672,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2144,720559,1,2,,90341584,3672,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2145,720572,1,2,,90341584,3672,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2146,720573,1,2,,90341584,3672,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2147,720579,2,1,,56422436,3672,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2148,720579,2,1,,124880372,3672,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2149,720580,1,1,,56422436,3672,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2150,720580,1,1,,124880372,3672,Inconclusive,222762.0,3707576.0,5.0119,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2151,720582,1,1,,855602,3672,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2152,720596,1,1,,855602,3672,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2153,720634,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2154,720634,2,1,,144208582,3672,Inconclusive,,,62.0642,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2155,720634,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2156,720635,2,1,,144203721,3672,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2157,720635,2,1,,144208582,3672,Inconclusive,,,0.2772,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2158,720635,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2159,720636,1,1,,144203721,3672,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2160,720637,2,1,,144203721,3672,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2161,720637,2,1,,144208582,3672,Active,,,11.0368,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2162,720637,2,1,,144213146,3672,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2163,720641,1,2,,92307453,3672,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2164,720641,1,2,,92308981,3672,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2165,720647,1,2,,855602,3672,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2166,720648,1,1,,855602,3672,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2167,720653,1,1,,26752326,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2168,720659,1,1,,26752326,3672,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2169,720674,2,2,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2170,720674,2,2,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2171,720674,2,2,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2172,720675,2,2,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2173,720675,2,2,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2174,720675,2,2,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2175,720678,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2176,720678,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2177,720678,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2178,720679,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2179,720679,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2180,720679,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2181,720680,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2182,720680,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2183,720680,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2184,720681,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2185,720681,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2186,720681,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2187,720682,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2188,720682,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2189,720682,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2190,720683,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2191,720683,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2192,720683,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2193,720684,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2194,720684,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2195,720684,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2196,720685,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2197,720685,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2198,720685,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2199,720686,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2200,720686,2,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2201,720686,2,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2202,720687,2,2,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2203,720687,2,2,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2204,720687,2,2,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2205,720691,4,1,,144203721,3672,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2206,720691,4,1,,144208582,3672,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2207,720691,4,1,,144213146,3672,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2208,720692,3,1,,144203721,3672,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2209,720692,3,1,,144208582,3672,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2210,720692,3,1,,144213146,3672,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2211,720693,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2212,720693,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2213,720693,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2214,720700,1,4,,855602,3672,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2215,720702,1,1,,855602,3672,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2216,720704,1,4,,855602,3672,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2217,720706,1,2,,855602,3672,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2218,720707,1,2,,56422436,3672,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2219,720708,1,2,,56422436,3672,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2220,720709,1,2,,56422436,3672,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2221,720711,1,2,,56422436,3672,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2222,720717,1,3,,92124039,3672,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2223,720717,1,3,,92307453,3672,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2224,720717,1,3,,92308981,3672,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2225,720719,2,1,,144203721,3672,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2226,720719,2,1,,144208582,3672,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2227,720719,2,1,,144213146,3672,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2228,720725,2,1,,144203721,3672,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2229,720725,2,1,,144208582,3672,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2230,720725,2,1,,144213146,3672,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2231,724441,1,2,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX1 to IC50 for human recombinant COX2",Other,23200247.0,
2232,724443,2,5,,103174500,3672,Active,754286265.0,443551.0,2.9,IC50,Inhibition of ovine COX1,Confirmatory,23200247.0,
2233,724444,2,5,,103174500,3672,Active,3915797.0,5743.0,1.1,IC50,Inhibition of human recombinant COX2,Confirmatory,23200247.0,
2234,725052,1,2,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Charles Foster albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 to 3 hrs by plethysmometer analysis",Other,23202484.0,
2235,735847,1,2,,103174500,3672,Active,,,,,"Antinociceptive activity in CD-1 mouse assessed as reduction of formalin-induced inflammatory pain at 100 mg/kg, sc administered 15 mins challenge measured after 10 to 50 mins",Other,23540838.0,
2236,735848,1,2,,103174500,3672,Inactive,,,,,"Antinociceptive activity in CD-1 mouse assessed as reduction of formalin-induced inflammatory pain at 100 mg/kg, sc administered 15 mins challenge measured up to 5 mins",Other,23540838.0,
2237,735852,1,2,,103174500,3672,Inactive,,,,,"Antiallodynic activity against capsaicin-induced secondary mechanical pain in CD-1 mouse assessed as paw withdrawal-latency at 100 mg/kg, sc measured after 30 mins post compound administration",Other,23540838.0,
2238,736264,1,2,,103174500,3672,Active,,,,,"Analgesic activity in CD-1 mouse assessed as inhibition of acetic acid-induced writhing response at 100 mg/kg, sc measured after 30 mins",Other,23540838.0,
2239,743012,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2240,743012,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2241,743012,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2242,743014,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2243,743014,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2244,743014,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2245,743015,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2246,743015,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2247,743015,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2248,743033,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2249,743033,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2250,743033,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2251,743035,2,1,,144203721,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2252,743035,2,1,,144208582,3672,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2253,743035,2,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2254,743036,2,1,,144203721,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2255,743036,2,1,,144208582,3672,Inconclusive,124375976.0,367.0,19.7899,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2256,743036,2,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2257,743040,3,1,,144203721,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2258,743040,3,1,,144208582,3672,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2259,743040,3,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2260,743041,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2261,743041,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2262,743041,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2263,743042,3,1,,144203721,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2264,743042,3,1,,144208582,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2265,743042,3,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2266,743053,2,1,,144203721,3672,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2267,743053,2,1,,144208582,3672,Inconclusive,124375976.0,367.0,6.25812,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2268,743053,2,1,,144213146,3672,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2269,743054,2,1,,144203721,3672,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2270,743054,2,1,,144208582,3672,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2271,743054,2,1,,144213146,3672,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2272,743063,2,1,,144203721,3672,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2273,743063,2,1,,144208582,3672,Inconclusive,124375976.0,367.0,78.7851,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2274,743063,2,1,,144213146,3672,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2275,743064,3,1,,144203721,3672,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2276,743064,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2277,743064,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2278,743065,3,1,,144203721,3672,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2279,743065,3,1,,144208582,3672,Inconclusive,399498506.0,24831.0,55.3148,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2280,743065,3,1,,144213146,3672,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2281,743066,3,1,,144203721,3672,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2282,743066,3,1,,144208582,3672,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2283,743066,3,1,,144213146,3672,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2284,743067,2,1,,144203721,3672,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2285,743067,2,1,,144208582,3672,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2286,743067,2,1,,144213146,3672,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2287,743069,2,1,,144203721,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2288,743069,2,1,,144208582,3672,Inactive,348019627.0,2099.0,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2289,743069,2,1,,144213146,3672,Inactive,348019627.0,2099.0,12.3013,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2290,743074,2,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2291,743074,2,1,,144208582,3672,Inconclusive,,,62.5812,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2292,743074,2,1,,144213146,3672,Inconclusive,,,12.3013,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2293,743075,2,1,,144203721,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2294,743075,2,1,,144208582,3672,Inactive,348019627.0,2099.0,12.4866,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2295,743075,2,1,,144213146,3672,Inactive,348019627.0,2099.0,15.4864,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2296,743077,2,1,,144203721,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2297,743077,2,1,,144208582,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2298,743077,2,1,,144213146,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2299,743078,2,1,,144203721,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2300,743078,2,1,,144208582,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2301,743078,2,1,,144213146,3672,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2302,743079,3,1,,144203721,3672,Inconclusive,348019627.0,2099.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2303,743079,3,1,,144208582,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2304,743079,3,1,,144213146,3672,Active,348019627.0,2099.0,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2305,743080,3,1,,144203721,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2306,743080,3,1,,144208582,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2307,743080,3,1,,144213146,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2308,743081,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2309,743081,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2310,743081,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2311,743083,3,1,,144203721,3672,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2312,743083,3,1,,144208582,3672,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2313,743083,3,1,,144213146,3672,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2314,743084,3,1,,144203721,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2315,743084,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2316,743084,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2317,743085,3,1,,144203721,3672,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2318,743085,3,1,,144208582,3672,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2319,743085,3,1,,144213146,3672,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2320,743086,3,1,,144203721,3672,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2321,743086,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2322,743086,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2323,743091,2,1,,144203721,3672,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2324,743091,2,1,,144208582,3672,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2325,743091,2,1,,144213146,3672,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2326,743094,3,1,,144203721,3672,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2327,743094,3,1,,144208582,3672,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2328,743094,3,1,,144213146,3672,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2329,743122,2,1,,144203721,3672,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2330,743122,2,1,,144208582,3672,Inconclusive,51095037.0,196.0,69.6372,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2331,743122,2,1,,144213146,3672,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2332,743126,1,1,,855602,3672,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2333,743139,2,1,,144203721,3672,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2334,743139,2,1,,144208582,3672,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2335,743139,2,1,,144213146,3672,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2336,743140,2,1,,144203721,3672,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2337,743140,2,1,,144208582,3672,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2338,743140,2,1,,144213146,3672,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2339,743191,3,1,,144208582,3672,Inconclusive,216409692.0,5468.0,55.7756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2340,743191,3,1,,144213146,3672,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2341,743191,3,1,,170464979,3672,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2342,743194,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2343,743194,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2344,743194,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2345,743199,2,1,,144208582,3672,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2346,743199,2,1,,144213146,3672,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2347,743199,2,1,,170464979,3672,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2348,743202,4,1,,144208582,3672,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2349,743202,4,1,,144213146,3672,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2350,743202,4,1,,170464979,3672,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2351,743203,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2352,743203,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2353,743203,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2354,743205,1,1,,90341584,3672,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2355,743205,1,1,,90341584,3672,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2356,743206,1,1,,90341584,3672,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2357,743206,1,1,,90341584,3672,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2358,743207,1,1,,90341584,3672,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2359,743207,1,1,,90341584,3672,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2360,743209,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2361,743209,3,1,,144213146,3672,Inconclusive,,,61.6524,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2362,743209,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2363,743210,4,1,,144208582,3672,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2364,743210,4,1,,144213146,3672,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2365,743210,4,1,,170464979,3672,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2366,743211,3,1,,144208582,3672,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2367,743211,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2368,743211,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2369,743212,3,1,,144208582,3672,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2370,743212,3,1,,144213146,3672,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2371,743212,3,1,,170464979,3672,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2372,743213,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2373,743213,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2374,743213,3,1,,170464979,3672,Inconclusive,,,0.0024,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2375,743215,3,1,,144208582,3672,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2376,743215,3,1,,144213146,3672,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2377,743215,3,1,,170464979,3672,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2378,743217,3,1,,144208582,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2379,743217,3,1,,144213146,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2380,743217,3,1,,170464979,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2381,743218,3,1,,144208582,3672,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2382,743218,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2383,743218,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2384,743219,3,1,,144208582,3672,Inconclusive,20149576.0,4780.0,73.7635,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2385,743219,3,1,,144213146,3672,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2386,743219,3,1,,170464979,3672,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2387,743220,3,1,,144208582,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2388,743220,3,1,,144213146,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2389,743220,3,1,,170464979,3672,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2390,743221,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2391,743221,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2392,743221,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2393,743222,3,1,,144208582,3672,Inconclusive,216409708.0,7421.0,6.2581,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2394,743222,3,1,,144213146,3672,Inconclusive,216409708.0,7421.0,3.89,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2395,743222,3,1,,170464979,3672,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2396,743223,3,1,,144208582,3672,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2397,743223,3,1,,144213146,3672,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2398,743223,3,1,,170464979,3672,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2399,743224,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2400,743224,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2401,743224,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2402,743225,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2403,743225,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2404,743225,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2405,743226,2,1,,144208582,3672,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2406,743226,2,1,,144213146,3672,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2407,743226,2,1,,170464979,3672,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2408,743227,2,1,,144208582,3672,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2409,743227,2,1,,144213146,3672,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2410,743227,2,1,,170464979,3672,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2411,743228,3,1,,144208582,3672,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2412,743228,3,1,,144213146,3672,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2413,743228,3,1,,170464979,3672,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2414,743238,1,1,,855602,3672,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2415,743239,2,1,,144208582,3672,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2416,743239,2,1,,144213146,3672,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2417,743239,2,1,,170464979,3672,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2418,743240,2,1,,144208582,3672,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2419,743240,2,1,,144213146,3672,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2420,743240,2,1,,170464979,3672,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2421,743241,2,1,,144208582,3672,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2422,743241,2,1,,144213146,3672,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2423,743241,2,1,,170464979,3672,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2424,743242,2,1,,144208582,3672,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2425,743242,2,1,,144213146,3672,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2426,743242,2,1,,170464979,3672,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2427,743244,1,1,,90341584,3672,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2428,743244,1,1,,144203721,3672,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2429,743247,1,2,,855602,3672,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2430,743255,1,1,,56422436,3672,Inconclusive,118600387.0,7398.0,11.2202,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2431,743266,1,2,,56422436,3672,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2432,743268,1,1,,172080581,3672,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2433,743269,1,1,,855602,3672,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2434,743269,1,1,,855602,3672,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2435,743270,1,1,,172080581,3672,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2436,743271,1,1,,172080581,3672,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2437,743272,1,1,,172080581,3672,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2438,743279,1,2,,56422436,3672,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2439,743287,1,1,,855602,3672,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2440,743288,1,1,,26752326,3672,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2441,743292,1,1,,26752326,3672,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2442,743344,1,1,,174007269,3672,Inactive,,,5.1694,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2443,743345,1,1,,174007269,3672,Inactive,,,0.0651,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2444,743346,1,1,,174007269,3672,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2445,743347,1,1,,174007269,3672,Inactive,,,0.0003,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2446,743397,1,1,,855602,3672,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2447,743398,1,1,,855602,3672,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2448,747924,1,5,,103174500,3672,Active,317373262.0,5742.0,,,Reversible inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay,Other,23651359.0,
2449,747925,1,5,,103174500,3672,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control,Other,23651359.0,
2450,747926,1,5,,103174500,3672,Active,317373262.0,5742.0,,,Reversible inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins followed by compound washout measured 30 mins post arachidonic acid challenge by radioimmunoassay,Other,23651359.0,
2451,747928,1,5,,103174500,3672,Unspecified,317373262.0,5742.0,,,Inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control,Other,23651359.0,
2452,747932,2,3,,103174500,3672,Active,317373262.0,5742.0,0.29,IC50,Inhibition of COX-1 in human washed platelet assessed as inhibition of 0.5 uM arachidonic acid-induced TXB2 formation incubated for 25 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay,Confirmatory,23651359.0,
2453,747933,2,3,,103174500,3672,Unspecified,317373262.0,5742.0,,IC50,Inhibition of COX-1 in human washed platelet assessed as inhibition of 10 uM arachidonic acid-induced TXB2 formation incubated for 25 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay,Confirmatory,23651359.0,
2454,754992,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as paw volume at 100 mg/kg administered 30 mins prior to carrageenan challenge measured at 6 hrs by plethysmographic analysis (Rvb = 0.96 +/- 0.03 ml),Other,23673015.0,
2455,754993,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as paw volume at 100 mg/kg administered 30 mins prior to carrageenan challenge measured at 4 hrs by plethysmographic analysis (Rvb = 1.2 +/- 0.05 ml),Other,23673015.0,
2456,754994,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as paw volume at 100 mg/kg administered 30 mins prior to carrageenan challenge measured at 2 hrs by plethysmographic analysis (Rvb = 1.07 +/- 0.08 ml),Other,23673015.0,
2457,754995,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in carrageenan-induced Wistar rat paw edema model assessed as paw volume at 100 mg/kg administered 30 mins prior to carrageenan challenge measured at 1 hr by plethysmographic analysis (Rvb = 0.90 +/- 0.05 ml),Other,23673015.0,
2458,761608,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs relative to control",Other,23792319.0,
2459,761609,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,23792319.0,
2460,761610,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs relative to control",Other,23792319.0,
2461,761611,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr relative to control",Other,23792319.0,
2462,761612,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 0.5 hrs relative to control",Other,23792319.0,
2463,762993,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs relative to control",Other,23914900.0,
2464,762994,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,23914900.0,
2465,762995,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs relative to control",Other,23914900.0,
2466,762996,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control",Other,23914900.0,
2467,767618,1,1,,103174500,3672,Unspecified,,,,,Antinociceptive activity in po dosed Albino-Swiss mouse assessed as acetic acid-induced abdominal writhing compound administered 30 mins prior challenge measured over 30 mins post acetic acid challenge,Other,23953687.0,
2468,781326,1,2,,103174500,3672,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
2469,895625,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/5,Other,,
2470,895626,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/5,Other,,
2471,895627,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/5,Other,,
2472,895628,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/5,Other,,
2473,895629,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/5,Other,,
2474,895630,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/5,Other,,
2475,895631,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/5,Other,,
2476,895632,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/5,Other,,
2477,896223,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/14,Other,,
2478,896224,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/14,Other,,
2479,896225,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/14,Other,,
2480,896226,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/14,Other,,
2481,896227,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/14,Other,,
2482,896228,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/14,Other,,
2483,896229,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/14,Other,,
2484,896230,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/14,Other,,
2485,896231,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/14,Other,,
2486,896232,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/15,Other,,
2487,896233,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/15,Other,,
2488,896234,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/15,Other,,
2489,896235,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/15,Other,,
2490,896236,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/15,Other,,
2491,896237,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/15,Other,,
2492,896238,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/15,Other,,
2493,896239,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/15,Other,,
2494,896240,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/15,Other,,
2495,896241,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/15,Other,,
2496,896242,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/15,Other,,
2497,896243,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/15,Other,,
2498,896244,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/15,Other,,
2499,896245,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/15,Other,,
2500,896246,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/15,Other,,
2501,896247,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/15,Other,,
2502,896248,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/15,Other,,
2503,896249,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/15,Other,,
2504,896250,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/15,Other,,
2505,896251,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/15,Other,,
2506,896252,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/15,Other,,
2507,896253,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/16,Other,,
2508,896254,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/16,Other,,
2509,896255,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/16,Other,,
2510,896256,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/16,Other,,
2511,896257,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/16,Other,,
2512,896258,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/16,Other,,
2513,896259,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/16,Other,,
2514,896260,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/16,Other,,
2515,896261,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/16,Other,,
2516,896300,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/11,Other,,
2517,896301,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/11,Other,,
2518,896302,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/11,Other,,
2519,896303,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/11,Other,,
2520,896304,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/11,Other,,
2521,896305,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/11,Other,,
2522,896306,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/11,Other,,
2523,896940,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/16,Other,,
2524,896941,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/16,Other,,
2525,896942,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/16,Other,,
2526,896943,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/16,Other,,
2527,896944,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/16,Other,,
2528,896945,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/16,Other,,
2529,896946,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/16,Other,,
2530,896947,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/16,Other,,
2531,896948,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/16,Other,,
2532,896985,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/11,Other,,
2533,896986,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/11,Other,,
2534,896987,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/12,Other,,
2535,896988,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/12,Other,,
2536,896989,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/12,Other,,
2537,896990,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/12,Other,,
2538,896991,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/12,Other,,
2539,896992,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/12,Other,,
2540,896993,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/12,Other,,
2541,896994,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/12,Other,,
2542,896995,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/12,Other,,
2543,896996,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/12,Other,,
2544,896997,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/12,Other,,
2545,896998,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/12,Other,,
2546,896999,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/12,Other,,
2547,897000,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/12,Other,,
2548,897001,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/12,Other,,
2549,897002,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/12,Other,,
2550,897003,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/12,Other,,
2551,897004,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/12,Other,,
2552,897005,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/12,Other,,
2553,897006,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/12,Other,,
2554,897007,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/12,Other,,
2555,897008,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/13,Other,,
2556,897009,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/13,Other,,
2557,897010,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/13,Other,,
2558,897011,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/13,Other,,
2559,897012,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/13,Other,,
2560,897013,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/13,Other,,
2561,897014,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/13,Other,,
2562,897015,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/13,Other,,
2563,897016,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/13,Other,,
2564,897017,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/13,Other,,
2565,897018,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/13,Other,,
2566,897019,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/13,Other,,
2567,897020,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/13,Other,,
2568,897021,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/13,Other,,
2569,897022,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/13,Other,,
2570,897023,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/13,Other,,
2571,897024,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/13,Other,,
2572,897816,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/5,Other,,
2573,897817,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/5,Other,,
2574,897818,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/5,Other,,
2575,897819,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/5,Other,,
2576,897820,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/5,Other,,
2577,897821,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/5,Other,,
2578,897822,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/5,Other,,
2579,897823,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/5,Other,,
2580,897824,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/5,Other,,
2581,897825,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/5,Other,,
2582,897826,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/5,Other,,
2583,897827,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/5,Other,,
2584,897828,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/5,Other,,
2585,897829,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/6,Other,,
2586,897830,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/6,Other,,
2587,897831,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/6,Other,,
2588,897832,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/6,Other,,
2589,897833,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/6,Other,,
2590,897834,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/6,Other,,
2591,897835,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/6,Other,,
2592,897836,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/6,Other,,
2593,897837,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/6,Other,,
2594,897838,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/6,Other,,
2595,897839,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/6,Other,,
2596,897840,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/6,Other,,
2597,897841,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/6,Other,,
2598,897842,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/6,Other,,
2599,897843,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/6,Other,,
2600,897844,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/6,Other,,
2601,897845,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/6,Other,,
2602,897846,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/6,Other,,
2603,897847,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/6,Other,,
2604,897848,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/6,Other,,
2605,898528,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/6,Other,,
2606,898529,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/7,Other,,
2607,898530,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/7,Other,,
2608,898531,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/7,Other,,
2609,898532,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/7,Other,,
2610,898533,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/7,Other,,
2611,898534,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/7,Other,,
2612,898535,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/7,Other,,
2613,898536,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/7,Other,,
2614,898537,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/7,Other,,
2615,898538,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/7,Other,,
2616,898539,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/7,Other,,
2617,898540,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/7,Other,,
2618,898541,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/7,Other,,
2619,898542,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/7,Other,,
2620,898543,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/7,Other,,
2621,899134,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/16,Other,,
2622,899135,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/16,Other,,
2623,899136,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/16,Other,,
2624,899137,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/5,Other,,
2625,899138,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/5,Other,,
2626,899139,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/5,Other,,
2627,899140,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/5,Other,,
2628,899141,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/5,Other,,
2629,899142,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/5,Other,,
2630,899143,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/5,Other,,
2631,899144,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/5,Other,,
2632,899145,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/5,Other,,
2633,899146,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/5,Other,,
2634,899147,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/5,Other,,
2635,899148,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/5,Other,,
2636,899149,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/5,Other,,
2637,899150,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/5,Other,,
2638,899151,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/5,Other,,
2639,899152,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/5,Other,,
2640,899153,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/5,Other,,
2641,899154,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/5,Other,,
2642,899155,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/5,Other,,
2643,899156,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/5,Other,,
2644,899157,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/5,Other,,
2645,899158,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/6,Other,,
2646,899159,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/6,Other,,
2647,899160,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/6,Other,,
2648,899161,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/6,Other,,
2649,899162,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/6,Other,,
2650,899163,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/6,Other,,
2651,899164,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/6,Other,,
2652,899842,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/6,Other,,
2653,899843,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/6,Other,,
2654,899844,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/6,Other,,
2655,899845,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/6,Other,,
2656,899846,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/6,Other,,
2657,899847,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/6,Other,,
2658,899848,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/6,Other,,
2659,899849,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/6,Other,,
2660,899850,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/6,Other,,
2661,899851,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/6,Other,,
2662,899852,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/6,Other,,
2663,899853,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/6,Other,,
2664,899854,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/6,Other,,
2665,899855,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/6,Other,,
2666,899856,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/7,Other,,
2667,899857,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/7,Other,,
2668,899889,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/13,Other,,
2669,899890,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/13,Other,,
2670,899891,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/13,Other,,
2671,899892,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/13,Other,,
2672,899893,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/14,Other,,
2673,899894,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/14,Other,,
2674,899895,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/14,Other,,
2675,899896,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/14,Other,,
2676,899897,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/14,Other,,
2677,899898,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/14,Other,,
2678,899899,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/14,Other,,
2679,899900,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/14,Other,,
2680,899901,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/14,Other,,
2681,899902,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/14,Other,,
2682,899903,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/14,Other,,
2683,899904,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/14,Other,,
2684,899905,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/14,Other,,
2685,899906,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/14,Other,,
2686,899907,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/14,Other,,
2687,899908,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/14,Other,,
2688,899909,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/14,Other,,
2689,899910,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/14,Other,,
2690,899911,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/14,Other,,
2691,899912,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/14,Other,,
2692,899913,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/14,Other,,
2693,899914,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/15,Other,,
2694,899915,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/15,Other,,
2695,899916,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/15,Other,,
2696,899917,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/15,Other,,
2697,899918,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/15,Other,,
2698,899919,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/15,Other,,
2699,899920,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/15,Other,,
2700,899921,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/15,Other,,
2701,899922,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/15,Other,,
2702,899923,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/15,Other,,
2703,899924,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/15,Other,,
2704,899925,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/15,Other,,
2705,899926,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/15,Other,,
2706,899927,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/15,Other,,
2707,899928,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/15,Other,,
2708,899929,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/15,Other,,
2709,899930,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/15,Other,,
2710,899931,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/15,Other,,
2711,899932,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/15,Other,,
2712,900616,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/15,Other,,
2713,900617,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/15,Other,,
2714,900618,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/16,Other,,
2715,900728,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/7,Other,,
2716,900729,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/7,Other,,
2717,900730,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/7,Other,,
2718,900731,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/7,Other,,
2719,900732,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/7,Other,,
2720,900733,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/7,Other,,
2721,900734,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/8,Other,,
2722,900735,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/8,Other,,
2723,900736,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/8,Other,,
2724,900737,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/8,Other,,
2725,900738,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/8,Other,,
2726,900739,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/8,Other,,
2727,900740,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/8,Other,,
2728,900741,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/8,Other,,
2729,900742,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/8,Other,,
2730,900743,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/8,Other,,
2731,900744,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/8,Other,,
2732,900745,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/8,Other,,
2733,900746,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/8,Other,,
2734,900747,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/8,Other,,
2735,900748,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/8,Other,,
2736,900749,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/8,Other,,
2737,900750,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/8,Other,,
2738,900751,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/8,Other,,
2739,901430,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/8,Other,,
2740,901431,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/8,Other,,
2741,901432,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/8,Other,,
2742,901433,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/9,Other,,
2743,901434,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/9,Other,,
2744,901435,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/9,Other,,
2745,901436,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/9,Other,,
2746,901437,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/9,Other,,
2747,901438,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/9,Other,,
2748,901439,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/9,Other,,
2749,901440,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/9,Other,,
2750,901441,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/9,Other,,
2751,901442,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/9,Other,,
2752,901443,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/9,Other,,
2753,901444,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/9,Other,,
2754,901445,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/9,Other,,
2755,901446,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/9,Other,,
2756,901447,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/9,Other,,
2757,901448,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/9,Other,,
2758,901449,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/9,Other,,
2759,901450,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/9,Other,,
2760,901451,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/9,Other,,
2761,901452,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/9,Other,,
2762,901453,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/9,Other,,
2763,902044,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/7,Other,,
2764,902045,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/7,Other,,
2765,902046,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/7,Other,,
2766,902047,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/7,Other,,
2767,902048,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/7,Other,,
2768,902049,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/7,Other,,
2769,902050,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/7,Other,,
2770,902051,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/7,Other,,
2771,902052,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/7,Other,,
2772,902053,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/7,Other,,
2773,902054,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/7,Other,,
2774,902055,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/7,Other,,
2775,902056,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/7,Other,,
2776,902057,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/7,Other,,
2777,902058,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/7,Other,,
2778,902059,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/7,Other,,
2779,902060,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/7,Other,,
2780,902061,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/7,Other,,
2781,902062,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/7,Other,,
2782,902063,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/8,Other,,
2783,902064,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/8,Other,,
2784,902065,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/8,Other,,
2785,902066,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/8,Other,,
2786,902067,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/8,Other,,
2787,902068,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/8,Other,,
2788,902747,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/8,Other,,
2789,902748,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/8,Other,,
2790,902749,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/8,Other,,
2791,902750,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/8,Other,,
2792,902751,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/8,Other,,
2793,902752,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/8,Other,,
2794,902753,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/8,Other,,
2795,902754,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/8,Other,,
2796,902755,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/8,Other,,
2797,902756,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/8,Other,,
2798,902757,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/8,Other,,
2799,902758,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/8,Other,,
2800,902759,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/8,Other,,
2801,902760,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/8,Other,,
2802,902761,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/8,Other,,
2803,902762,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/9,Other,,
2804,902763,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/9,Other,,
2805,902764,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/9,Other,,
2806,902765,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/9,Other,,
2807,902766,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/9,Other,,
2808,902767,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/9,Other,,
2809,902768,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/9,Other,,
2810,902802,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/16,Other,,
2811,902803,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/16,Other,,
2812,902804,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/16,Other,,
2813,902805,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/16,Other,,
2814,902806,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/16,Other,,
2815,902807,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/16,Other,,
2816,902808,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/16,Other,,
2817,902809,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/16,Other,,
2818,902810,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/16,Other,,
2819,902811,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/16,Other,,
2820,902812,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/16,Other,,
2821,902813,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/16,Other,,
2822,902814,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/16,Other,,
2823,902815,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/16,Other,,
2824,902816,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/16,Other,,
2825,902817,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/16,Other,,
2826,902818,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/16,Other,,
2827,902819,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/16,Other,,
2828,902820,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/16,Other,,
2829,902821,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/16,Other,,
2830,903641,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/10,Other,,
2831,903642,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/10,Other,,
2832,903643,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/10,Other,,
2833,903644,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/10,Other,,
2834,903645,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/10,Other,,
2835,903646,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/10,Other,,
2836,903647,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/10,Other,,
2837,903648,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/10,Other,,
2838,903649,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/10,Other,,
2839,903650,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/10,Other,,
2840,903651,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/10,Other,,
2841,903652,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/10,Other,,
2842,903653,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/10,Other,,
2843,903654,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/10,Other,,
2844,903655,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/10,Other,,
2845,904200,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/12,Other,,
2846,904338,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/10,Other,,
2847,904339,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/10,Other,,
2848,904340,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/10,Other,,
2849,904341,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/10,Other,,
2850,904342,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/10,Other,,
2851,904343,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/10,Other,,
2852,904344,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/11,Other,,
2853,904345,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/11,Other,,
2854,904346,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/11,Other,,
2855,904347,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/11,Other,,
2856,904348,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/11,Other,,
2857,904349,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/11,Other,,
2858,904350,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/11,Other,,
2859,904351,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/11,Other,,
2860,904352,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/11,Other,,
2861,904353,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/11,Other,,
2862,904354,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/11,Other,,
2863,904355,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/11,Other,,
2864,904356,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/11,Other,,
2865,904357,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/11,Other,,
2866,904358,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/11,Other,,
2867,904359,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/11,Other,,
2868,904360,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/11,Other,,
2869,904361,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/11,Other,,
2870,904362,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/11,Other,,
2871,904363,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/11,Other,,
2872,904364,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/11,Other,,
2873,904365,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/12,Other,,
2874,904366,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/12,Other,,
2875,904367,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/12,Other,,
2876,904368,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/12,Other,,
2877,904369,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/12,Other,,
2878,904370,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/12,Other,,
2879,904883,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/12,Other,,
2880,904884,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/12,Other,,
2881,904885,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/12,Other,,
2882,904886,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/12,Other,,
2883,904887,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/12,Other,,
2884,904888,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/12,Other,,
2885,904889,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/12,Other,,
2886,904890,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/12,Other,,
2887,904891,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/12,Other,,
2888,904892,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/12,Other,,
2889,904893,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/12,Other,,
2890,904894,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/12,Other,,
2891,904895,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/12,Other,,
2892,904896,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/12,Other,,
2893,904897,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/13,Other,,
2894,904898,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/13,Other,,
2895,904899,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/13,Other,,
2896,904900,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/13,Other,,
2897,904901,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/13,Other,,
2898,904902,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/13,Other,,
2899,904903,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/13,Other,,
2900,904904,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/13,Other,,
2901,904905,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/13,Other,,
2902,904906,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/13,Other,,
2903,904907,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/13,Other,,
2904,904908,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/13,Other,,
2905,904909,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 345/13,Other,,
2906,904910,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 345/13,Other,,
2907,904911,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 345/13,Other,,
2908,904912,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 345/13,Other,,
2909,904913,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 345/13,Other,,
2910,904914,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 345/13,Other,,
2911,904915,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 345/13,Other,,
2912,904916,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 345/13,Other,,
2913,904917,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 345/13,Other,,
2914,904918,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 345/14,Other,,
2915,904919,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 345/14,Other,,
2916,904920,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 345/14,Other,,
2917,904921,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 345/14,Other,,
2918,904922,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 345/14,Other,,
2919,904923,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 345/14,Other,,
2920,904924,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 345/14,Other,,
2921,904925,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 345/14,Other,,
2922,904926,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 345/14,Other,,
2923,904927,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 345/14,Other,,
2924,904928,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 345/14,Other,,
2925,904957,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/9,Other,,
2926,904958,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/9,Other,,
2927,904959,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/9,Other,,
2928,904960,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/9,Other,,
2929,904961,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/9,Other,,
2930,904962,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/9,Other,,
2931,904963,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/9,Other,,
2932,904964,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/9,Other,,
2933,904965,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/9,Other,,
2934,904966,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/9,Other,,
2935,904967,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/9,Other,,
2936,904968,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/9,Other,,
2937,904969,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/9,Other,,
2938,904970,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/9,Other,,
2939,904971,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/10,Other,,
2940,904972,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/10,Other,,
2941,904973,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/10,Other,,
2942,905607,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 345/14,Other,,
2943,905652,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/10,Other,,
2944,905653,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/10,Other,,
2945,905654,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/10,Other,,
2946,905655,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/10,Other,,
2947,905656,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/10,Other,,
2948,905657,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/10,Other,,
2949,905658,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/10,Other,,
2950,905659,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/10,Other,,
2951,905660,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/10,Other,,
2952,905661,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 346/10,Other,,
2953,905662,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 346/10,Other,,
2954,905663,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 346/10,Other,,
2955,905664,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 346/10,Other,,
2956,905665,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 346/10,Other,,
2957,905666,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 346/10,Other,,
2958,905667,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 346/10,Other,,
2959,905668,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 346/10,Other,,
2960,905669,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 346/10,Other,,
2961,905670,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 346/11,Other,,
2962,905671,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 346/11,Other,,
2963,905672,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 346/11,Other,,
2964,905673,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 346/11,Other,,
2965,905674,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 346/11,Other,,
2966,905675,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 346/11,Other,,
2967,905676,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 346/11,Other,,
2968,905677,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 346/11,Other,,
2969,905678,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 346/11,Other,,
2970,905679,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 346/11,Other,,
2971,905680,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 346/11,Other,,
2972,905681,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 346/11,Other,,
2973,930279,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2974,930280,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2975,930281,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
2976,930282,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
2977,930283,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
2978,930284,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2979,930285,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2980,930286,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
2981,930287,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
2982,930288,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
2983,930289,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
2984,930290,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
2985,930291,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2986,930292,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2987,930293,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
2988,930294,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
2989,930295,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2990,930296,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
2991,930297,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
2992,931644,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
2993,931645,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
2994,931646,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
2995,931647,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
2996,931648,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
2997,931649,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
2998,931650,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
2999,931651,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
3000,931652,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
3001,931653,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
3002,931654,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
3003,931655,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
3004,931656,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
3005,931657,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
3006,931658,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
3007,931659,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
3008,931660,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
3009,931661,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
3010,931662,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
3011,944057,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
3012,944058,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
3013,944059,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
3014,944060,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
3015,944061,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
3016,944062,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
3017,944063,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
3018,944064,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
3019,944065,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
3020,944066,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
3021,944067,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
3022,944068,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
3023,944069,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
3024,944070,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
3025,944071,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
3026,944072,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
3027,944073,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
3028,944074,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
3029,944075,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
3030,947410,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011016,Other,,
3031,947411,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011016,Other,,
3032,947412,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011016,Other,,
3033,947413,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011016,Other,,
3034,947414,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011016,Other,,
3035,947415,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011016,Other,,
3036,947416,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011016,Other,,
3037,947417,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011016,Other,,
3038,947418,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011016,Other,,
3039,947419,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011016,Other,,
3040,947420,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011016,Other,,
3041,947421,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011016",Other,,
3042,947422,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011016,Other,,
3043,947423,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011016,Other,,
3044,947424,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011016,Other,,
3045,947425,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011016,Other,,
3046,947426,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011016,Other,,
3047,947427,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011016,Other,,
3048,947428,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011016,Other,,
3049,953677,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3050,953678,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3051,953679,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3052,953680,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3053,953681,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3054,953682,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3055,954315,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3056,954316,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3057,954317,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3058,954318,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3059,954319,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3060,954320,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3061,954321,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3062,954322,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3063,954323,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3064,954324,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3065,954325,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3066,954326,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3067,954327,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3068,960011,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3069,960012,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3070,960013,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3071,960014,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3072,960015,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3073,960016,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3074,960017,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3075,960018,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3076,960019,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3077,960020,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3078,960021,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3079,960022,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3080,960023,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3081,960024,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3082,960025,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3083,960026,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3084,960027,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3085,960028,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3086,960029,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3087,964441,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3088,964444,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3089,964445,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3090,964446,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3091,964447,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3092,964448,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3093,964449,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3094,964450,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3095,964451,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3096,964452,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3097,964453,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3098,964454,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3099,964455,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3100,964456,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3101,964457,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3102,964458,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3103,964459,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3104,964460,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011016,Other,,
3105,964461,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3106,966210,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3107,966211,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011016,Other,,
3108,966212,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011016,Other,,
3109,966213,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011016,Other,,
3110,966214,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011016,Other,,
3111,966215,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011016,Other,,
3112,966216,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011016,Other,,
3113,966217,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011016,Other,,
3114,966218,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011016,Other,,
3115,966219,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011016,Other,,
3116,966220,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011016,Other,,
3117,966221,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011016,Other,,
3118,966222,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011016,Other,,
3119,966223,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011016,Other,,
3120,966224,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011016,Other,,
3121,966225,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011016,Other,,
3122,966226,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011016,Other,,
3123,966227,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011016,Other,,
3124,969317,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011016,Other,,
3125,977599,1,1,,103174500,3672,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3126,977602,1,2,,103174500,3672,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3127,996200,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
3128,996201,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3129,996202,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3130,996203,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3131,998649,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3132,998650,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3133,998651,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3134,998652,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
3135,998653,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
3136,998654,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
3137,998655,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
3138,998656,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Epithelial Atrophy; Study_ID: S011016,Other,,
3139,998657,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3140,998658,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3141,998659,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3142,998660,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3143,998661,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3144,998662,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3145,998663,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3146,998664,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3147,998665,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3148,998666,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3149,998667,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3150,998668,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3151,998669,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3152,998670,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
3153,998671,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
3154,998672,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3155,998673,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3156,998674,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3157,998675,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3158,998676,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3159,998677,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3160,998678,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3161,998679,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3162,998680,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3163,998681,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3164,998682,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3165,998683,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
3166,998684,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
3167,999266,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
3168,999267,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3169,999268,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3170,999269,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3171,1001129,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3172,1001130,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3173,1001131,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3174,1001132,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3175,1001133,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
3176,1001134,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
3177,1001135,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
3178,1001136,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
3179,1001137,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3180,1001138,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
3181,1001139,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3182,1001140,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3183,1001141,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3184,1001142,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3185,1001143,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3186,1001144,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3187,1001145,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3188,1001146,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
3189,1001147,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
3190,1001148,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3191,1001149,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3192,1001150,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3193,1001151,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3194,1001152,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
3195,1001153,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
3196,1001154,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
3197,1001155,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
3198,1001156,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Peritonitis; Study_ID: S011016,Other,,
3199,1001157,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Villus Tip Fusion; Study_ID: S011016,Other,,
3200,1001158,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
3201,1001159,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3202,1001160,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3203,1001742,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3204,1001743,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3205,1001744,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
3206,1001745,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
3207,1001746,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3208,1001747,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3209,1001748,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3210,1001749,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3211,1001750,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3212,1003618,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3213,1003619,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
3214,1009787,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
3215,1009788,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3216,1009789,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3217,1009790,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3218,1009791,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3219,1009792,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3220,1009793,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
3221,1009794,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
3222,1009795,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
3223,1009796,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
3224,1009797,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
3225,1009798,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3226,1009799,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3227,1009800,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3228,1009801,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3229,1009802,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3230,1009803,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3231,1009804,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3232,1009805,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3233,1009806,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3234,1010388,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3235,1010389,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3236,1010390,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3237,1010391,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3238,1010392,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
3239,1010393,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
3240,1010394,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3241,1010395,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3242,1010396,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3243,1010397,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3244,1010398,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3245,1010868,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3246,1010869,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3247,1010870,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3248,1010871,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3249,1010872,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3250,1010873,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
3251,1010874,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
3252,1010875,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
3253,1010876,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3254,1010877,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3255,1010878,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3256,1010879,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3257,1010880,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3258,1010881,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3259,1010882,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
3260,1010883,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
3261,1010884,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
3262,1010885,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
3263,1010886,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3264,1010887,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
3265,1010888,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3266,1010889,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3267,1010890,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3268,1011474,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3269,1011475,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3270,1011476,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3271,1011477,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3272,1011478,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
3273,1011479,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
3274,1011480,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3275,1011481,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3276,1011482,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3277,1011483,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3278,1011484,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3279,1011485,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
3280,1011486,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
3281,1011487,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
3282,1011488,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
3283,1011489,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
3284,1011490,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3285,1013360,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3286,1013361,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3287,1013362,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3288,1013363,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
3289,1013364,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3290,1013365,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3291,1013366,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3292,1013367,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3293,1013368,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3294,1013369,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3295,1013370,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3296,1013371,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3297,1013372,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
3298,1016928,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
3299,1016929,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3300,1016930,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3301,1016931,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3302,1016932,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3303,1016933,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3304,1016934,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3305,1016935,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
3306,1016936,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
3307,1016937,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
3308,1016938,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
3309,1016939,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3310,1016940,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3311,1016941,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3312,1016942,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3313,1016943,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3314,1016944,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3315,1016964,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3316,1016965,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3317,1016966,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3318,1016967,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
3319,1016968,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
3320,1016969,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3321,1016970,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3322,1016971,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3323,1016972,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3324,1016973,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3325,1016974,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
3326,1016975,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
3327,1016976,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
3328,1016977,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
3329,1016978,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
3330,1016979,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3331,1016980,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3332,1016981,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3333,1016982,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3334,1016983,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
3335,1016984,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
3336,1016985,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3337,1016986,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3338,1016987,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3339,1016988,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3340,1016989,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3341,1016990,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3342,1017575,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3343,1017576,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
3344,1018818,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3345,1018819,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3346,1019403,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3347,1019404,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3348,1019405,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3349,1019406,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3350,1019407,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
3351,1019408,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
3352,1019409,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3353,1019410,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3354,1019411,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3355,1019412,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3356,1019413,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3357,1019414,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3358,1019415,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3359,1019416,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3360,1019417,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3361,1019418,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3362,1019419,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3363,1019420,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
3364,1019421,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
3365,1019422,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
3366,1019423,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3367,1019424,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3368,1019425,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3369,1019426,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3370,1019427,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3371,1019428,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3372,1019429,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
3373,1019430,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
3374,1019431,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
3375,1019432,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
3376,1019433,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3377,1019434,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
3378,1019435,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3379,1019436,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3380,1019437,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3381,1019438,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3382,1019439,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3383,1019440,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3384,1021890,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3385,1021891,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011016",Other,,
3386,1021892,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011016",Other,,
3387,1021893,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3388,1021894,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3389,1021895,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3390,1021896,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3391,1021897,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3392,1021898,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011016",Other,,
3393,1021899,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011016",Other,,
3394,1021900,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011016",Other,,
3395,1021901,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011016",Other,,
3396,1021902,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011016",Other,,
3397,1021903,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3398,1021904,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3399,1021905,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3400,1021906,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3401,1021907,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011016",Other,,
3402,1021908,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011016",Other,,
3403,1021909,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3404,1021910,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3405,1021911,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3406,1021912,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3407,1021913,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3408,1021914,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3409,1021915,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3410,1021916,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011016",Other,,
3411,1021917,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011016,Other,,
3412,1021918,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3413,1021919,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3414,1021920,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3415,1021921,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3416,1021922,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3417,1021923,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011016",Other,,
3418,1021924,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011016",Other,,
3419,1021925,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011016",Other,,
3420,1021926,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011016",Other,,
3421,1021927,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3422,1022510,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3423,1022511,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3424,1022512,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3425,1024379,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3426,1024380,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3427,1024381,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3428,1024382,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3429,1024383,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3430,1024384,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3431,1024385,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3432,1024386,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3433,1024387,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3434,1024388,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011016",Other,,
3435,1024389,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011016,Other,,
3436,1024390,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3437,1024391,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3438,1024392,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3439,1024393,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3440,1024394,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3441,1024395,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3442,1024396,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3443,1024397,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3444,1024398,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3445,1024399,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3446,1024400,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3447,1024401,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011016",Other,,
3448,1024402,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011016",Other,,
3449,1024403,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011016",Other,,
3450,1024404,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3451,1024405,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3452,1024406,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3453,1024407,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3454,1024408,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3455,1024409,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3456,1024410,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011016",Other,,
3457,1024993,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011016",Other,,
3458,1024994,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011016",Other,,
3459,1024995,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011016",Other,,
3460,1024996,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3461,1024997,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011016",Other,,
3462,1024998,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3463,1024999,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3464,1025000,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3465,1025001,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M2; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3466,1029593,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011016",Other,,
3467,1029594,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Peritonitis; Study_ID: S011016,Other,,
3468,1029595,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Villus Tip Fusion; Study_ID: S011016,Other,,
3469,1029596,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011016",Other,,
3470,1029597,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011016,Other,,
3471,1029598,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3472,1029599,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011016",Other,,
3473,1029600,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011016",Other,,
3474,1029601,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011016,Other,,
3475,1029602,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3476,1029603,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011016",Other,,
3477,1029604,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3478,1029605,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3479,1029606,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3480,1029607,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011016",Other,,
3481,1032723,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011016",Other,,
3482,1032724,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011016,Other,,
3483,1032725,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011016",Other,,
3484,1032726,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3485,1032727,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011016",Other,,
3486,1032728,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011016",Other,,
3487,1032729,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3488,1032730,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3489,1032731,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011016",Other,,
3490,1032732,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011016",Other,,
3491,1032733,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3492,1032734,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3493,1032735,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3494,1032736,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011016",Other,,
3495,1032737,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3496,1032738,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3497,1032739,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3498,1032740,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011016",Other,,
3499,1032741,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3500,1032742,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011016",Other,,
3501,1032743,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011016",Other,,
3502,1032744,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3503,1032745,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011016,Other,,
3504,1032746,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011016,Other,,
3505,1032747,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011016",Other,,
3506,1032748,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011016",Other,,
3507,1032749,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3508,1032750,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011016",Other,,
3509,1032751,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011016,Other,,
3510,1032752,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3511,1033336,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3512,1033337,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3513,1033338,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011016",Other,,
3514,1033339,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011016,Other,,
3515,1033340,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011016",Other,,
3516,1033341,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011016",Other,,
3517,1033342,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011016",Other,,
3518,1033343,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011016",Other,,
3519,1033344,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011016",Other,,
3520,1035186,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3521,1035187,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011016",Other,,
3522,1035188,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011016",Other,,
3523,1035189,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011016",Other,,
3524,1035190,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011016",Other,,
3525,1035191,1,3,,103174500,3672,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011016",Other,,
3526,1035192,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Epithelial Atrophy; Study_ID: S011016,Other,,
3527,1035193,1,3,,103174500,3672,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011016,Other,,
3528,1036728,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/11,Other,,
3529,1036729,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/11,Other,,
3530,1036730,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/12,Other,,
3531,1036731,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/12,Other,,
3532,1036732,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/12,Other,,
3533,1036733,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/12,Other,,
3534,1036734,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/12,Other,,
3535,1036735,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/13,Other,,
3536,1036736,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/13,Other,,
3537,1036737,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/13,Other,,
3538,1036738,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/13,Other,,
3539,1036739,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/13,Other,,
3540,1036740,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/14,Other,,
3541,1036741,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/14,Other,,
3542,1036742,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/14,Other,,
3543,1036743,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/14,Other,,
3544,1036744,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/14,Other,,
3545,1036745,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/15,Other,,
3546,1036746,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/15,Other,,
3547,1036747,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/15,Other,,
3548,1036748,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/15,Other,,
3549,1036749,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/15,Other,,
3550,1036750,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/16,Other,,
3551,1036751,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/16,Other,,
3552,1036752,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/16,Other,,
3553,1036753,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/16,Other,,
3554,1036754,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/16,Other,,
3555,1041703,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/5,Other,,
3556,1041704,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/5,Other,,
3557,1041705,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/5,Other,,
3558,1041706,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/5,Other,,
3559,1041707,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/5,Other,,
3560,1041708,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/6,Other,,
3561,1041709,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/6,Other,,
3562,1042375,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/6,Other,,
3563,1042376,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/6,Other,,
3564,1042377,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/6,Other,,
3565,1042378,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/7,Other,,
3566,1042379,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/7,Other,,
3567,1042380,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/7,Other,,
3568,1042381,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/7,Other,,
3569,1042382,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/7,Other,,
3570,1042383,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/8,Other,,
3571,1042384,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/8,Other,,
3572,1042385,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/8,Other,,
3573,1042386,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/8,Other,,
3574,1042387,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/8,Other,,
3575,1042388,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/9,Other,,
3576,1042389,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/9,Other,,
3577,1042390,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/9,Other,,
3578,1042391,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/9,Other,,
3579,1042392,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/9,Other,,
3580,1042393,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/10,Other,,
3581,1042394,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/10,Other,,
3582,1042395,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/10,Other,,
3583,1042396,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/10,Other,,
3584,1042397,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/10,Other,,
3585,1042398,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/11,Other,,
3586,1042399,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/11,Other,,
3587,1042400,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/11,Other,,
3588,1042401,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/11,Other,,
3589,1042402,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/11,Other,,
3590,1042403,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/12,Other,,
3591,1042404,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/12,Other,,
3592,1042405,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/12,Other,,
3593,1042406,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/12,Other,,
3594,1042407,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/12,Other,,
3595,1042408,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/13,Other,,
3596,1042409,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/13,Other,,
3597,1042410,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/13,Other,,
3598,1042411,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/13,Other,,
3599,1042412,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/13,Other,,
3600,1042413,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/14,Other,,
3601,1045224,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/14,Other,,
3602,1045225,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/14,Other,,
3603,1045226,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/14,Other,,
3604,1045227,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/14,Other,,
3605,1045228,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/15,Other,,
3606,1045229,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/15,Other,,
3607,1045230,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/15,Other,,
3608,1045231,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/15,Other,,
3609,1045232,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/15,Other,,
3610,1045233,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 345/16,Other,,
3611,1045234,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 345/16,Other,,
3612,1045235,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 345/16,Other,,
3613,1045236,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 345/16,Other,,
3614,1045237,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 345/16,Other,,
3615,1045238,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/5,Other,,
3616,1045239,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/5,Other,,
3617,1045240,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/5,Other,,
3618,1045241,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/5,Other,,
3619,1045242,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/5,Other,,
3620,1045243,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/6,Other,,
3621,1045244,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/6,Other,,
3622,1045245,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/6,Other,,
3623,1045246,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/6,Other,,
3624,1045247,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/6,Other,,
3625,1045248,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/7,Other,,
3626,1045249,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/7,Other,,
3627,1045250,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/7,Other,,
3628,1045251,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/7,Other,,
3629,1045252,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/7,Other,,
3630,1045253,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/8,Other,,
3631,1045254,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/8,Other,,
3632,1045255,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/8,Other,,
3633,1045256,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/8,Other,,
3634,1045257,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/8,Other,,
3635,1045258,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/9,Other,,
3636,1045259,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/9,Other,,
3637,1045260,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/9,Other,,
3638,1045261,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/9,Other,,
3639,1045262,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/9,Other,,
3640,1045263,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/10,Other,,
3641,1045264,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/10,Other,,
3642,1045265,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/10,Other,,
3643,1045266,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 346/10,Other,,
3644,1045267,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 346/10,Other,,
3645,1045268,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 346/11,Other,,
3646,1045938,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 346/11,Other,,
3647,1045939,1,2,,103174500,3672,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 346/11,Other,,
3648,1053175,2,1,,178126838,3672,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3649,1053188,2,1,,855602,3672,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3650,1053197,1,1,,855602,3672,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3651,1077233,1,1,,103174500,3672,Unspecified,,,,,"Ulcerogenic effect in fasted Wistar albino rat at 25 mg/kg, po measured 2 hrs post last dose",Other,24607877.0,
3652,1079931,1,1,,103174500,3672,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3653,1079932,1,1,,103174500,3672,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3654,1079933,1,1,,103174500,3672,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3655,1079934,1,1,,103174500,3672,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3656,1079935,1,1,,103174500,3672,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3657,1079936,1,1,,103174500,3672,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3658,1079937,1,1,,103174500,3672,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3659,1079938,1,1,,103174500,3672,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3660,1079939,1,1,,103174500,3672,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3661,1079940,1,1,,103174500,3672,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3662,1079941,1,1,,103174500,3672,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3663,1079942,1,1,,103174500,3672,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3664,1079943,1,1,,103174500,3672,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3665,1079944,1,1,,103174500,3672,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3666,1079945,1,1,,103174500,3672,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3667,1079946,1,1,,103174500,3672,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3668,1079947,1,1,,103174500,3672,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3669,1079948,1,1,,103174500,3672,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3670,1079949,1,1,,103174500,3672,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3671,1083294,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity against carageenaan-induced paw edema in Rattus norvegicus albino (rat) at 100 mg/kg, po administered 1 hr prior to carageenaan-challenge measured up to 3 hr",Other,,
3672,1083295,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as carageenaan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carageenaan-challenge measured at 120 min (Rvb = 100%)",Other,,
3673,1083296,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as carageenaan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carageenaan-challenge measured at 90 min (Rvb = 100%)",Other,,
3674,1083297,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as carageenaan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carageenaan-challenge measured at 30 min (Rvb = 100%)",Other,,
3675,1084019,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min before carrageenan challenge measured after 1 to 3 hr by plethysmometer analysis",Other,,
3676,1084350,1,2,,103174500,3672,Unspecified,,,,,"Ulcerogenic activity in Rattus norvegicus Wistar albino (rat) assessed as ulcer index at 200 mg/kg, po after 17 hr",Other,,
3677,1084371,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Mus musculus Swiss albino (mouse) assessed as increase in reaction time at 10 mg/kg, po after 1.5 hr by tail-flick method relative to control",Other,,
3678,1084372,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Mus musculus Swiss albino (mouse) assessed as increase in reaction time at 10 mg/kg, po after 1 hr by tail-flick method relative to control",Other,,
3679,1084373,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 3 hr relative to control",Other,,
3680,1084374,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 2.5 hr relative to control",Other,,
3681,1084375,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 2 hr relative to control",Other,,
3682,1084376,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 1.5 hr relative to control",Other,,
3683,1084377,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 1 hr relative to control",Other,,
3684,1084378,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 0.5 hr relative to control",Other,,
3685,1084379,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Mus musculus Swiss albino (mouse) assessed as increase in reaction time at 10 mg/kg, po after 0.5 hr by tail-flick method relative to control",Other,,
3686,1084671,1,2,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus albino (rat) assessed as ulcer index at 25 mg/kg, po for 3 days measured 2 hr after last dose",Other,,
3687,1084676,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 4 hr after carrageenan challenge (Rvb = 0%)",Other,,
3688,1084677,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 3 hr after carrageenan challenge (Rvb = 0%)",Other,,
3689,1084678,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 2 hr after carrageenan challenge (Rvb = 0%)",Other,,
3690,1084679,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 1 hr after carrageenan challenge (Rvb = 0%)",Other,,
3691,1086069,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 5 hr (Rvb = 1.24 +/- 0.0754 mm3)",Other,,
3692,1086070,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 4 hr (Rvb = 1.2825 +/- 0.0862 mm3)",Other,,
3693,1086071,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 3 hr (Rvb = 1.225 +/- 0.0484 mm3)",Other,,
3694,1086073,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw volume at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 1 hr (Rvb = 1.2075 +/- 0.0405 mm3)",Other,,
3695,1086074,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 2 hr relative to control",Other,,
3696,1086302,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Charles Foster albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min post carrageenan-challenge measured up to 3 hr relative to control",Other,,
3697,1086922,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered for 30 min followed by carrageenan challenge measured after 1 to 3 hr relative to control",Other,,
3698,1086978,1,2,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg administered for 1 hr prior to carrageenan challenge measured at 5 hr relative to control,Other,,
3699,1086980,1,2,,103174500,3672,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg administered for 1 hr prior to carrageenan challenge measured at 1 hr relative to control,Other,,
3700,1091955,1,2,,103174500,3672,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
3701,1091956,1,1,,103174500,3672,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
3702,1091957,1,1,,103174500,3672,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
3703,1091958,2,1,,103174500,3672,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
3704,1094456,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 to 3 hr prior challenge",Other,,
3705,1095009,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control",Other,,
3706,1095010,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 100 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control",Other,,
3707,1095011,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 24 hr prior to xylene challenge measured at 24 hr post xylene challenge relative to control",Other,,
3708,1095012,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 4 hr prior to xylene challenge measured at 4 hr post xylene challenge relative to control",Other,,
3709,1095013,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 3 hr prior to xylene challenge measured at 3 hr post xylene challenge relative to control",Other,,
3710,1095014,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 1 hr prior to xylene challenge measured at 1 hr post xylene challenge relative to control",Other,,
3711,1095015,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 0.5 hr prior to xylene challenge measured at 0.5 hr post xylene challenge relative to control",Other,,
3712,1095016,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control",Other,,
3713,1095865,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 3 hr relative to control",Other,,
3714,1095866,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 2 hr relative to control",Other,,
3715,1095867,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 1 hr relative to control",Other,,
3716,1095873,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 15 mg/kg, po measured after 5 min for 15 min relative to control",Other,,
3717,1095942,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Charles Foster albino (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min prior to carrageenan-challenge measured up to 3 hr relative to control",Other,,
3718,1096317,1,2,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Rattus norvegicus Wistar (rat) assessed as ulcer index at 60 mg/kg, po",Other,,
3719,1096318,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Mus musculus Swiss albino (mouse) assessed as protection against acetic acid-induced writhing effect at 20 mg/kg, po after 3 hr relative to control",Other,,
3720,1096319,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po after 3 hr relative to control",Other,,
3721,1097008,2,3,,103174500,3672,Unspecified,126398.0,547923.0,200.0,IC50,Inhibition of Glycine max (soybean) lipoxygenase assessed as formation of 13-hydroperoxylinoleic acid using sodium linoleate as substrate after 7 min,Confirmatory,,
3722,1107311,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Rattus norvegicus (rat)  assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po treated 60 min prior to carrageenan injection measured after 1 to 5 hr",Other,,
3723,1113815,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 4 hr post-carrageenan challenge by water plethysmometer",Other,,
3724,1113816,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 3 hr post-carrageenan challenge by water plethysmometer",Other,,
3725,1113817,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 2 hr post-carrageenan challenge by water plethysmometer",Other,,
3726,1113818,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema administered at 70 mg/kg, sc at 1 hr prior to carrageenan injection measured at 1 hr post-carrageenan challenge by water plethysmometer",Other,,
3727,1115043,1,2,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as hepatocyte with clearing of cytoplasm and compression of sinusoidal spaces at 210 mg/kg, po qd for 15 days measured after 24 hr of last dosage of drug by hematoxylin-eosin staining based light microscopy",Other,,
3728,1115045,1,2,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as serum total albumin level at 210 mg/kg, po qd for 15 days (Rvb = 1.63 +/-0.02 g/dl)",Other,,
3729,1115046,1,3,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as serum total protein level at 210 mg/kg, po qd for 15 days (Rvb = 1.72 +/-0.02 g/dl)",Other,,
3730,1115047,1,2,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as serum alkaline phosphatase activity at 210 mg/kg, po qd for 15 days",Other,,
3731,1115048,2,1,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as serum glutamate pyruvate transaminase activity at 210 mg/kg, po qd for 15 days (Rvb = 32.46 +/-0.76 units/ml)",Other,,
3732,1115049,2,1,,103174500,3672,Unspecified,,,,,"Hepatotoxicity in Wistar albino Rattus norvegicus (rat) assessed as serum glutamate oxaloacetate transaminase activity at 210 mg/kg, po qd for 15 days (Rvb = 143.71 +/-1.10 units/ml)",Other,,
3733,1115050,1,2,,103174500,3672,Unspecified,,,,,"Effect on lipid peroxidation in Wistar Rattus norvegicus (rat) gastric mucosa assessed as malondialdehyde content at 210 mg/kg, po measured per 100 mg of tissue by UV spectrophotometric analysis (Rvb = 3.26 +/-0.01 nmol)",Other,,
3734,1115051,1,2,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Wistar Rattus norvegicus (rat) assessed as ulcerogenicity index at 210 mg/kg, po (Rvb = 0 No unit)",Other,,
3735,1115052,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino Mus musculus (mouse) assessed as inhibition of pain at 70 mg/kg, po measured after 4 hr by tail immersion method",Other,,
3736,1115053,1,2,,103174500,3672,Unspecified,,,,,"Potency index, ratio of ibuprofen analgesic activity to compound analgesic in Swiss albino Mus musculus (mouse) at 70 mg/kg, po measured after 4 hr by tail immersion method",Other,,
3737,1115054,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Swiss albino Mus musculus (mouse) assessed as time required for tail withdrawal at 70 mg/kg, po measured after 4 hr by tail immersion method",Other,,
3738,1115055,1,2,,103174500,3672,Unspecified,,,,,"Potency index, Rattus norvegicus (rat)io of ibuprofen anti-inflammatory activity to compound anti-inflammatory activity in Wistar Rattus norvegicus (rat) at 70 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 4 hr by plethysmometer analysis",Other,,
3739,1115056,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 4 hr by plethysmometer analysis",Other,,
3740,1115057,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr by plethysmometer analysis",Other,,
3741,1115428,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr relative to untreated control",Other,,
3742,1115429,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Kunming Mus musculus (mouse) assessed as inhibition of xylene-induced ear swelling at 200 mg/kg, po administered 1 hr prior to xylene challenge measured after 30 min relative to untreated control",Other,,
3743,1115430,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Kunming Mus musculus (mouse) assessed as increase in pain threshold at 200 mg/kg, po after 1 hr by hot plate method (Rvb = 4.2%)",Other,,
3744,1115431,1,2,,103174500,3672,Unspecified,,,,,"Analgesic activity in Kunming Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 200 mg/kg, po administered 1 hr prior to acetic acid challenge measured for 15 min relative to untreated control",Other,,
3745,1116287,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity against albino Charles Foster Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min prior to carrageenan injection measured after 1-3 hr by plethysmometer",Other,,
3746,1116653,1,2,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po measured after 3 hr",Other,,
3747,1117298,1,2,,170464979,3672,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3748,1117304,1,2,,170464979,3672,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3749,1117305,1,2,,170464979,3672,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3750,1117310,1,1,,170464979,3672,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3751,1117312,1,1,,170464979,3672,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3752,1117314,1,1,,170464979,3672,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3753,1117319,1,2,,855602,3672,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3754,1117319,1,2,,855602,3672,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3755,1117326,1,1,,170464979,3672,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3756,1117329,1,1,,170464979,3672,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3757,1117336,1,1,,170464979,3672,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3758,1117340,1,1,,170464979,3672,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3759,1117341,1,1,,170464979,3672,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3760,1117342,1,1,,170464979,3672,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3761,1117343,1,1,,170464979,3672,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3762,1117346,1,1,,170464979,3672,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3763,1124463,1,1,,103174500,3672,Unspecified,,,,,"Ex vivo antiplatelet activity in Sprague-Dawley rat assessed as inhibition of collagen-induced platelet aggregation at 10 mg/kg, po after 1 hr",Other,458803.0,
3764,1124464,1,1,,103174500,3672,Unspecified,,,,,"Ex vivo antiplatelet activity in Sprague-Dawley rat assessed as inhibition of collagen-induced platelet aggregation at 40 mg/kg, po after 1 hr",Other,458803.0,
3765,1125683,1,3,,103174500,3672,Active,548483.0,19225.0,0.86,IC50,Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay,Confirmatory,24656662.0,
3766,1125684,1,3,,103174500,3672,Active,754286265.0,443551.0,26.0,IC50,Inhibition of ovine COX-1 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay,Confirmatory,24656662.0,
3767,1125685,1,3,,103174500,3672,Active,3915797.0,5743.0,30.0,IC50,Inhibition of human recombinant COX-2 assessed as decrease in PGH2 production using arachidonic acid as substrate treated with enzyme for 10 mins prior to substrate challenge for 2 mins by enzyme immunoassay,Confirmatory,24656662.0,
3768,1125686,1,1,,103174500,3672,Unspecified,,,,,"Selectivity index, ratio of IC50 for ovine COX-1 to IC50 for human recombinant COX-2",Other,24656662.0,
3769,1134827,1,1,,103174500,3672,Unspecified,,,,,Acute toxicity in po dosed mouse,Other,102794.0,
3770,1134828,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced foot edema,Other,102794.0,
3771,1134829,1,1,,103174500,3672,Unspecified,,,,,Antiarthritic activity in rat assessed as reduction in adjuvant-induced arthritic pain,Other,102794.0,
3772,1134830,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in rat assessed as dose required to give 50% inhibition of weight increment per ear,Other,102794.0,
3773,1134831,1,3,,103174500,3672,Unspecified,7387730.0,9536.0,,,Inhibition of prostaglandin synthetase (unknown origin),Other,102794.0,
3774,1135111,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg,Other,140243.0,
3775,1135112,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in rabbit assessed as inhibition of edema at 200 ug per site by reversed passive arthus test,Other,140243.0,
3776,1136186,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 30 mins prior challenge measured after 3 hrs,Other,300806.0,
3777,1136187,1,1,,103174500,3672,Unspecified,,,,,Acute toxicity in ip dosed ddY mouse measured after 168 hrs,Other,300806.0,
3778,1136188,1,1,,103174500,3672,Unspecified,,,,,"Analgesic activity in ip dosed ddY mouse assessed as prevention of pseudoavoidance reflex co-administered with 5 mg/kg, sc morphine hydrochloride by tail pinch method",Other,300806.0,
3779,1136203,1,1,,103174500,3672,Unspecified,,,,,Analgesic activity in po dosed rat assessed as inhibition of yeast-induced inflammatory pain,Other,309947.0,
3780,1136204,1,1,,103174500,3672,Unspecified,,,,,Antipyretic activity in po dosed rat,Other,309947.0,
3781,1136206,1,1,,103174500,3672,Unspecified,,,,,Analgesic activity in po dosed rat assessed as inhibition of adjuvant-induced arthritis pain,Other,309947.0,
3782,1136207,1,1,,103174500,3672,Unspecified,,,,,Inhibition of PG synthase (unknown origin),Other,309947.0,
3783,1136209,1,1,,103174500,3672,Unspecified,,,,,Toxicity in po dosed rat assessed as intestinal perforating ulcer,Other,309947.0,
3784,1136211,1,1,,103174500,3672,Unspecified,,,,,Toxicity in po dosed rat assessed as gastric hemorrhage,Other,309947.0,
3785,1141759,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 150 umol/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs",Other,24763362.0,
3786,1141760,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 150 umol/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs",Other,24763362.0,
3787,1146531,1,1,,103174500,3672,Unspecified,,,,,Gastrointestinal toxicity in po dosed rat assessed as ulcerogenic activity after 6 hrs administered in 1% w/v arabic gum,Other,309949.0,
3788,1146532,1,1,,103174500,3672,Unspecified,,,,,Analgesic activity in po dosed rat assessed as inhibition of phenylbenzoquinone-induced writhing administered in 1% w/v arabic gum,Other,309949.0,
3789,1146533,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced edema administered in 1% w/v arabic gum,Other,309949.0,
3790,1150152,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema compound administered 1 hr prior challenge measured 3 hrs post challenge,Other,926121.0,
3791,1155668,1,2,,103174500,3672,Unspecified,,,,,"AUC (0 to t) in Kunming mouse blood at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3792,1155669,1,1,,103174500,3672,Unspecified,,,,,"Mean residence time in Kunming mouse blood at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3793,1155670,1,1,,103174500,3672,Unspecified,,,,,"Cmax in Kunming mouse blood at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3794,1155671,1,1,,103174500,3672,Unspecified,,,,,"Tmax in Kunming mouse blood at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3795,1155676,1,2,,103174500,3672,Unspecified,,,,,"AUC (0 to t) in Kunming mouse brain at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3796,1155677,1,1,,103174500,3672,Unspecified,,,,,"Mean residence time in Kunming mouse brain at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3797,1155678,1,1,,103174500,3672,Unspecified,,,,,"Cmax in Kunming mouse brain at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3798,1155679,1,1,,103174500,3672,Unspecified,,,,,"Tmax in Kunming mouse brain at 48 mmol/g, iv administered as single dose by HPLC analysis",Other,24927052.0,
3799,1159509,1,1,,144208582,3672,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3800,1159509,1,1,,144213146,3672,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3801,1159509,1,1,,170464979,3672,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3802,1159515,1,1,,144208582,3672,Inconclusive,,,9.9185,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3803,1159515,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3804,1159515,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3805,1159516,1,1,,144208582,3672,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3806,1159516,1,1,,144213146,3672,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3807,1159516,1,1,,170464979,3672,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3808,1159517,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3809,1159517,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3810,1159517,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3811,1159518,1,1,,144208582,3672,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3812,1159518,1,1,,144213146,3672,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3813,1159518,1,1,,170464979,3672,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3814,1159519,1,1,,144208582,3672,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3815,1159519,1,1,,144213146,3672,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3816,1159519,1,1,,170464979,3672,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3817,1159520,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3818,1159520,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3819,1159520,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3820,1159521,1,1,,144208582,3672,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3821,1159521,1,1,,144213146,3672,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3822,1159521,1,1,,170464979,3672,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3823,1159523,1,1,,144208582,3672,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3824,1159523,1,1,,144213146,3672,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3825,1159523,1,1,,170464979,3672,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3826,1159524,1,1,,56422436,3672,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3827,1159524,1,1,,124880372,3672,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3828,1159524,1,1,,124880375,3672,Inconclusive,,,0.631,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3829,1159525,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3830,1159525,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3831,1159525,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3832,1159526,1,1,,144208582,3672,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3833,1159526,1,1,,144213146,3672,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3834,1159526,1,1,,170464979,3672,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3835,1159527,1,1,,144208582,3672,Inconclusive,325495497.0,6256.0,24.914,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3836,1159527,1,1,,144213146,3672,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3837,1159527,1,1,,170464979,3672,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3838,1159528,1,1,,144208582,3672,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3839,1159528,1,1,,144213146,3672,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3840,1159528,1,1,,170464979,3672,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3841,1159529,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3842,1159529,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3843,1159529,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3844,1159531,1,1,,144208582,3672,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3845,1159531,1,1,,144213146,3672,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3846,1159531,1,1,,170464979,3672,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3847,1159537,2,2,,252208980,3672,Inactive,,,,,qHTS screening for TAG (triacylglycerol) accumulators in algae,Screening,28652262.0,
3848,1159550,3,1,,252402247,3672,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3849,1159551,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3850,1159551,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3851,1159551,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3852,1159552,1,1,,144208582,3672,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3853,1159552,1,1,,144213146,3672,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3854,1159552,1,1,,170464979,3672,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3855,1159553,2,1,,144208582,3672,Inconclusive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3856,1159553,2,1,,144213146,3672,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3857,1159553,2,1,,170464979,3672,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3858,1159555,1,1,,144208582,3672,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3859,1159555,1,1,,144213146,3672,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3860,1159555,1,1,,170464979,3672,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3861,1159580,2,1,,268734580,3672,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3862,1159580,2,1,,273002862,3672,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3863,1159583,2,1,,178126838,3672,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3864,1159606,1,1,,56422436,3672,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3865,1159607,2,1,,312310273,3672,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3866,1159614,1,2,,170464979,3672,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3867,1159620,1,1,,103174500,3672,Active,,,,,Summary of drug indications.,Other,,
3868,1164201,1,2,,103174500,3672,Active,754286265.0,443551.0,10.1,IC50,"Inhibition of purified ovine COX1 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Confirmatory,25221653.0,
3869,1164202,1,2,,103174500,3672,Unspecified,754286265.0,443551.0,,,"Inhibition of purified ovine COX1 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Other,25221653.0,
3870,1164203,1,2,,103174500,3672,Active,3915797.0,5743.0,4.3,IC50,"Inhibition of human recombinant COX2 pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Confirmatory,25221653.0,
3871,1164204,1,2,,103174500,3672,Unspecified,3915797.0,5743.0,,,"Inhibition of human recombinant COX2 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay",Other,25221653.0,
3872,1164212,1,1,,103174500,3672,Unspecified,,,,,Analgesic activity in Sprague-Dawley rat assessed as protection against acetic acid-induced abdominal constriction dosed 1 hr before acetic acid challenge measured for 20 mins post acetic acid challenge,Other,25221653.0,
3873,1164213,1,1,,103174500,3672,Active,,,,,"Anti-inflammatory activity in Swiss mouse model of carrageenan-induced paw edema assessed as reduction in paw swelling at 50 mg/kg, sc dosed 30 mins before carrageenan challenge measured at 1 to 4 hrs post carrageenan challenge by mercury plethysmometry",Other,25221653.0,
3874,1174762,1,1,,103174500,3672,Unspecified,,,,,Antiinflammatory activity against carrageenan-induced ip dosed Wistar rat paw edema model assessed as inhibition of edema administered 30 mins prior to carrageenan challenge measured after 60 mins,Other,25462274.0,
3875,1175391,1,2,,103174500,3672,Unspecified,296452849.0,7442.0,,,Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 250 uM after 30 mins by Fluo-4 AM fluorescence assay,Other,25467164.0,
3876,1175392,1,2,,103174500,3672,Unspecified,296452849.0,7442.0,,,Inhibition of human TRPV1 overexpressed in BEAS-2B cells assessed as residual activity at 50 uM after 30 mins by Fluo-4 AM fluorescence assay,Other,25467164.0,
3877,1192231,1,1,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar rat assessed as reduction in carrageenan induced paw edema by measuring paw volume as ml of Hg at 100 mg/kg, po administered 30 mins before carrageenan challenge measured 1 hr post carrageenan challenge (Rvb = 0.36 +/- 0.3 ml of Hg)",Other,25708616.0,
3878,1192232,1,1,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar rat assessed as reduction in carrageenan induced paw edema by measuring paw volume as ml of Hg at 100 mg/kg, po administered 30 mins before carrageenan challenge measured 2 hrs post carrageenan challenge (Rvb = 0.36 +/- 0.3 ml of Hg)",Other,25708616.0,
3879,1192233,1,1,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar rat assessed as reduction in carrageenan induced paw edema by measuring paw volume as ml of Hg at 100 mg/kg, po administered 30 mins before carrageenan challenge measured 4 hrs post carrageenan challenge (Rvb = 0.36 +/- 0.3 ml of Hg)",Other,25708616.0,
3880,1192234,1,1,,103174500,3672,Unspecified,,,,,"Anti-inflammatory activity in Wistar rat assessed as reduction in carrageenan induced paw edema by measuring paw volume as ml of Hg at 100 mg/kg, po administered 30 mins before carrageenan challenge measured 6 hrs post carrageenan challenge (Rvb = 0.36 +/- 0.3 ml of Hg)",Other,25708616.0,
3881,1193500,1,1,,103174500,3672,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound",Other,25740159.0,
3882,1194673,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced paw edema at 150 umol/kg, po administered 1 hr before LPS-stimulation and measured 3 hrs post LPS challenge",Other,25824662.0,
3883,1194674,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced paw edema at 150 umol/kg, po administered 1 hr before LPS-stimulation and measured 5 hrs post LPS challenge",Other,25824662.0,
3884,1198256,1,1,,103174500,3672,Inactive,,,,,Antiproliferative activity against human U373MG cells assessed as effect on cell number at 1 nM to 10 uM incubated for 1 to 6 days by trypan blue dye exclusion dye based inverted microscopy,Other,25666913.0,
3885,1198262,1,1,,103174500,3672,Inconclusive,,,,IC50,Antiproliferative activity against human U373MG cells assessed reduction in cell number at 10 uM incubated for 6 days by trypan blue dye exclusion dye based inverted microscopy,Confirmatory,25666913.0,
3886,1204855,1,1,,103174500,3672,Active,,,,,"Antiinflammatory activity against carrageenan-induced albino Wistar rat hind paw edema model assessed as decrease in paw volume at 10 mg/kg, ip treated 45 mins prior to carrageenan injection measured at the end of 24 hrs after carrageenan injection by plethysmometer analysis",Other,26010018.0,
3887,1204856,1,1,,103174500,3672,Active,,,,,Anti-arthritic activity against against Complete Freund's adjuvant-induced arthritis albino Wistar rat model assessed as decrease in paw volume at 10 mg/kg administered via gavage daily started from day 7 and continued till day 21 after CFA injection measured at at 21 days after induction of paw edema by plethysmometer analysis,Other,26010018.0,
3888,1204857,1,2,,103174500,3672,Active,,,,,In vivo inhibition of COX-2 activity in Complete Freund's adjuvant-induced arthritic albino Wistar rat serum assessed as decrease in peroxidase activity measured as TMPD oxidation rate at 10 mg/kg administered via gavage daily started from day 7 and continued till day 21 after CFA injection by colorimetric analysis,Other,26010018.0,
3889,1204858,1,1,,103174500,3672,Active,,,,,Reduction in neutrophil infiltration in Complete Freund's adjuvant-induced arthritic albino Wistar rat ankle joint at 10 mg/kg administered via gavage daily started from day 7 and continued till day 21 after CFA injection by hematoxylin-eosin staining based microscopic analysis,Other,26010018.0,
3890,1204859,1,1,,103174500,3672,Unspecified,,,92.97,LD50,Cytotoxicity against human SW982 cells after 24 hrs by MTT assay,Confirmatory,26010018.0,
3891,1209455,1,2,,103174500,3672,Unspecified,262527527.0,8647.0,598.6,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3892,1209456,1,2,,103174500,3672,Unspecified,12585136.0,83569.0,290.9,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
3893,1209457,1,1,,103174500,3672,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
3894,1210069,1,2,,103174500,3672,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
3895,1211791,1,1,,103174500,3672,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
3896,1211792,1,1,,103174500,3672,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
3897,1211794,1,2,,103174500,3672,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
3898,1211795,1,1,,103174500,3672,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
3899,1211797,1,1,,103174500,3672,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
3900,1211798,1,1,,103174500,3672,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
3901,1212314,1,1,,103174500,3672,Unspecified,,,500.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
3902,1212341,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
3903,1215120,1,1,,103174500,3672,Unspecified,,,52.7,Kd,Binding affinity to Wistar rat brain lipid by TRANSIL assay,Confirmatory,21071520.0,
3904,1215123,1,2,,103174500,3672,Active,124028612.0,24186.0,1.47,Kd,Binding affinity to Wistar rat serum albumin,Confirmatory,21071520.0,
3905,1215124,1,1,,103174500,3672,Unspecified,,,,,Binding affinity to Wistar rat brain lipid assessed as fraction unbound by TRANSIL assay,Other,21071520.0,
3906,1221772,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM by MTT assay,Other,20926620.0,
3907,1221774,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay,Other,20926620.0,
3908,1221776,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against mock transfected HEK293 cells assessed as decrease in cell viability at 1 mM by MTT assay,Other,20926620.0,
3909,1221778,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against mock transfected HEK293 cells assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay,Other,20926620.0,
3910,1221782,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay,Other,20926620.0,
3911,1221789,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against human hepatocytes assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM measured at 6 hrs by CellTiter-Glo luminescent assay in presence of acyl glucuronidation inhibitor (-)-borneol,Other,20926620.0,
3912,1221791,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against human hepatocytes assessed as decrease in cell viability at 1 mM measured at 6 hrs by MTT assay in presence of acyl glucuronidation inhibitor (-)-borneol,Other,20926620.0,
3913,1221794,1,1,,103174500,3672,Active,,,,,Cellular uptake in human hepatocytes at 1 mM measured at 6 hrs by LC-MS/MS analysis in presence of acyl glucuronidation inhibitor (-)-borneol,Other,20926620.0,
3914,1221796,1,1,,103174500,3672,Active,,,,,Cellular uptake in human hepatocytes at 1 mM measured at 6 hrs by LC-MS/MS analysis in absence of acyl glucuronidation inhibitor (-)-borneol,Other,20926620.0,
3915,1221799,1,1,,103174500,3672,Unspecified,,,,,Genotoxicity in HEK293 cells expressing UGT1A3 assessed as DNA strand breaks at 1 mM after 24 hrs by comet assay,Other,20926620.0,
3916,1221814,1,2,,103174500,3672,Unspecified,136731.0,54657.0,,,Activity of human UGT1A4 expressed in HEK293 cells assessed as enzyme-mediated ibuprofen acyl-beta-D-glucuronide formation at 1 mM measured at 24 hrs by LC-MS/MS analysis,Other,20926620.0,
3917,1221815,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM by MTT assay,Other,20926620.0,
3918,1221817,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM by CellTiter-Glo luminescent assay,Other,20926620.0,
3919,1221819,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against HEK293 cells expressing UGT assessed as LDH leakage at 1 mM after 6 to 24 hrs by spectrophotometric analysis relative to total cell LDH level,Other,20926620.0,
3920,1221831,1,2,,103174500,3672,Unspecified,549152.0,54659.0,,,Activity of human UGT1A3 expressed in HEK293 cells assessed as enzyme-mediated ibuprofen acyl-beta-D-glucuronide formation at 1 mM measured at 24 hrs by LC-MS/MS analysis,Other,20926620.0,
3921,1221846,1,1,,103174500,3672,Unspecified,,,,,Cytotoxicity against human hepatocytes assessed as decrease in cell viability by measuring intracellular ATP content at 1 mM measured at 6 hrs by CellTiter-Glo luminescent assay in absence of acyl glucuronidation inhibitor (-)-borneol,Other,20926620.0,
3922,1223476,1,1,,103174500,3672,Unspecified,,,,,"Elimination half life in chimeric mouse with humanized liver at 5 mg/kg, iv by LC-MS/MS method",Other,22048522.0,
3923,1223477,1,1,,103174500,3672,Unspecified,,,,,Total clearance in iv dosed human,Other,22048522.0,
3924,1223479,1,1,,103174500,3672,Unspecified,,,,,"Total clearance in chimeric mouse with humanized liver at 5 mg/kg, iv by LC-MS/MS method",Other,22048522.0,
3925,1223481,1,1,,103174500,3672,Unspecified,,,,,Elimination half life iv dosed human,Other,22048522.0,
3926,1223482,1,2,,103174500,3672,Unspecified,,,,,Ratio of drug level in blood to plasma in iv dosed human,Other,22048522.0,
3927,1223483,1,2,,103174500,3672,Unspecified,,,,,Unbound fraction in iv dosed human plasma,Other,22048522.0,
3928,1223486,1,1,,103174500,3672,Unspecified,,,,,Intrinsic clearance in human hepatocytes from chimeric mouse with humanized liver assessed per 10'6 cells at 10 uM after 0.25 to 2 hrs by LC-MS/MS method,Other,22048522.0,
3929,1224818,1,1,,312344816,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3930,1224819,1,1,,312344816,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3931,1224820,1,1,,312344816,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3932,1224821,1,1,,312344816,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3933,1224822,1,1,,312344816,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3934,1224823,1,1,,312344816,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3935,1224824,1,1,,174007269,3672,Inactive,,,2.0398,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
3936,1224825,1,1,,174007269,3672,Inactive,,,0.5749,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
3937,1224834,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3938,1224834,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3939,1224834,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3940,1224835,1,1,,144208582,3672,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3941,1224835,1,1,,144213146,3672,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3942,1224835,1,1,,170464979,3672,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3943,1224836,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3944,1224836,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3945,1224836,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3946,1224837,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3947,1224837,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3948,1224837,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3949,1224838,1,1,,144208582,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3950,1224838,1,1,,144213146,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3951,1224838,1,1,,170464979,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3952,1224839,1,1,,144208582,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3953,1224839,1,1,,144213146,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3954,1224839,1,1,,170464979,3672,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3955,1224840,3,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3956,1224840,3,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3957,1224840,3,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3958,1224841,3,1,,144208582,3672,Inactive,325495545.0,2101.0,78.1343,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3959,1224841,3,1,,144213146,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3960,1224841,3,1,,170464979,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3961,1224842,3,1,,144208582,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3962,1224842,3,1,,144213146,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3963,1224842,3,1,,170464979,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3964,1224843,1,1,,144208582,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3965,1224843,1,1,,144213146,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3966,1224843,1,1,,170464979,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3967,1224844,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3968,1224844,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3969,1224844,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3970,1224845,1,1,,144208582,3672,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3971,1224845,1,1,,144213146,3672,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3972,1224845,1,1,,170464979,3672,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3973,1224846,1,1,,144208582,3672,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3974,1224846,1,1,,144213146,3672,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3975,1224846,1,1,,170464979,3672,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3976,1224847,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3977,1224847,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3978,1224847,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3979,1224848,3,1,,144208582,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3980,1224848,3,1,,144213146,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3981,1224848,3,1,,170464979,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3982,1224849,3,1,,144208582,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3983,1224849,3,1,,144213146,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3984,1224849,3,1,,170464979,3672,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3985,1224857,2,1,,170464979,3672,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3986,1224857,2,1,,174007269,3672,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3987,1224857,2,1,,312344816,3672,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3988,1224859,2,1,,90341584,3672,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3989,1224859,2,1,,170464979,3672,Inconclusive,,,12.5893,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3990,1224859,2,1,,174007269,3672,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3991,1224863,1,1,,176484156,3672,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3992,1224863,1,1,,176484721,3672,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3993,1224863,1,1,,316920364,3672,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3994,1224864,1,2,,316934097,3672,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3995,1224865,1,2,,56422436,3672,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3996,1224867,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3997,1224867,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3998,1224867,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3999,1224868,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4000,1224868,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4001,1224868,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4002,1224869,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4003,1224869,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4004,1224869,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4005,1224870,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4006,1224870,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4007,1224870,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4008,1224871,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4009,1224871,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4010,1224871,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4011,1224872,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4012,1224872,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4013,1224872,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4014,1224873,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4015,1224873,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4016,1224873,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4017,1224874,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4018,1224874,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4019,1224874,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4020,1224875,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4021,1224875,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4022,1224875,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4023,1224876,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4024,1224876,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4025,1224876,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4026,1224877,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4027,1224877,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4028,1224877,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4029,1224878,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4030,1224878,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4031,1224878,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4032,1224879,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4033,1224879,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4034,1224879,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4035,1224880,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4036,1224880,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4037,1224880,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4038,1224881,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4039,1224881,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4040,1224881,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4041,1224882,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4042,1224882,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4043,1224882,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4044,1224883,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4045,1224883,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4046,1224883,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4047,1224884,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4048,1224884,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4049,1224884,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4050,1224885,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4051,1224885,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4052,1224885,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4053,1224886,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4054,1224886,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4055,1224886,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4056,1224887,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4057,1224887,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4058,1224887,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4059,1224888,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4060,1224888,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4061,1224888,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4062,1224889,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4063,1224889,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4064,1224889,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4065,1224890,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4066,1224890,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4067,1224890,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4068,1224892,1,1,,144208582,3672,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4069,1224892,1,1,,144213146,3672,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4070,1224892,1,1,,170464979,3672,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4071,1224893,1,1,,144208582,3672,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4072,1224893,1,1,,144213146,3672,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4073,1224893,1,1,,170464979,3672,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4074,1224894,1,1,,144208582,3672,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4075,1224894,1,1,,144213146,3672,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4076,1224894,1,1,,170464979,3672,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4077,1224895,1,1,,144208582,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4078,1224895,1,1,,144213146,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4079,1224895,1,1,,170464979,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4080,1224896,1,1,,144208582,3672,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4081,1224896,1,1,,144213146,3672,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4082,1224896,1,1,,170464979,3672,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4083,1224905,2,1,,92308981,3672,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4084,1224905,2,1,,92308981,3672,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4085,1224905,2,1,,121361647,3672,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4086,1224905,2,1,,121361647,3672,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4087,1232164,1,1,,103174500,3672,Unspecified,,,,,Fraction unbound in human plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4088,1232166,1,1,,103174500,3672,Unspecified,,,,,Fraction unbound in rat plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
4089,1248211,1,1,,103174500,3672,Unspecified,,,,,"Gastrointestinal toxicity in Norwegian rat assessed as ulcerative index at 50 mg/kg, po after 17 hrs",Other,26385444.0,
4090,1254089,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, ip administered 30 mins before xylene challenge relative to control",Other,26490095.0,
4091,1256770,1,1,,103174500,3672,Unspecified,,,,,"Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw oedema at 0.15 mmol/kg, ip administered 5 mins before carrageenan challenge measured after 3.5 hrs",Other,26494261.0,
4092,1259241,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4093,1259241,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4094,1259241,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4095,1259242,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4096,1259242,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4097,1259242,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4098,1259243,1,1,,144208582,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4099,1259243,1,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4100,1259243,1,1,,170464979,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4101,1259244,1,1,,144208582,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4102,1259244,1,1,,144213146,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4103,1259244,1,1,,170464979,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4104,1259247,1,1,,144208582,3672,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4105,1259247,1,1,,144213146,3672,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4106,1259247,1,1,,170464979,3672,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4107,1259248,1,1,,144208582,3672,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4108,1259248,1,1,,144213146,3672,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4109,1259248,1,1,,170464979,3672,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4110,1259252,1,1,,174007269,3672,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
4111,1259253,1,1,,174007269,3672,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
4112,1259255,1,1,,174007269,3672,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
4113,1259256,1,1,,174007269,3672,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
4114,1259309,1,1,,178126838,3672,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
4115,1259310,1,1,,104169956,3672,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4116,1259310,1,1,,321942779,3672,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4117,1259310,1,1,,332876198,3672,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4118,1259311,1,1,,178126838,3672,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
4119,1259313,1,1,,56422436,3672,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
4120,1259318,1,1,,855602,3672,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
4121,1259325,1,2,,336955780,3672,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
4122,1259344,1,1,,144203721,3672,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
4123,1259354,1,1,,348427247,3672,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
4124,1259354,1,1,,348463992,3672,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
4125,1259355,1,1,,26752326,3672,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
4126,1259356,1,1,,144203721,3672,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
4127,1259364,1,1,,144208582,3672,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4128,1259364,1,1,,144213146,3672,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4129,1259364,1,1,,170464979,3672,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4130,1259365,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4131,1259365,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4132,1259365,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4133,1259366,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4134,1259366,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4135,1259366,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4136,1259367,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4137,1259367,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4138,1259367,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4139,1259368,1,1,,144208582,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4140,1259368,1,1,,144213146,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4141,1259368,1,1,,170464979,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4142,1259369,1,1,,144208582,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4143,1259369,1,1,,144213146,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4144,1259369,1,1,,170464979,3672,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4145,1259370,2,2,,124636790,3672,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4146,1259370,2,2,,124636790,3672,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4147,1259370,2,2,,124636790,3672,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4148,1259377,1,1,,144208582,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4149,1259377,1,1,,144213146,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4150,1259377,1,1,,170464979,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4151,1259378,1,1,,144208582,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4152,1259378,1,1,,144213146,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4153,1259378,1,1,,170464979,3672,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4154,1259379,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4155,1259379,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4156,1259379,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4157,1259380,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4158,1259380,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4159,1259380,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4160,1259381,1,1,,144208582,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4161,1259381,1,1,,144213146,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4162,1259381,1,1,,170464979,3672,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4163,1259382,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4164,1259382,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4165,1259382,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4166,1259383,1,1,,144208582,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4167,1259383,1,1,,144213146,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4168,1259383,1,1,,170464979,3672,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4169,1259384,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4170,1259384,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4171,1259384,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4172,1259385,1,1,,144208582,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4173,1259385,1,1,,144213146,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4174,1259385,1,1,,170464979,3672,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4175,1259386,1,1,,144208582,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4176,1259386,1,1,,144213146,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4177,1259386,1,1,,170464979,3672,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4178,1259387,1,1,,144208582,3672,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4179,1259387,1,1,,144213146,3672,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4180,1259387,1,1,,170464979,3672,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4181,1259388,1,1,,144208582,3672,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4182,1259388,1,1,,144213146,3672,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4183,1259388,1,1,,170464979,3672,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4184,1259389,1,1,,124636790,3672,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4185,1259390,1,1,,144208582,3672,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4186,1259390,1,1,,144213146,3672,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4187,1259390,1,1,,170464979,3672,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4188,1259391,1,1,,144208582,3672,Inconclusive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4189,1259391,1,1,,144213146,3672,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4190,1259391,1,1,,170464979,3672,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4191,1259392,1,1,,144208582,3672,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4192,1259392,1,1,,144213146,3672,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4193,1259392,1,1,,170464979,3672,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4194,1259393,1,1,,144208582,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4195,1259393,1,1,,144213146,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4196,1259393,1,1,,170464979,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4197,1259394,1,1,,144208582,3672,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4198,1259394,1,1,,144213146,3672,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4199,1259394,1,1,,170464979,3672,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4200,1259395,1,1,,144208582,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4201,1259395,1,1,,144213146,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4202,1259395,1,1,,170464979,3672,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4203,1259396,1,1,,144208582,3672,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4204,1259396,1,1,,144213146,3672,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4205,1259396,1,1,,170464979,3672,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4206,1259400,1,1,,170464979,3672,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
4207,1259401,1,1,,144208582,3672,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4208,1259401,1,1,,144213146,3672,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4209,1259401,1,1,,170464979,3672,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4210,1259402,1,1,,144208582,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4211,1259402,1,1,,144213146,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4212,1259402,1,1,,170464979,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4213,1259403,1,1,,144208582,3672,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4214,1259403,1,1,,144213146,3672,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4215,1259403,1,1,,170464979,3672,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4216,1259404,1,1,,144208582,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4217,1259404,1,1,,144213146,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4218,1259404,1,1,,170464979,3672,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4219,1259406,1,1,,363920307,3672,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
4220,1259406,1,1,1.0,363920307,3672,Inactive,26638650.0,3778.0,0.0419254,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
4221,1259406,1,1,2.0,363920307,3672,Inactive,4758626.0,3779.0,-0.021706700000000002,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4222,1259406,1,1,3.0,363920307,3672,Inactive,5031823.0,10242.0,0.032131,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
4223,1259406,1,1,4.0,363920307,3672,Inactive,26051275.0,27345.0,0.025416499999999998,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
4224,1259406,1,1,5.0,363920307,3672,Inactive,160410009.0,389816.0,-0.026668,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4225,1259406,1,1,6.0,363920307,3672,Inactive,26638650.0,3778.0,0.00709457,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
4226,1259406,1,1,7.0,363920307,3672,Inactive,4758626.0,3779.0,-0.000830296,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
4227,1259406,1,1,8.0,363920307,3672,Inactive,5031823.0,10242.0,-0.00840803,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
4228,1259406,1,1,9.0,363920307,3672,Inactive,26051275.0,27345.0,-0.047050699999999994,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
4229,1259406,1,1,10.0,363920307,3672,Inactive,5031823.0,10242.0,0.032771800000000004,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
4230,1259407,1,1,,363901173,3672,Inactive,,,,,CCRIS mutagenicity studies,Other,,
4231,1259408,1,1,,363897926,3672,Active,,,,,GENE-TOX mutagenicity studies,Other,,
4232,1259409,1,1,,363901173,3672,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
4233,1259413,1,2,,104169956,3672,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
4234,1259415,1,1,,855602,3672,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
4235,1259416,1,2,,855602,3672,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4236,1259416,1,2,,340080043,3672,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4237,1259416,1,2,,375178251,3672,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4238,1259421,1,1,,340080043,3672,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4239,1259421,1,1,,375178251,3672,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4240,1259423,1,2,,354803005,3672,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4241,1259423,1,2,,354917053,3672,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4242,1259423,1,2,,354927322,3672,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
